These guidelines were created to assist state, district and local health departments in controlling, monitoring, treating, notifying, and testing tuberculosis (TB) disease and infection for the State of Georgia. It is not possible for any guideline to address all situations for individuals; therefore, clinical judgment must always be exercised. Tuberculosis standards have been well established by nationally accepted scientific authorities, such as the American Thoracic Society (ATS), the Infectious Diseases Society of America (IDSA) and the U.S. Centers for Disease Control and Prevention (CDC), as well as generally recognized TB control experts such as the National Tuberculosis Nurse Coalition (NTNC) and National Tuberculosis Controllers Association (NTCA). The standards of care for the medical treatment and control of TB are published jointly by ATS, IDSA, and CDC. Georgia follows these national standards and recommendations and in addition, has state-specific standards for TB control and prevention. References to these standards are listed below:


TUBERCULOSIS PROGRAM CONTACT INFORMATION:
Georgia Department of Public Health (GDPH)
Division of Health Protection
Office of Infectious Disease Control
Tuberculosis Prevention and Control Unit
Two Peachtree Street, Northwest
12th Floor
Atlanta, Georgia 30303
(P) 404-657-2634  (F) 404-463-3460

ACKNOWLEDGEMENTS
Brenda Fitzgerald, MD, Commissioner of Public Health, GDPH
J. Patrick O’Neal, MD, Director Health Protection, GDPH
Rose-Marie Sales, MPH, Program Director, Georgia Tuberculosis Program
Susan M. Ray, MD, State Medical Consultant, Georgia Tuberculosis Program
Kortney Floyd, MSN, APRN, Nurse Consultant, Georgia Tuberculosis Program
Marjorie McDermott, RN, Nurse Consultant, Georgia Tuberculosis Program
Carolyn Martin, RN, Nurse Consultant, Georgia Tuberculosis Program
Lauren Dimiceli, DrPh, MSPH, Epidemiologist, Georgia Tuberculosis Program
## Table of Contents

<table>
<thead>
<tr>
<th>1. Mission and Responsibilities</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mission</td>
<td>9</td>
</tr>
<tr>
<td>Legislative Authority</td>
<td>9</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>9</td>
</tr>
<tr>
<td>Responsibilities of the State TB Program</td>
<td>9</td>
</tr>
<tr>
<td>Responsibilities of the District TB Program</td>
<td>11</td>
</tr>
<tr>
<td>Responsibilities of the County TB Program</td>
<td>13</td>
</tr>
<tr>
<td>National TB Indicators</td>
<td>14</td>
</tr>
<tr>
<td>2. Medical Records and Surveillance</td>
<td>15</td>
</tr>
<tr>
<td>Retention of Records</td>
<td>17</td>
</tr>
<tr>
<td>Reporting and Counting Cases</td>
<td>17</td>
</tr>
<tr>
<td>SENDSS Reporting Requirements and Timelines</td>
<td>19</td>
</tr>
<tr>
<td>Interjurisdictional Transfers</td>
<td>20</td>
</tr>
<tr>
<td>Refugee or Immigrant Class B1 or B2</td>
<td>21</td>
</tr>
<tr>
<td>3. Overview of Tuberculosis Services</td>
<td>24</td>
</tr>
<tr>
<td>Medical Care</td>
<td>26</td>
</tr>
<tr>
<td>Office Visits/Home Visits</td>
<td>27</td>
</tr>
<tr>
<td>Screening for TB</td>
<td>28</td>
</tr>
<tr>
<td>TST by Unlicensed Personnel</td>
<td>28</td>
</tr>
<tr>
<td>Sample Medical Delegation</td>
<td>30</td>
</tr>
<tr>
<td>Administration, Measurement, Interpretation of TST</td>
<td>31</td>
</tr>
<tr>
<td>Chest X-rays and other Imaging or Procedures</td>
<td>34</td>
</tr>
<tr>
<td>Laboratory testing</td>
<td>34</td>
</tr>
<tr>
<td>Incentives and Enablers</td>
<td>35</td>
</tr>
<tr>
<td>Medical Interpretation Services</td>
<td>35</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>35</td>
</tr>
<tr>
<td>Housing Homeless Clients (see also Section 9)</td>
<td>35</td>
</tr>
<tr>
<td>State TB Social Services</td>
<td>36</td>
</tr>
<tr>
<td>Program Evaluation</td>
<td>36</td>
</tr>
<tr>
<td>4. Pharmacy</td>
<td>37</td>
</tr>
<tr>
<td>Medications, Transport of Dangerous Drugs, 340B</td>
<td>39</td>
</tr>
<tr>
<td>Medications Requiring Approval by State Medical Consultant</td>
<td>39</td>
</tr>
<tr>
<td>5. Directly Observed Therapy</td>
<td>41</td>
</tr>
<tr>
<td>Video Observed Therapy</td>
<td>44</td>
</tr>
<tr>
<td>Education</td>
<td>46</td>
</tr>
<tr>
<td>Procedure</td>
<td>49</td>
</tr>
</tbody>
</table>
# 6. Contact Investigation

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions and Background</td>
<td>54</td>
</tr>
<tr>
<td>Children Less than 5 Years of Age</td>
<td>58</td>
</tr>
<tr>
<td>Patients with Extra-Pulmonary TB</td>
<td>58</td>
</tr>
<tr>
<td>Patients with Active TB</td>
<td>59</td>
</tr>
<tr>
<td>Contact Priority</td>
<td>60</td>
</tr>
<tr>
<td>Contact Evaluation</td>
<td>63</td>
</tr>
<tr>
<td>Presumptive Latent TB Infection Treatment</td>
<td>66</td>
</tr>
<tr>
<td>Treatment of Infected Contacts</td>
<td>67</td>
</tr>
<tr>
<td>Investigations across Jurisdictions</td>
<td>67</td>
</tr>
<tr>
<td>Expanding the Investigation</td>
<td>69</td>
</tr>
<tr>
<td>7. Evaluation and Monitoring</td>
<td>71</td>
</tr>
<tr>
<td>Evaluation for TB Screening</td>
<td>73</td>
</tr>
<tr>
<td>Evaluation for Treatment</td>
<td>74</td>
</tr>
<tr>
<td>Monthly Treatment Monitoring</td>
<td>76</td>
</tr>
<tr>
<td>Lab Quick Reference</td>
<td>76</td>
</tr>
<tr>
<td>Telephone Nurse Monitoring Program</td>
<td>77</td>
</tr>
<tr>
<td>Patient Education</td>
<td>80</td>
</tr>
<tr>
<td>8. Georgia TB Laws and Court-Ordered Treatment</td>
<td>82</td>
</tr>
<tr>
<td>Adherence</td>
<td>84</td>
</tr>
<tr>
<td>Assessment Tool</td>
<td>85</td>
</tr>
<tr>
<td>Escalation of Issues</td>
<td>86</td>
</tr>
<tr>
<td>Court-Ordered Treatment and/or Confinement of Non-Adherent TB Patients</td>
<td>86</td>
</tr>
<tr>
<td>Sample Medical Care Plan for CorrectCare Referral</td>
<td>89</td>
</tr>
</tbody>
</table>

## Appendices:

**A: National TB Indicators** - Program evaluation is an essential component of an effective public health program. Since 2005, DTBE has included program evaluation as a core requirement of the cooperative agreement. With the understanding of the resource limitations and constraints faced by TB programs, NTIP was developed to facilitate the use of existing data to help programs prioritize activities and focus program evaluation efforts.

**B: HIPAA Letter from Commissioner Fitzgerald**

**C: Interjurisdictional Form** - An interjurisdictional referral system is supported by the NTCA/NTNC in order to promote continuity of care for TB patients who move from one state to another during the course of TB treatment. This system also facilitates the completion of contact tracing for contacts who move prior to completion of TB exposure evaluation.
**D: International TB Notification Form** - Some patients under treatment for active TB disease in the United States move to another country before completing treatment. To assist in treatment completion and continuity of care, CDC has developed a process for international notification.

**E: TBNNet Referral Forms** - TBNNet is a multi-national tuberculosis patient tracking and referral program designed to keep mobile, underserved populations in care. TB patients moving outside of the U.S. while still on TB treatment are referred to TBNNet for linkage to care while abroad.

**F: Clinic Forms**

- **3121-R Tuberculosis Services** - Required intake form of all TB clients, whether active TB disease or LTBI. Used to obtain demographic, medical history and TB history. This form can also be forwarded to delegating physician in order to consult with care of patient.

- **3126 Contact Investigation Report** - Required form to track information of all contacts to a TB case. Information should then be entered into SENDSS. The goal is to document at least 10 contacts for each TB case.

- **3130 DOT Medication Sheet** - Required form to document all medication doses administered to a patient receiving Directly Observed Therapy whether active TB disease or LTBI.

- **3144 Active TB Treatment Plan** - Required form completed by the healthcare provider in the TB program as well as signed by the TB patient. Outlines important educational information regarding TB such as infectiousness, medications, appointment adherence and legal action for non-adherence. Available in many languages on the TB website.

- **3609 LTBI Consent and Treatment Plan/ Consent for DOT** - Required form completed by the healthcare provider in the TB program as well as signed by the LTBI patient. Outlines important educational information regarding LTBI such as signs/symptoms of active TB disease, medications, and the health department’s contact info. Available in many languages on the TB website.

- **3609 TB Consent to Treatment** - Required form completed by the healthcare provider in the TB program as well as signed by the TB patient. Outlines important educational information regarding TB such as infectiousness, HIV testing consent and link with TB and HIV, appointment adherence and legal action for non-adherence. Available in many languages on the TB website.

- **3610 Video DOT Agreement** – Required form completed by the healthcare provider in the TB program as well as TB patient prior to beginning Video DOT. The form discusses the parameters Video DOT can be discontinued, acknowledgement of the lack of security when using the internet and release of liability to the health department.
<table>
<thead>
<tr>
<th>Document Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT Instruction Sheet</td>
<td>A tool that can be used by any provider of DOT. Can be especially helpful for new TB staff or non-health department workers administering DOT. Contains pictures of each 1&lt;sup&gt;st&lt;/sup&gt; line TB medication, contact info for patient, DOT worker and TB Nurse Case Manager as well. (not required)</td>
</tr>
<tr>
<td>603 DOT Agreement</td>
<td>Required form to be completed by the TB patient, TB nurse and DOT provider. The form outlines the schedule for DOT, contact information and alternate arrangements if routine DOT cannot be completed as usual.</td>
</tr>
<tr>
<td>2nd Line Therapy Request</td>
<td>Form to be completed by TB nurse or Physician requesting 2&lt;sup&gt;nd&lt;/sup&gt; line medications to treat a TB patient, whether active TB disease or LTBI. When submitting request please provide all documentation requested.</td>
</tr>
<tr>
<td>12 Points of TB Education</td>
<td>Handout that can be given to TB patients as a way to educate regarding TB. Points include differences between LTBI and active TB disease, importance of HIV testing, respiratory isolation, etc.</td>
</tr>
<tr>
<td>Case Review Form</td>
<td>Form to be completed by local TB staff in order to conduct yearly case review with State TB staff.</td>
</tr>
<tr>
<td>Patient Education Review of Systems Aid</td>
<td>Optional tool to use when asking TB patient about any side effects, adverse reactions experienced while taking medications. Can be used daily with each DOT appointment or as clinic visits are scheduled.</td>
</tr>
<tr>
<td>Refusal of HIV testing</td>
<td>Required form to document when TB patient chooses to opt out of HIV testing.</td>
</tr>
<tr>
<td>TB Flow Sheet</td>
<td>Optional sheet that can be used to summarize patient care while treatment being managed by TB program.</td>
</tr>
<tr>
<td>TB Risk Assessment</td>
<td>Form used to assist TB staff in determining a client’s risk level for TB and whether an evaluation for TB is necessary. If a client is coming to the health department to obtain testing for school, work, etc the form also helps determine cutoff measurement for positive Tuberculin Skin Tests if a client has a positive reaction.</td>
</tr>
<tr>
<td>TB Symptom Screen</td>
<td>Form used by TB staff to document that a client has been evaluated for TB and any actions taken as a result. This completed form can then be forwarded to the client’s employer, school or Primary Care Physician if necessary.</td>
</tr>
<tr>
<td>G: Georgia Official Code, Chapter 14, Title 31</td>
<td>Most recent statute outlining Hospitalization for Tuberculosis.</td>
</tr>
<tr>
<td>H: Court Order Templates</td>
<td>Samples of Court Orders for TB patients for commitment, consent, emergency commitment, confinement, etc.</td>
</tr>
<tr>
<td><strong>J: GA DPH Laboratory Tests</strong> – List of lab tests performed by the GA Public Health Laboratory. Table includes order code, description, specimen requirements, test method, values, turnaround time, contact information and CPT codes.</td>
<td></td>
</tr>
<tr>
<td><strong>K: Memo Regarding Notification to Persons Exposed to Tuberculosis</strong> – Memo drafted by Legal at GA State Office to address when TB staff may notify a contact that they have been exposed to TB, what TB staff should or should not say, and efforts that should be made to provide notice.</td>
<td></td>
</tr>
</tbody>
</table>
Mission and Responsibilities

Table of Contents

<table>
<thead>
<tr>
<th>Mission and Responsibilities</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mission</td>
<td>9</td>
</tr>
<tr>
<td>Legislative Authority</td>
<td>9</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>9</td>
</tr>
<tr>
<td>Responsibilities of the State TB Program</td>
<td>11</td>
</tr>
<tr>
<td>Responsibilities of the District TB Program</td>
<td>13</td>
</tr>
<tr>
<td>Responsibilities of the County TB Program</td>
<td>14</td>
</tr>
<tr>
<td>National TB Indicators</td>
<td>14</td>
</tr>
</tbody>
</table>
MISSION
The mission of the Georgia Tuberculosis (TB) program is to control transmission, prevent illness and ensure treatment of disease due to TB. This is accomplished by identifying and treating persons who have active TB disease, finding, screening and treating contacts, and screening high-risk populations.

The Georgia TB Program has the legal responsibility for all TB clients in Georgia regardless of who provides the direct services. TB services are available to all who fall within the service criteria without regard to the client’s ability to pay. Tuberculosis services in Georgia are provided on a cooperative basis by local county health departments, district health offices, the private medical sector, other public agencies and the Georgia Tuberculosis Program.

LEGISLATIVE AUTHORITY
Copies of the laws and regulations can be downloaded from these links:
Title 31-2A, 31-12-2, 31-12-4, and 31-14

Rules and Regulations: Department of Public Health, Tuberculosis Control, Chapter 511-2-3 http://rules.sos.state.ga.us/cgi-bin/page.cgi?g=Georgia_Department_of_Public_Health%2Findex.html&d=1

REPORTING REQUIREMENTS
In Georgia, all persons with active tuberculosis must be reported immediately to the local county health department.

Physicians, hospitals, laboratories and other health care providers are also required to report any of the following:
• Any child less than 5 years of age or younger with Latent TB Infection
• Any person diagnosed with TB disease
• Any person suspected to have TB disease
• Any person being treated with or prescribed two or more anti-tuberculosis drugs
  Any positive culture for Mycobacterium tuberculosis

HOW TO REPORT
• Report persons with active TB disease electronically through the State Electronic Notifiable Disease Surveillance System (SendSS)
• Complete a Notifiable Disease Report Form and mail in an envelope marked CONFIDENTIAL
• Call your local County Health Department
• If your County Health Department cannot be reached, call the Georgia Department of Public Health at 404657-2534.
RESPONSIBILITIES OF THE STATE TB PROGRAM STATE MEDICAL CONSULTANT

The State Medical Consultant responsibilities include:

- Providing medical consultation to district contract physicians, local health departments, and private physicians, other providers and agencies.
- Providing TB treatment recommendations upon request.
- Providing clinical updates to district contract TB physicians and district TB coordinators as needed.
- Reviewing all TB cases and suspects during state case/cohort reviews to ensure quality care and adequate/appropriate treatment regimens are delivered.
- Reviewing and approving all second-line TB medication requests.

EPIDEMIOLOGY

The State Epidemiology staff will:

- Collect, manage, analyze and interpret TB surveillance and genotyping data to describe tuberculosis morbidity and mortality trends, demographic characteristics and risk factors of TB cases, the incidence of TB among high-risk populations and assist in the development of program policies and procedures.
- Manage state genotype database, notify districts of genotype clusters in their districts, conduct genotype cluster investigations, and recommend measures to control TB transmission.
- Monitor resistance levels to anti-TB drugs.
- Evaluate the implementation of core TB program strategies and attainment of program outcome measures. Some outcome measures include completion of therapy among active TB cases, directly observed therapy, completed contact evaluations, and completion of treatment for latent TB infection among contacts.
- Conduct TB outbreak investigations, other epidemiologic studies and evaluation of special project interventions.
- Review surveillance data for completeness, accuracy and timeliness.
- Review secondary data sources (e.g., hospital discharge summaries, AIDS registries, laboratory reports) in order to detect failure to report TB cases.
- Produce the annual Georgia TB Report, annual progress reports, program management reports and other statistical data.

STATE TB PROGRAM STAFF

The State TB Program staff responsibilities include:

- Formulating and distributing state tuberculosis guidelines, procedures and protocols based on best practices.
• Consulting with district health departments, correctional facilities, hospitals, and all other health care providers regarding general concerns relating to tuberculosis management and/or specific tuberculosis cases.
• Providing social service consultation and assessment on TB patients as needed.
• Maintaining lists of current educational materials and information regarding proper management and treatment of tuberculosis and act as a resource to provide these materials and information as requested.
• Maintaining the Georgia Department of Public Health tuberculosis website with current and accurate information.
• Conduct trainings for district and local TB staff and maintain up-to-date training tool kits.
  □ Provide program evaluation, technical consultation and support. □ Lead state case/cohort reviews.
• Maintain budget and financial data of all state and federal funds.
• Manage grant deliverables.
• Establish, update and maintain charts for all tuberculosis suspects and tuberculosis cases. Maintain medical records on TB cases for at least twenty-one years. Information should include name, birth date, and county of residence, medications, drug susceptibility results, and record of disposition.
• Obtain documentation for out-of-state TB cases and/or contacts and provide information to requesting district/county health departments.
• Maintain the TB patient management module of the State Electronic Notifiable Disease Surveillance System (SendSS) and monitor the status of immigrants and refugees in the Electronic Disease Notification System (EDN). Provide consultation and technical support to end users on these systems.
• Monitor accuracy of data, establish files and internal databases, back up files, enter data and maintain tuberculosis documentation.
• Facilitate the process for court-ordered treatment/confine ment.
• Recertify covered entities for 340B TB drugs annually or as scheduled by the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs.

RESPONSIBILITIES OF THE DISTRICT TB PROGRAM DISTRICT HEALTH DIRECTOR
The District Health Director:
• Has the ultimate responsibility for ensuring appropriate TB management in their district. This includes implementing TB guidelines, policies, procedures, and protocols in county health departments within the district. Provide supervision and delegate activities to staff and may delegate certain medical acts such as tuberculin skin testing, venipuncture and sputum collection to trained unlicensed public health staff.
• Acts as mediator between health care providers, the local health department, the contract TB physician and the state office to facilitate best practices for TB programs in the district.
• Produces and delivers health order directives as first legal step to ensure compliance for evaluation and/or treatment of tuberculosis.
• Develops and maintains a working relationship with the county’s attorney, the sheriff’s office, hospitals and other community organizations in the district to facilitate access to
needed resources, assist with patient adherence issues, and/or court-ordered therapy or confinement.

**DISTRICT CONTRACT PHYSICIAN/CONSULTANT**

The responsibilities of the District Contract Physician/Consultant include:

- Providing for the overall medical management of clients in the county health department TB programs. The physician/consultant must provide recommendations for clients within the specified time frame after referred; TB suspect/case within 48 hours, close contact to TB cases/suspects and all children within 48 – 72 hours, all other clients within two weeks.
- Conducting and participating in case/cohort reviews regularly.
- Maintain knowledge of current recommendations regarding the clinical management of TB disease and latent TB infection.
- Consult with the State TB Medical Consultant regarding the treatment of multi-drug resistant tuberculosis (TB resistant to at least isoniazid and rifampin) before prescribing second-line drug regimens.
- Monitor the care and treatment of clients with TB disease and latent TB infection being followed by private physicians. Consult as needed with healthcare providers to ensure appropriate medical treatment. When contract physician is not available, provide contact information for a back-up physician for consultation.

**DISTRICT TB COORDINATORS**

The responsibilities of District TB Coordinators include:

- Providing oversight, consultation and assistance to county health departments.
- Providing consultation and assistance to other health care providers (e.g., hospitals, nursing homes, private physicians, correctional facilities, etc.) as needed.
- Collaborating with physicians, hospitals, substance abuse centers, correctional facilities and community organizations to promote best practices, foster continuity of care, and provide needed social services for TB clients.
- Facilitating hospitalization and/or discharge planning with social worker and/or infection control nurse. Becoming a state certified TB Trainer and conduct *TB Skin Test (TST) Certification and Update* courses, Contact Investigation/Directly Observed Therapy courses, TB Case Management courses and other educational activities for public health staff, correctional facilities and private sector providers within the district. Ensure TST certification is maintained by all public health staff who provide direct TB clinical services. Submit all rosters, evaluation summaries and registration forms to the State TB Program within two weeks of each class.
- Provide in-service training on tuberculosis to county health departments, local communities and other agencies.
- Serve as the point of contact for counties needing emergency and long-term housing services for infectious, homeless or non-adherent clients. Identify and establish partnerships with local resources to provide placement as needed.
• Monitor the care and case management of all TB clients to ensure outcomes are achieved according to established state indicators and time frames.
• Develop district policies, procedures and protocols to include an infection control plan for health departments under direction of the District Health Director.
• Promote and conduct regular case reviews with local staff and contract physician.
• Facilitate court-ordered TB treatment as needed.
• Attend and participate in conference calls, in-person meetings, state sponsored meetings and trainings in order to disseminate the information obtained to the county health department TB staff. Assign a representative to participate in these activities if the coordinator is unable to participate. Promote and conduct program evaluation activities.
• Perform chart audits and send summaries of findings to the State TB Office.
• Promote and attend state case/cohort reviews.
• Maintain a current listing of all Public Health TB facilities that receive TB drugs through the 340B TB Drug Pricing Program. Include the National Provider Identifier (NPI) numbers, the physical address of the facility and information regarding the contact person (e.g., name, title, phone/fax numbers, email address, etc.) who will verify 340B TB status during the State TB Office recertification period, unless a District pharmacist or pharmacy technician is already maintaining this listing. Maintain records and ensure proper documentation of all clients receiving 340B TB drugs.
• Coordinate the submission of patient data to the state office. The state patient records should mirror the district patient records.
• District Coordinators are to submit, to the State TB Program the following information on all TB cases and suspects including but not limited to:
  o Consent and treatment plans
  o Physicians’ notes
  o Progress reports
  o Admission and discharge summaries
  o Bacteriology results and laboratory reports
  o Radiology results
  o Any additional supporting documentation
• District coordinators should refer to the case management timeline for a complete list of time-sensitive case management documents to report to the state office.
• Submit Grant-in-Aid information to the State TB Program regularly. Grant-in-Aid quarterly reports are due on the 15th of the month following the end of each quarter. Grant-in-Aid annual report is due by July 15th of every year.
RESPONSIBILITY OF THE COUNTY TB PROGRAM

County Health Departments are responsible for the medical supervision and case management of all known TB cases and suspects in order to prevent the spread of tuberculosis within their county.

TB NURSE

The TB Nurse’s responsibilities include:

• Collaborating with local physicians, local hospitals, substance abuse centers, correctional facilities and community organizations to promote TB education, best practices, foster continuity of care, and provide needed social services for TB clients.
• Facilitating hospitalization and/or discharge planning with social worker and/or infection control nurse.
• Provides tuberculin skin testing as requested.
• Collaborates with community organizations and facilities to perform targeted high risk TB screening and education about TB.
• Ensures submissions of all isolates from local hospitals and laboratories to state laboratory for genotyping.
• Upon notification of a TB case/suspect, performs a home visit within 24 – 48 hours to assess the home environment for home isolation. If the patient is hospitalized, the home visit may be done within 24- 48 hours after discharge. Legal agreements and consents should be signed at this time.
• Provides case management and follow-up of all known TB clients (cases, suspects, contacts, LTBI) to ensure timely and appropriate treatment.
  o Appropriate treatment on the recommended four drug therapy should be initiated and treatment completion obtained be within 12 months, unless medically indicated otherwise.
  o TB clients will be assessed for adverse reactions to medications at every encounter. o Clinic visit, clinical status, and adherence shall be monitored and documented monthly.
  o Directly observed therapy (DOT) is the standard of care for all TB cases, children under 4 years of age and younger with active TB disease or LTBI, and for all HIV-infected persons with active TB disease or LTBI.
  o Documentation of the conversion of positive cultures to negative. o Drug susceptibilities will be completed on all initial specimens.
• Cooperates with and assists private physicians treating tuberculosis clients. Obtains information from physicians assuring the private provider completes the Initial Report on Clients with TB (form 3141) and Follow-up Report on Clients (form 3142) monthly.
• Facilitates the enforcement, when necessary of tuberculosis laws and regulations to protect the health of the public.
• Perform thorough contact investigations to elicit and evaluate identified contacts. Infected contacts should be started on appropriate therapy with completion of treatment within 12 months.
• Provides documentation for and participates in local, district and state case reviews, cohort reviews, chart audits and other program evaluation activities.
• Receive reports of TB suspects/cases from other health care providers and promptly submit these reports (physicians’ notes, progress notes, admission and discharge notes and bacteriology and radiology results) to the district TB Coordinator.

COMMUNICABLE DISEASE SPECIALIST (CDS)/OUTREACH WORKER (ORW) (*If the county does not have CDS/ORWs, the TB Nurse is responsible for these duties*)

CDS/ORW is responsible for the following duties:
• Assist with contact investigations for cases and suspects to elicit and evaluate identified contacts.
  Provide tuberculin skin testing, venipuncture and sputum collection if properly trained and these acts are delegated by the District Health Director.
• Provide DOT. TB clients will be assessed for adverse reactions to medications at every encounter. In the event of an adverse reaction, medication should be discontinued and the TB Nurse contacted immediately. Follow-up with and locate TB clients who miss appointments.
• Coordinate transportation of TB clients for clinic appointments.
• Educate communities, clients and families about tuberculosis.
• Provide reports to TB nurse and/or the district TB coordinator as requested.

NATIONAL TB INDICATORS
For tuberculosis (TB) programs, quality of care is measured by means of objectives and standards. Such objectives and standards are used as yardsticks to direct the program and measure its success. Objectives reflect outcomes or results and program desires. Programs require objectives to define expected outcomes and results for case management activities. Standards are an accepted set of conditions or behaviors that define what is expected and acceptable regarding job duties, performance, and provision of services. The TB control program works to achieve objectives through a series of standards. National TB indicators and State targets can be found in Appendix A.
Medical Records and Surveillance

Table of Contents

| Medical Records and Surveillance | 15 |
MEDICAL RECORDS AND SURVEILLANCE
All tuberculosis records are confidential. Their release to health and non-health agencies (excluding agencies within DPH) and Quality Service Agreements should be made only with a signed authorization to release information. Health Insurance Portability and Accountability Act (HIPAA) guidelines must be followed. Public Health does have some exceptions. See letter from Commissioner of Public Health on following page. Additional information about HIPAA is available on the DPH website: http://dph.georgia.gov/notice-privacy-policies.

The district TB coordinators are to coordinate the submission of patient data to the state office. The state patient records should mirror the district patient records.

RETENTION OF MEDICAL RECORDS
The Georgia Archives maintains the record retention timelines and is located at http://www.georgiaarchives.org/records/retention_schedules
### Table: Record Title, Description, Retention

<table>
<thead>
<tr>
<th>Record Title</th>
<th>Description</th>
<th>Retention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases/Treatment</td>
<td>All documents relating to health services provided to tuberculosis patients; &quot;cases&quot; includes those clients with active TB infection and/or with latent TB infection (LTBI) and an abnormal chest x-ray</td>
<td>21 years from the date of the last service</td>
</tr>
<tr>
<td>Tuberculosis Records (Negative x-rays)</td>
<td></td>
<td>10 years from end of calendar year in which x-ray was taken</td>
</tr>
<tr>
<td>Tuberculosis Records (Positive x-rays)</td>
<td></td>
<td>10 years from end of calendar year in which x-ray was taken</td>
</tr>
<tr>
<td>Tuberculosis Records (Prophylaxis/Prevention)</td>
<td>All documents relating to health services provided to tuberculosis clients; &quot;prophylaxis&quot; includes those clients with LTBI and a normal chest x-ray</td>
<td>21 years from date of last service</td>
</tr>
</tbody>
</table>

### TB SURVEILLANCE

**STATE ELECTRONIC NOTIFICATION DISEASE SURVEILLANCE SYSTEM (SendSS)**

Approved users of the TB module in the State Electronic Notification Disease Surveillance System (SendSS) can report TB cases, TB suspects, LTBI in children younger than 5 years old, and contacts of TB cases, electronically at [http://sendss.state.ga.us](http://sendss.state.ga.us)

Update the case verification status of all TB suspects in SendSS as a verified TB case or not a TB case within 90 days from date of report.

**REPORTING AND COUNTING CASES OF M. TUBERCULOSIS**

The district TB coordinator or designee shall report new suspects/cases of tuberculosis within 24 hours of notification to the state TB Program office using the TB patient management module in SendSS. The state TB program reviews each TB case to ensure that it meets CDC’s surveillance case definition criteria. All cases that meet the surveillance definition of a verified TB case and cases whose TB diagnosis are certified by a licensed health provider are included in Georgia’s annual TB morbidity count. Timely reporting of information is imperative to ensure that all verified cases are counted in the year the patient’s diagnosis was verified.

Information concerning TB/HIV co-infected patients, MDR cases, airline flight exposures, clusters of TB cases, children suspected of, or diagnosed with TB, or any instance that might precipitate media attention, is to be immediately reported to the district TB Coordinator who will in turn, report it to the state TB program office.
CRITERIA FOR TB SUSPECT

TB suspects are persons for whom there is a high index of suspicion for active TB (e.g., a known contact to an active TB case or a person with signs or symptoms consistent with TB) who is being evaluated for TB disease. A TB suspect may be referred to as Class V TB. Any pediatric TB suspect under 5 years of age should be IMMEDIATELY reported to the State Medical Consultant for evaluation.

The TB suspect will have a prescription for two or more TB drugs and one or more of the following:

- Signs/symptoms of tuberculosis
- Positive AFB smear
- Abnormal chest x-ray
- History of exposure to tuberculosis
- Initial sputum reports, microbiology reports, prescriptions, chest x-ray reports and other provider notes are reviewed by the state medical consultant. If the client meets the above criteria, they will be placed on the State TB Program’s active suspect list. TB suspects from districts with contract physicians are placed on the list based on recommendations from clinic notes. State TB program staff enter refugees and immigrants with a Class B1 or B2 (non-LTBI) status as TB suspects in SendSS and county health departments should complete their evaluation within 90 days of arrival in Georgia to rule out TB.

CASE DEFINITIONS

- **Laboratory confirmed case**: Isolation of *M. tuberculosis* complex from clinical specimen by culture, or demonstration of *M. tuberculosis* from a clinical specimen by nucleic acid amplification test.
- **Clinical case**: In the absence of a laboratory confirmation of *M. tuberculosis*, a person must meet all of the following criteria to be considered a clinical case of tuberculosis:
  - Positive tuberculin skin test or IGRA
  - Signs and symptoms compatible with TB (e.g., abnormal chest x-ray, abnormal chest CT scan, or clinical evidence of current disease such as fever, night sweats, cough, weight loss, hemoptysis)
  - Receiving treatment with two or more anti-tuberculosis medications.
- **Provider Diagnosis**: If a case does not meet the laboratory or clinical definition, the case may be counted as a verified case of TB by provider diagnosis if clinical evidence of TB is present and a client shows clinical improvement with TB medications.
- **Recurrent TB cases**: New record in SendSS should be created for all recurrent TB cases, whether the recurrent case occurred 12 months before or after treatment completion or closure from supervision by a county health department. However, a case should not be counted twice within a 12-month period. An active TB case diagnosed in a previously verified TB case within 12 months after completion of therapy or after being closed to supervision is not counted as a new case for surveillance purposes. Active
TB diagnosed in a previously verified TB case should be counted as a new case if more than 12 months has elapsed since the patient completed treatment or was closed to supervision by the county health department.

- **Non-tuberculous Mycobacterial Disease (NTM):** person who has disease attributed to or caused by NTM only; should not be counted or reported as a case of tuberculosis. A person who has tuberculosis disease diagnosed with both *M. tuberculosis* and other NTM shall be counted and reported as a case of tuberculosis.

- **Tuberculosis case diagnosed after death:** Tuberculosis cases reported to health departments should be reported and counted as a case if evidence of current disease was present at time of death.

### REPORTING LATENT TB INFECTION (LTBI)

Any pediatric suspect for LTBI under 5 years of age should be **IMMEDIATELY** reported to the State Medical Consultant for evaluation as well. The finding of latent TB infection (LTBI) in a child less than five years of age is a reportable disease. When LTBI in a child less than five years of age is reported, public health personnel will initiate a contact investigation to identify the source of the infection, recommend treatment for latent TB infection, follow-up the child to ensure completion of LTBI treatment by directly observed therapy, and monitor for development of active disease. Early identification of TB infection and treatment in children can prevent progression to active disease. The contact investigation of a young child with LTBI may identify a previously undiagnosed and untreated case of active TB.

### SendSS REPORTING REQUIREMENTS AND TIMELINES TB CASES AND TB SUSPECTS:

- Patient’s basic demographic information (name, birth date, age, sex, race/ethnicity, address) will be entered in the Patient tab of the SendSS within 24 hours after public health (county, district or state level) is notified of a TB suspect/case started on treatment for active TB. Other data in the Patient tab that are not available at time of notification will be updated in SendSS within 24–72 hours after the missing data are received by the end user responsible for data entry in SendSS.

- Data for the Assessment tab in SendSS and the patient’s initial drug regimen for the Medication tab in SendSS will be entered within 24 hours after a patient is diagnosed as a verified case of TB by a county health department or within 24 hours after information of the patient’s TB diagnosis is received by the end user responsible for data entry in SendSS. Other data in the Assessment or Medication tab that are not available at time of diagnosis will be updated in SendSS within 24–72 hours after the missing data are received.

- The Report of Verified Case of TB (RVCT) form should be generated (by clicking the Generate button) when data for the Patient, Assessment, and initial drug regimen in the Medication tab have been entered in SendSS.
• Initial TST/IGRA, chest radiographs, chest CT scans, bacteriology and drug susceptibility test results will be entered in SendSS within 24 hours after results are received. After entering the initial drug susceptibility test results, the end user should click the Generate button in SendSS to generate the RVCT Follow-up 1 form.

• Information on whether the patient moved while on TB treatment and the reason for stopping TB treatment (found in the Medication tab) and DOT information (found in the DOT tab) will be entered in SendSS within 24–72 hours after the client has completed therapy or within 24–72 hours after the county health department has determined that the patient cannot complete therapy because patient died, is lost to follow-up or has moved, etc. After entering this information, the end user should click the Generate button in SendSS to generate the RVCT Follow-up 2 form.

CONTACT INVESTIGATION AND LTBI TREATMENT:
• Any child under 5 years of age being evaluated in a contact investigation should be reported to the State Medical Consultant and delegating/contract physician for evaluation.

• Contact’s basic demographic information will be entered in SendSS within 72 hours after contacts are identified or 72 hours after the data are received by the end user responsible for data entry of contacts in SendSS.

• Results of contact evaluations will be updated within 24 hours after receiving the first TST/IGRA result, within 24 hours after receiving the follow-up TST/IGRA results, and within 24 hours after the initial chest radiograph reading is obtained.

• The start date for LTBI treatment will be entered within 24 hours after contacts start LTBI therapy or within 24 hours after receipt of this information.

• The date LTBI treatment was stopped will be entered within 24–72 hours after contact stops treatment or within 24-72 hours after receipt of this information.

OTHER TB PROGRAM REPORTING REQUIREMENTS AND TIMELINES
• District TB Coordinators for Health Districts receiving Grant-in-Aid (GIA) allocations from the Georgia TB Program should submit the GIA Quarterly Report to the state TB Office by the 15th of October, January, April, and July.

• The GIA Annual Report is to be completed and submitted to the state TB Office by July 15 each year.

• GIA District Education Reports are to be submitted quarterly.

• Copies of all current contracts and memorandums of understanding/agreement (e.g., medical consultative, radiology, laboratory, etc.) funded with GIA dollars should be on file at the state TB Office.

• Submit all TB program reports to the state TB program point of contact.

INTERJURISDICTIONAL TRANSFERS
The district office should submit an Interjurisdictional Notification form to the state TB program’s point of contact when a TB patient who is still on TB treatment moves to another district or state. If the TB patient moves to another country while still on treatment, the district...
The state office should submit an International TB Notification form to the state TB program’s point of contact. The state office will send the Interjurisdictional or International TB Notification form to the TB program of the patient’s new state or country of residence, respectively. The state office will also refer patients who move to Mexico to CureTB and refer patients who move to countries other than Mexico to TBNet, for treatment follow-up. The state office is responsible for following up treatment completion data from the state TB program of the patient’s new state of residence and entering the data in SendSS. The state office will inform CDC’s Atlanta Quarantine Station of patients who have moved to another country to request their assistance to follow-up treatment abroad and/or request CDC to place the patient on a Do Not Board list.


When patients move to another district, state or country, the District TB coordinator or their designee should document the move in SendSS by the following procedure;
  a. Enter the patient’s new address in the Patient Information Tab in SendSS
  b. Open the Meds tab and select “Yes” where it asks “Did the patient move during TB therapy?”
  c. Enter the new county, state, or country where the patient has moved

For foreign-born TB patients who have immigrated to the U.S. in the last five years, District TB coordinators and county health department nurses are encouraged to identify a patient’s family member or point of contact from the patient’s country of origin, to avoid the difficulty of locating patients that move back to their country of origin without a forwarding address.

**DISTRICT- TO-DISTRICT TRANSFER**

When a TB patient plans to move (or has moved) from one District to another, District TB Coordinators or their designee should complete an Interjurisdictional Notification form (Appendix C) and fax it to the Medical Records Operations Analyst at the state TB program office, inform the District TB Coordinator of the District the patient is moving to about the transfer, and document the transfer in SendSS.

**OUT-OF-STATE TRANSFER**

When a TB patient plans to move (or has moved) from Georgia to another state, District TB Coordinators or their designee should complete an Interjurisdictional Notification form (Appendix C) and fax it to the Medical Records Operations Analyst at the state office who will in turn notify the TB control program of the patient’s new state of residence. The state office will fax all pertinent medical documents to that state and respond to any additional request for information. District offices or county health departments in Georgia should
communicate directly with the county health department in the other state to provide detailed information on TB treatment, laboratory reports and clinical notes, to ensure continuity of care. District TB Coordinators or their designee should document the transfer in SendSS.

OUT-OF-THE-U.S. TRANSFERS
When a TB patient plans to move (or has moved) to another country while still on treatment, or has moved before TB diagnosis was confirmed, or before TB treatment was started, District TB Coordinators should call or email the TB Program Director directly, or in the Director’s absence, the TB epidemiology unit. Patient can travel internationally if they have three consecutively negative sputum AFB smears, have completed at least two weeks of appropriate TB medications, and do not have MDRTB/XDR-TB. If these criteria are not met, the TB Program Director or TB epidemiologist will contact CDC’s Division of Global Migration and Quarantine (DGMQ) to discuss whether the patient should be placed on a federal Do Not Board list or other means to restrict travel. For patients who move to Mexico, Districts should fill out an International TB notification form (Appendix D) and fax it to the state TB program Medical Records Operations Analyst who will contact CureTB for follow-up. For countries other than Mexico, Districts should fill out both the International TB notification form (Appendix D) and TBNe referral forms (Appendix E) and fax them to the state TB program Medical Records Operations Analyst who will contact TBNet for follow-up. The Immigration and Customs Enforcement (ICE) agency is responsible for referring undocumented immigrants on TB treatment under ICE custody to CureTB or TBNet on deportation.

REFUGEE OR IMMIGRANT CLASS B1 OR B2
CDC Electronic Disease Notification (EDN) System notifies the Georgia State TB Program of aliens arriving in Georgia with a Class B1/B2 TB condition which is assessed during their screening abroad by U.S. Department of State panel physicians. Newly arrived immigrants, refugees, parolees¹ and asylees² with a B1/B2 TB classification should receive thorough and timely TB evaluations to ensure prompt detection of TB disease. Appropriate treatment should be completed to prevent future cases.

CLASS B CONDITION
A classification based on clinical evaluations performed abroad indicating findings consistent with a specific disease:

¹ Parolees: A parolee is an alien, appearing to be inadmissible to the inspecting officer, allowed into the United States for urgent humanitarian reasons or when that alien’s entry is determined to be for significant public benefit. Parole does not constitute a formal admission to the United States and confers temporary status only, requiring parolees to leave when the conditions supporting their parole cease to exist.

² Asylee: An alien in the United States or at a port of entry who is found to be unable or unwilling to return to his or her country of nationality, or to seek the protection of that country because of persecution or a well-founded fear of persecution. Persecution or the fear thereof must be based on the alien’s race, religion, nationality, membership in a particular social group, or political opinion. For persons with no nationality, the country of nationality is considered to be the country in which the alien last habitually resided. Asylees are eligible to adjust to lawful permanent resident status after one year of continuous presence in the United States. These immigrants are limited to 10,000 adjustments per fiscal year.
B-1 Tuberculosis, clinically active, not infectious
B-2 Tuberculosis, not clinically active, not infectious
   B-2 Latent TB Infection

INSTRUCTIONS TO COUNTY HEALTH DEPARTMENTS: B1/B2 NOTIFICATIONS
1. Upon receipt of the Class B1/B2 notification from the state TB program, contact the refugee and immigrant immediately and instruct him/her to report to the county health department for a TB skin test and clinical evaluation.
2. Assess the alien for TB signs and symptoms.
3. Administer tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA)
4. Read TST after 48-72 hours
5. Order chest radiograph if TST is greater than or equal to 10 mm or the IGRA is positive
6. After TB evaluation is completed, treat appropriately if diagnosed with LTBI or active TB
7. Complete TB Follow-up Worksheet when evaluation is completed and fax the worksheet to District TB Coordinator who will submit the worksheet to the Georgia TB Program Office
8. If person was started on LTBI treatment, update the section on LTBI treatment on the same TB Followup Worksheet when the person completes LTBI treatment or stops treatment, and submit the worksheet to the District TB Coordinator who will submit the updated worksheet to the Georgia TB Program

B1/B2 SendSS PROCESSING PROCEDURES FOR DISTRICT TB COORDINATORS
Aliens with a B1 or B2 classification should be located and TB evaluation initiated within 30 days of arrival.

State TB Program staff enter all B1 and B2 (non-LTBI) aliens into SendSS as TB suspects.

Some B2 aliens are classified as having LTBI (depending on their country of origin) and therefore are not entered in SendSS as TB suspects, but should still be evaluated by the county health department.

Alien TB suspect status should be changed in SendSS within 90 days of date reported.

SendSS DATA ENTRY FOR CLASS B1/B2
The case verification status of B1/B2 TB suspects should be updated in SendSS when data on their final diagnosis become available. To update the case verification status in SendSS:

• Open the Diagnosis Tab
• Enter correct diagnosis from the Case Verification Status drop down box
• Click on the Add button
• Open the RVCT tab
• Click on the Generate button
TB ALIEN FOLLOW-UP WORKSHEET COMPLETION
State TB program staff enters the TB Follow-up Worksheet data in CDC’s Electronic Disease Notification (EDN) software. DeKalb County TB Program staff enters their own data directly in EDN.

The highlighted fields in the follow-up worksheet are mandatory fields needed to successfully upload the data in EDN. Submit the completed worksheet to state TB Medical Records with attention to Medical Records supervisor. Resubmit the completed worksheet when the alien completes therapy, if applicable.

ELECTRONIC DISEASE NOTIFICATION SYSTEM QUALITY IMPROVEMENT PROCEDURES
A monthly report of un-submitted TB Alien Follow-up Worksheets and missing worksheet data is distributed by TB Epidemiology staff to District TB Coordinators.

A quarterly report of unclassified TB suspects greater than or equal to 90 days that include B1/B2 TB suspects is sent out to District TB Coordinators by Medical Records.
Overview of Tuberculosis Services
# Table of Contents

<table>
<thead>
<tr>
<th>Overview of Tuberculosis Services</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Care</td>
<td>26</td>
</tr>
<tr>
<td>Office Visits/Home Visits</td>
<td>27</td>
</tr>
<tr>
<td>Screening for TB</td>
<td>28</td>
</tr>
<tr>
<td>Tuberculin Skin Testing by Unlicensed Personnel</td>
<td>28</td>
</tr>
<tr>
<td>Sample Medical Delegation</td>
<td>30</td>
</tr>
<tr>
<td>Administration, Measurement, Interpretation of TST</td>
<td>31</td>
</tr>
<tr>
<td>Chest X-rays and other Imaging or Procedures</td>
<td>34</td>
</tr>
<tr>
<td>Laboratory testing</td>
<td>34</td>
</tr>
<tr>
<td>Incentives and Enablers</td>
<td>35</td>
</tr>
<tr>
<td>Medical Interpretation Services</td>
<td>35</td>
</tr>
<tr>
<td>Hospitalization</td>
<td>35</td>
</tr>
<tr>
<td>Housing Homeless Clients (see also Appendix J)</td>
<td>35</td>
</tr>
<tr>
<td>State TB Social Services</td>
<td>36</td>
</tr>
<tr>
<td>Program Evaluation</td>
<td>36</td>
</tr>
</tbody>
</table>
TUBERCULOSIS SERVICES

Active tuberculosis is a public health threat. Latent TB infection (LTBI) is a reservoir for future active TB cases. TB prevention and control programs need to address both active TB and LTBI to protect the health of the community. TB services must be rendered at the time of client presentation regardless of the client’s ability to pay.

Medicaid and third party payers may be billed for all TB services but should not bill for TB medicines or the PPD solution which are purchased by the state at a discount from the federal 340B TB Drug Pricing Program and provided to all District TB programs. TB services can be billed according to the county sliding fee scale, however, treatment may not be refused if the patient is unable to pay. All out of pocket payments for TB suspects, confirmed TB cases, converters, contacts to TB suspects or cases, and children under five years of age with LTBI are to slide to zero dollars ($0). For clients who fall outside these parameters (screening for employment, school, etc.), if the client does not have the money on the day of service, the client can be billed for service.

It may be possible for contracts or MOUs to be executed with local facilities that frequently send employees or students to the health department for TB screening as a way to generate funds to cover these services.

Ideally, clients from high risk populations should not incur or only incur minimal charges from a county health department TB clinic because the benefit of providing TB services to them to prevent a future case far outweighs the cost of the service. An example would be a client who is enrolling in a substance abuse program and needs a TST or chest x-ray in order to be accepted to the program.

MEDICAL CARE

Each health district in Georgia has a District Health Director and a contract with a practicing physician for oversight in providing medical care to TB clients. The district varies widely in how the oversight is implemented. Some districts have the physician see every TB client, while in others; the physicians never see the clients but review the charts on a regular basis and provide consultation to the nurses. If the direct care is provided by a private physician, the county TB nurse is to obtain monthly reports to maintain oversight.

The nurse protocols describe the management of uncomplicated pulmonary TB and LTBI. Anything that falls outside of the protocols is to be managed by the contract physician and the nurse will work under those orders and will not be working under protocol. The district contract physician will write the order and sign off on the chart. The district pharmacy or contract pharmacy will dispense the medication. If a patient is being co-managed by a private physician in the community, the district contract physician will have to collaborate for care and write the orders for any health department involvement. This is especially important concerning medications. Public health nurses do not work under community physician’s orders. They can only work under the Georgia Standard Nursing Protocol or the district contract physician’s orders. A registered professional nurse or physician’s assistant is only authorized to dispense
pursuant to an order issued in conformity with a nurse protocol or job description, not a prescription or an order written on a chart or phoned in by a physician. For more information, please see the “Drug Dispensing Procedure” in the Nurse Protocols for Registered Professional Nurses in Public Health, current edition. Located on the web pages at https://dph.georgia.gov/nurse-protocols

Diagnostics, treatment, clinical care, case management and infection control guidelines and standards should be available for reference by each TB staff member. Instead of repeating these guidelines in this document, please refer to the following sources:


CDC. Core Curriculum on Tuberculosis: What the Clinician Should Know, 2011. Each district health office was sent a copy in 2012. It can also be ordered from CDC or downloaded at http://www.cdc.gov/tb/education/corecurr/

ATS, CDC, IDSA. “Treatment of Tuberculosis” (MMWR 2003; 52[No. RR-11]). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf

CDC, NTCA. “Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC” (MMWR 2005; 54 [No. RR-15]). Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf


ATS, CDC, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at: http://www.thoracic.org/statements/resources/archive/tbadult1-20.pdf

OFFICE VISITS
All legal forms are to be completed at the first office visit. This includes consent for treatment, treatment plan, medication information, Directly Observed Therapy (DOT) agreement and/or refusal of care.

Gather as much locating information as possible. Some examples would be emergency contact information, email address, cell phone number, screen name, face book or other social network. Upon evaluation of non-US born, "recent" (past 5 years) immigrants, please identify a family member or another close contact in their home of origin, as an emergency contact. This will assist in locating patients that are "lost" while infectious.

All persons on treatment are expected to have a clinic visit at least once a month. More frequent clinical visits may be needed depending on the complexity of the case. See Section 7: Nursing Evaluation and Monitoring for specific information.

HOME VISITS
All active TB cases are expected to have at least one home visit to evaluate the living situation of the client to determine the suitability of home isolation, the presence of children and to educate and build rapport with the client and the client’s family.

SCREENING FOR TB
When a client has a tuberculin skin test (TST) placed at an HIV clinic or a correctional facility and comes to the health department for it to be read, it would be advisable to read the TST without any barriers, i.e., not to bill for the TST reading, as HIV and TB programs often collaborate in the case management of clients. Other facilities may place a TST and tell the client to go to the health department for it to be read. In these cases, collaboration with the facilities would be encouraged to assure proper placement and a possible MOU might be feasible.

All health departments have the ability to administer and read TSTs. Persons who perform and/or interpret this test should have obtained initial TST certification when newly hired and have it maintained by completing the recertification requirements every two years.

Interferon Gamma Release Assay (IGRA) is available through contracts with laboratories as well as the GA Public Health Lab. Testing through GA Public Health Lab is prioritized for
targeted areas with large numbers of foreign-born clients or homeless persons, and for TB outbreak investigations.

**TUBERCULIN SKIN TESTING BY UNLICENSED PUBLIC HEALTH PERSONNEL**

Georgia law permits physicians to delegate the administration of TSTs to unlicensed medical assistants (O.C.G.A. 43-34-44) that they supervise. The law does not require on-site supervision by the delegating physician at all times. District Health Directors (DHD) may delegate the administration and/or reading of tuberculin skin tests (TST) to unlicensed public health personnel when all of the following criteria have been met:

1. The DHD has reviewed and approved the standard training curriculum for the *TB Update and Skin Test Certification* course.
2. The DHD has a written delegation signed by the DHD and the unlicensed public health personnel outlining the specific parameters of the delegation.
3. The DHD has a system in place in which the skill competency of the individual can be validated on an annual basis.
4. The individual has obtained TST certification from the Georgia Tuberculosis Program and maintains certification by timely renewal every two years.

The DHD can set up any system to validate the skill competency of the individual in any way that is feasible for the district. It might be feasible to have a skill competency day at the district health office once a year at which time all unlicensed public health staff could be observed at one time. In other districts, it might be reasonable for an individual in the field to be observed while performing and reading the test. TST-certified nurse trainers can supervise the administration and reading of the TSTs by unlicensed personnel, consistent with usual practice in county health departments, if it is difficult or impractical for DHDs to do so. While unlicensed public health personnel may administer and/or read a TST, they must refer any induration to a licensed medical professional for interpretation of the induration.

The current standard training curriculum for the *TB Update and Skin Test Certification* course is available to healthcare workers in both the public and private sectors. The calendar of training dates along with the registration forms can be accessed on the State TB training website: [www.dph.georgia.gov/tb-educational-and-trainingopportunities-georgia](http://www.dph.georgia.gov/tb-educational-and-trainingopportunities-georgia) or by calling 404-657-2634. For unlicensed public health personnel, the process includes a full day course which covers didactics regarding tuberculosis and testing process, a video demonstrating the correct procedure and a practicum where the participant must provide a return demonstration of the proper procedure. After the class, the participant is required to perform 10 satisfactory administrations and 10 satisfactory readings under supervision in his/her clinic setting. Validation of completion of all steps must be sent to the Georgia Tuberculosis Program prior to a certificate being issued. The Georgia Tuberculosis Program issues a paper certificate once all components of the TST certification process are complete. Each individual may be required to submit a copy of his/her current certification to the DHD at the time of signing the delegation document every 2 years.
SAMPLE MEDICAL DELEGATION

The signatures below indicate a mutual agreement between the delegating physician(s) and the unlicensed public health (PH) personnel who are authorized to perform administration of tuberculin skin test (TST) and reading (measurement) of tuberculin test for the purpose of screening for active TB and latent TB infection.

All public health personnel whose signatures appear on this page:

1. Have been adequately trained to perform the delegated act of administering and/or reading tuberculin skin tests

2. Have obtained certification in TST reading and administration from a certified instructor for the Tuberculosis Program, Georgia Department of Public Health AND maintain and renew their TST administration and reading certification every two years, AND, and such training is documented by a state certification form in each person’s training file.

3. Have immediate access to a licensed medical professional for consultation and for referral of any induration read for interpretation.

4. Participate in an annual skill competency event that is observed by the delegating physician.

5. Have been given an opportunity to have questions answered.

__________________________________________________________________________________________
Signature of Delegating Physician                       Date

__________________________________________________________________________________________
Signature of PH Personnel                               Date

__________________________________________________________________________________________
Signature of PH Personnel                               Date

__________________________________________________________________________________________
Signature of PH Personnel                               Date

__________________________________________________________________________________________
Signature of PH Personnel                               Date
ADMINISTRATION OF MANTOUX TUBERCULIN SKIN TEST (TST)

**Purpose of test:** To determine whether a person has become infected with the TB germ. This test cannot determine whether the person has active TB disease or Latent TB infection.

**Supplies:** Tuberculin syringe (27 gauge needle, ½” or 3/8” needle length), 5 Tuberculin unit strength PPD solution, alcohol pads, cotton ball, gloves. *Note: gloves may or may not be worn according to facility policy*  

**Procedure:**
1. Draw up 0.1 ml of PPD solution into tuberculin syringe
2. Expel excess air bubbles
3. Clean area of forearm (dorsal or volar surface) with alcohol pad. Let dry.
4. With bevel of needle facing upwards, inject the solution intradermally (just under the 1st layer of skin). A tense wheal (bubble) approximately 6 - 10 mm should be visible at the injection site.
5. Withdraw the needle and dispose into SHARPS container.
6. Patient (or nurse if wearing gloves) may “dab” any spot of blood appearing at the site with a cotton ball. Do not place a Band-Aid on the site.
7. Instruct patient to return in 48 – 72 hours for reading.

MEASUREMENT OF THE MANTOUX TUBERCULIN SKIN TEST (TST)

**Purpose:** To determine a reaction to the tuberculin solution and measure the size of the induration (raised hardened area)

**Procedure:**
1. Test is read by a trained healthcare worker 48 – 72 hours after the TST Placement. If a patient fails to show up for the scheduled reading, a positive reaction may still be
measurable up to 1 week after testing. However, if a patient fails to return within 72 hours and shows no induration, the TST should be repeated.

2. The area of induration (palpable raised hardened area) around the site of injection is the reaction to tuberculin that is to be measured. Erythema (redness) and soft tissue swelling are not to be measured.

3. Palpate the injection site for induration. The borders of the induration can be marked with a ball point pen or with the fingernail.

4. Using either a flexible ruler or caliper ruler with millimeter markings, measure across the forearm (perpendicular to the long axis or transversely). All reactions should be recorded in millimeters (e.g. 12 mm). If no induration is found, “0 mm” should be recorded.

---

**INTERPRETATION OF THE MANTOUX TUBERCULIN SKIN TEST (TST)**

**Purpose:** Skin test interpretation depends on the measurement of the induration and the person’s risk of being infected with TB and/or progression to disease if infected.

**Procedure:**

1. Match the measurement of the induration with the person’s risk factors from the chart below.

2. Record the size of the induration in millimeters (mm)
   - Do not write “negative”, but record as 00mm, 7mm.
   - Do not write “positive”, but write as a number such as 10mm, 12mm.


<table>
<thead>
<tr>
<th>Induration of 5mm or greater is considered positive in:</th>
<th>Induration of 10mm or greater is considered positive in:</th>
<th>Induration of 15mm or greater is considered positive in:</th>
</tr>
</thead>
</table>

3 For persons who are otherwise at low risk for TB and who are tested at the start of employment, a reaction of >15 mm is considered positive.
- Human immunodeficiency virus (HIV) positive persons
- Recent contacts of TB case patients
- Persons with fibrotic changes on chest radiograph consistent with prior TB
- Patients with organ transplants and other immunosuppressed patients (Receiving the equivalent of 15 mg/d or greater of prednisone for 1 month or more. Risk of TB in patients with corticosteroids increases with higher dose and longer duration.)

- Recent immigrants (i.e., within the last 5 years) from high-prevalence countries
- Injection drug users
- Residents and employees\(^3\) of the following high-risk congregate settings: prisons and jails, nursing homes and other long-term facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome (AIDS), and homeless shelters
- Mycobacteriology laboratory personnel
- Persons with the following clinical conditions that place them at high risk: silicosis, diabetes mellitus, chronic renal failure, some hematologic disorders (e.g., leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head, neck, or lung), weight loss of \(\geq 10\%\) of ideal body weight, gastrectomy, and jejunooileal bypass
- Children less than 5 years of age, or infants, children and adolescents exposed to adults at high-risk

### CHEST X-RAYS
Health districts and/or county health departments may have on-site radiology services or the services may be provided through contracts with local facilities.

Chest x-rays should be performed on the following persons:

- Person with signs and/or symptoms of active TB regardless of TST or IGRA result
- Contacts with a positive reaction to a TST (greater than or equal to 5mm induration) or IGRA
- Contacts to cases that have a previous positive TST
- Contacts with HIV infection
- Contacts for whom window period treatment is being considered
- Persons with documented evidence of converting from a negative TST to a positive TST within the past 2 years
• Persons on LTBI treatment that develop signs and/or symptoms of active TB
• Children under five years of age with a positive TST referred for a chest x-ray to diagnose LTBI or rule out TB

Chest x-rays for follow-up of an initial positive skin test as a result of routine testing or in conjunction with employment, school, etc. may be provided through memorandums of agreement or at a nominal cost according to local health department policies. All fees should be based on the county sliding fee scale. Annual chest x-rays for previous TST positive clients are not recommended (although some facilities will still require them). The use of a clinical symptom screen is recommended to document the symptom screen. Education about signs and symptoms so that the person knows when to seek health care can be found at https://dph.georgia.gov/sites/dph.georgia.gov/files/12%20Points%20of%20TB.pdf. This document can be signed and kept with the facility’s annual screening paperwork.

A clinical symptom screen is required for all clients who have a lapse in LTBI treatment. A repeat chest x-ray evaluation is required for clients who are symptomatic or who have had a lapse in therapy for two months or more.

OTHER IMAGING AND/OR NECESSARY MEDICAL PROCEDURES
The state TB Program is to be notified immediately of any necessary medical procedures that are not in the state nursing protocols. The state medical consultant must approve all procedures. The county will pay for the procedure at the current Medicaid rate.

LABORATORY TESTING
Certain blood and mycobacteriology testing is required to diagnose and monitor TB cases and LTBI. Detailed information about the tests required can be found in the Standard Nurse Protocols for Public Health Nurses and in Section 7 of this document. Laboratory results not performed by the State Laboratory are done through a contract with a local laboratory and county and/or district. For more information about the state laboratory, please refer to the current Laboratory Services Manual at https://dph.georgia.gov/lab or Appendix K for a list of Laboratory Services offered by Georgia Public Health Laboratory.

HIV test results should be documented on all patients receiving TB care through the health departments. An opt-out approach is recommended. This means the patient is informed of the laboratory tests that will be performed, including an HIV test. The patient can decline the HIV test. Otherwise, the test will be performed. Documentation of a patient’s refusal should be in the medical record. During the course of treatment, HIV testing should continue to be offered until results can be obtained. If a client continues to refuse, have the client a Refusal of HIV Testing form (Appendix F) and notify the contract physician. For more information and background on this approach, please refer to CDC’s “Revised Recommendations for HIV Testing of Adults, Adolescents, and
Pregnant Women in Health-Care Settings” at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm.

INCENTIVES AND ENABLERS
Incentives and enablers for TB patients and contacts on LTBI treatment are available from the American Lung Association (ALA) of Georgia through a contract with the Georgia TB Program. Refer to the Alternative Housing Project for Homeless Tuberculosis Patients in Georgia brochure (Appendix J), or call ALA at 770-434-5864 for current procedures to request and obtain incentives/enablers. Districts may request approval from the state TB program director or deputy director to use unexpended GIA funds to purchase incentives and enablers. On occasion, there may be incentive/enabler monies available from the state TB Program. Contact the TB program deputy director at 404-657-2634 to request these funds. Ensure is also supplied without charge to supplement the nutritional status of patients. Contact the TB Program to order Ensure.

MEDICAL INTERPRETATION SERVICES
The State of Georgia has a statewide contract with AT&T Language Line to provide medical interpretation services to the clients of Georgia. No person should be turned away because of the inability to speak or understand English. Family members of the client are not to be used to interpret for the client and staff. Information packets can be requested from AT&T free of charge by calling the customer service number 1-800-752-6096.

PROCEDURE FOR USE OF AT&T LANGUAGE LINE
- Place the non-English speaker on hold
- Dial 1-866-874-3972
- Enter your client ID [513565] on the keypad or stay on the line for assistance • Press 1 for Spanish or • Press 2 for all other languages
- Speak the name of the language at the prompt
- An interpreter will be connected to the call
- Brief the interpreter. Summarize what you wish to accomplish and give any special instructions.
- Add the non-English speaker to the line
- Conduct your business

HOSPITALIZATION
The state office TB Program is to be notified immediately of any pending hospitalization of a TB suspect/case. If the client has no insurance or Medicaid/Medicare, then the county is expected to negotiate with the local county hospital to use the hospital indigent care funds.

HOUSING HOMELESS CLIENTS
Each county and district should maintain a current listing of single occupancy motels in their area. The ALA has a contract to verify suitable housing for homeless clients. Refer to the American Lung Alternative Housing Project for Homeless Tuberculosis Patients in Georgia (Appendix J).
STATE TB SOCIAL SERVICES
Contact the state TB Program Social Services Provider for assistance with referrals and consultations on complicated clients. The State TB Social Service Provider can provide the following services:

- Provide psychosocial assessments (to determine the problem(s), level of functioning and appropriate services and treatment plans for the patient)
- Provide referral/linkage to appropriate resources
- Provide direct services/counseling to patients and families
- Provide phone consultation to districts on complex cases
- Provide onsite consultation to districts on complex cases
- Provide educational programs to District staff regarding social service issues
- Provide assistance to districts with resource development and coordination by collaborating with local agencies and organizations
- Provide assistance to districts by collaboration with ALA on complex patients
- Provide assistance to districts on special projects

Who can be referred to the State Social Service Provider?
1. Patients referred to ALA for services
2. Patients with complex psychosocial problems (homeless, uninsured, no income, substance abuse, mental health, undocumented, etc.)

Items needed for referral to State Social Service Provider:
2. Social service referral form (completely filled out with relevant information i.e., infectious status, insurance type, family members, family support, next of kin, income, unemployment history, etc.)
3. Any other referrals or social services notes from hospital and/or community agencies
   It would also be very helpful to refer complex patients to the state social worker at the same time as they are referred to ALA for services (Appendix J).

PROGRAM EVALUATION
Program evaluation is a core activity of TB control. Self-evaluation is needed in order to identify key intervention points during therapy in which action can be taken to promote optimal patient outcomes. The TB Program encourages participation in the Office of Nursing Quality Assurance/Quality Improvement initiative. During each grant cycle, an evaluation plan is developed and implemented.

CASE REVIEWS
The district and local jurisdictions are expected to perform regular case reviews. The state medical consultant and other state office personnel will attend one case review per district per
year. The state office will coordinate with each district to conduct these reviews. See Case Review Sheet in Appendix F.

COHORT REVIEWS
The state office will conduct four cohort reviews per year. Usually, these will be in the high morbidity districts. The state office will coordinate with each selected district to conduct these reviews. For more information on program evaluation expectations, processes and procedures, please refer to Tuberculosis Program Evaluation Guidelines available at https://dph.georgia.gov/tb-publications-reports-manuals-and-guidelines
Pharmacy

Table of Contents

<table>
<thead>
<tr>
<th>Pharmacy</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medications, Transport of Dangerous Drugs, 340B</td>
<td>39</td>
</tr>
<tr>
<td>Medications Requiring Approval by State Medical Consultant</td>
<td>39</td>
</tr>
</tbody>
</table>
MEDICATIONS

The state provides TB medications free of charge to all TB clients treated through the local health departments. Clients, Medicaid and insurance companies are not to be charged under any circumstance for TB medications or PPD solution. Any client receiving medications through the county health department must be clinically assessed at least monthly by a registered nurse, advance practice registered nurse, physician’s assistant or medical doctor for clinical improvement and adverse reactions to the medications. Each patient on TB medications should have a monthly clinical assessment.

For the current list of drugs available from the Department of Public Health's Office of Pharmacy, drug ordering procedures and storage considerations please refer to the current Drug Catalog. Your District Pharmacist or Drug Coordinator can provide you with a copy. The Drug Dispensing Procedure is located in the current Nurse Protocol Manual.
TRANSPORT OF DANGEROUS DRUGS

The DOT agreement signed by the client authorizes the DOT staff person to act as an agent of the client and gives permission for them to transport the client’s medication. This medication is dispensed and labeled with the patient’s information. PPD solution is not dispensed but is carried in bulk (multi-dose vials) to perform contact investigations. The Standard Nurse Protocols allows Registered Nurses to transport PPD solution to a non-public health clinic site. Non-licensed public health staff is not allowed to transport PPD solution into the field.

340B INFORMATION AND DRUG DISPENSING PROCEDURE


MEDICATIONS REQUIRING APPROVAL BY STATE MEDICAL CONSULTANT

- Second-line anti-TB medications
- Corticosteroids for patients with TB meningitis or pericarditis
- To receive second-line TB drugs please fax the following information/documentation to (404)463-3460:
  1. Copy of the prescription for ALL TB medications.
  2. List of ALL TB medications in the patient’s planned drug regimen (including 2nd line medications) as well as any other prescription medications the patient may be taking.
  3. Progress Note stating the reason for an alternate regimen.

The Second-Line Therapy Authorization Form can be found in Appendix F as well as on the TB web pages at https://dph.georgia.gov/tb-public-health-clinic-forms. The state TB Nurse will verify the documentation and consult with the State Medical Consultant. Additional information may be requested. Once the State Medical Consultant has signed the approval, the State Office TB Nurse will supply a copy of the signed authorization to the state Office of Pharmacy and back to the requestor. The requestor will contact the district drug coordinator or pharmacy to have the order placed into Cardinal.com (district drug coordinator or pharmacist sends an e-mail to the State Pharmacy Section verifying the order was placed). Once the State Pharmacy Section receives the signed second-line approval form and the e-mail from the district drug coordinator/pharmacist, the pending order can be approved (if the product is not on hand locally). The pharmacist can dispense the order. If there is no district pharmacist, seek Physicians or contracted pharmacy services to dispense since there is no nurse protocol for ordering and dispensing second-line drug treatment.
Directly Observed Therapy

Table of Contents

<table>
<thead>
<tr>
<th>Directly Observed Therapy</th>
<th>41</th>
</tr>
</thead>
<tbody>
<tr>
<td>Video Observed Therapy</td>
<td>44</td>
</tr>
</tbody>
</table>

Georgia Tuberculosis Policy and Procedure Manual
<table>
<thead>
<tr>
<th>Education</th>
<th>46</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure</td>
<td>49</td>
</tr>
<tr>
<td>Dose Counting</td>
<td>50</td>
</tr>
<tr>
<td>Interruptions in Treatment</td>
<td>52</td>
</tr>
</tbody>
</table>
Directly Observed Therapy (DOT)

Tuberculosis (TB) treatment can seem difficult. It requires taking multiple medications for at least 6 months. Most people have trouble remembering to take their medicines, especially after symptoms of the disease improve or have disappeared completely. DOT is an essential element for the prevention of further transmission of infection and disease. The ultimate purpose is to have each patient fully complete his/her first-ever TB treatment. Having every initial treatment fully completed, patients can be cured of TB and relapses are kept to a minimum. This is the only effective means to avoid MDR-TB and XDR-TB, which, in developing, high burden countries, is still almost incurable. DOT entails the direct observation, whether face-to-face or via video of the patient’s self-administering and swallowing the correct dose of anti-tuberculosis medications at the proper time for the complete period of therapy by a designated, trained and responsible agent of the patient. However, DOT is not just providing medication. DOT involves front line interaction with the patient. The DOT worker has the opportunity to make a genuine contribution not only to the patient’s physical health but also his or her well-being. Frequently, the DOT worker will identify social service or personal needs that could interfere with completion of treatment. Helping the patient resolve these problems not only helps achieve program outcomes but it also helps the patient find the assistance needed with their problems. DOT is the standard of care in Georgia to ensure an individual who has been prescribed medication for the treatment of active TB disease or LTBI completes the recommended course of drug therapy by taking all the medication.

1. DOT is required for:
   - All suspected and/or confirmed active cases of disease.
   - All children being treated for LTBI/presumptive LTBI less than 5 years of age.
   - All persons being treated for LTBI/presumptive LTBI who are co-infected with HIV.
   - All persons being treated for LTBI/presumptive LTBI on an intermittent dosing regimen.
   - All persons on the combined Isoniazid and Rifapentine regimen for LTBI.

2. If financial resources allow, DOT is strongly recommended for:
   - Persons infected with LTBI/presumptive LTBI that are at risk for active disease (e.g., close contacts, immunocompromised persons, converters, etc.).
   - All children five to fifteen (5–14) years of age being treated for LTBI/presumptive LTBI.
   - Any person being treated for LTBI/presumptive LTBI that has adherence problems.

3. Each person (or legal guardian) on DOT should sign and have a copy of a DOT agreement/Form 603 (Appendix F). If a patient is participating in VDOT a Patient Consent and Release of Liability form (Appendix F) should also be signed.

4. DOT is considered to be given Monday through Friday except in the case of MDR-TB or XDR-TB. Only DOT doses are counted towards completion of treatment.

5. DOT provision sites: DOT can be carried out at any site mutually agreed upon by the patient and DOT provider.

6. The standard DOT Screening Questions regarding TB symptoms, medication side effects and adverse reactions is to be completed at each DOT visit. The results are to be documented on the DOT sheet (Appendix F), in the appropriate computer system and
communicated to the nurse. Appendix F provides a Patient Education Review of Systems Aid to assist with questions to ask patients. If at any time the patient displays symptoms of adverse reactions or side effects, please notify the TB Nurse Case Manager immediately.

7. Each dose is to be documented and counted on the DOT sheet, at the time of ingestion. Each dose is to be transferred to the electronic database (SendSS) in a timely manner if data entry resources allow.

8. Education should be provided to the patient at each visit.

9. The DOT worker is expected to be alert for information concerning any identified or unidentified contacts, early warning signs of adherence problems and possible relocation of the patient and to communicate this information to the TB Nurse Case Manager promptly.

10. Any missed DOT appointments will be brought to the attention of the TB Nurse Case Manager and will be dealt with promptly according to procedures.

11. Who can provide DOT
   - Supervised and trained licensed or non-licensed employees of local and regional health departments.
   - Any supervised and trained responsible person mutually agreed upon by the patient and the health department including (but not limited to) health care personnel, employers, school staff, clergy, staff of a drug treatment center, fireman or staff of a CBO.
   - Employees of institutions responsible for the TB care of their residents.
   - As a rule, DOT cannot be provided by a family member.
   - For complex regimens including IV/IM medications or twice daily dosing, home care agencies may provide DOT or share responsibilities with the local health department.

12. Personnel without a nursing license are not allowed to pour medications from bottles, pour pills out of packets, crush pills, or mix pills with food or liquids. They are to support the patient in self-preparation and self-administration of his/her own medications.

13. DOT providers are required to complete the orientation and education process outlined in the current Georgia Tuberculosis Program Policy and Procedure Manual. DOT training must be documented on the DOT Provider Agreement and kept at the clinic level. All DOT workers are to sign a Provider Agreement.

14. Supervisors or TB Nurse case managers will accompany DOT providers on field visits each quarter for quality assurance purposes.

15. All medications must be stored and delivered according to the current Georgia Tuberculosis Program Policy and Procedure Manual.

16. Case conferences between the DOT worker and the TB Nurse Case Manager should be held at least weekly to share information concerning the patient’s care.

**VIDEO OBSERVED THERAPY (VDOT)**

In order to perform VDOT the outreach worker, RN, or LPN observes a patient taking his/her medication in their homes, workplace, or other location of patient’s choice via smartphone, laptop, or desktop.

All patients with suspected or confirmed active TB disease will start TB therapy using traditional DOT. Only after the patient has demonstrated adherence to the treatment plan over the first
eight (8) weeks of therapy will he/she be considered eligible for VDOT as an incentive for continued therapy. All patients with active TB should be evaluated during the first eight weeks of traditional DOT by the health department to determine if they may be a candidate for switching to VDOT. Patients must achieve at least 80% compliance during this initial phase of therapy in order to be considered eligible for VDOT. Participation in VDOT is voluntary and may be forfeited at any time by the patient or revoked by the health department.

VDOT should be used with carefully selected patients meeting established minimum criteria. Local TB program staff must be trained in appropriate patient selection, use of the VDOT equipment, procedures for observing treatment, as well as the additional VDOT aspects listed in this policy. VDOT staff must be trained on the use of video equipment to include patient confidentiality. VDOT staff must document each patient encounter as directed by the local health department policy. In case of smartphone/laptop/desktop technical failure, the DOT worker will make a home visit to deliver DOT. The DOT worker must provide the patient with written instructions on what to do in an emergency (such as patient becomes hospitalized, equipment for VDOT is not working/accessible, etc.), who to call with questions regarding treatment, and a plan of what to do if the regular staff person providing VDOT is not available.

Once local TB staff selects a patient that meets the criteria to receive VDOT, State TB Office must be notified prior to beginning VDOT. The local/district TB staff must submit a signed copy of the Patient Consent and Release of Liability form (Appendix F), Medication Administration Record (MAR) (Appendix F) to reflect patient was at least 80% adherent during initial phase, as well as brief explanation why patient is believed to be a good candidate for VDOT. Information may be faxed to 404-463-3460.

TB staff must ensure patient is seen in the clinic by appointment with the TB nurse or physician at least once a month per protocol. This will ensure appropriate clinical and laboratory monitoring, provide the patient with a one-month supply of his/her TB medication, and confirm the date/time of the next clinic appointment.

PATIENT CRITERIA
Patients can qualify for VDOT after the initial phase of treatment if all of the following apply:

- Pan-sensitive TB disease
- At least 80% adherent during initial phase
- Converted sputum smear and culture negative in initial phase of treatment
- No adverse reactions during the initial phase of treatment
- Can be served by a health care worker that speaks the same language or has the ability to use an interpreter
- No current history of alcohol or drug abuse
- No current history of mental illness e.g. psychiatric/sociopathic or depression
- Patient must not be considered at risk for poor adherence (homeless, prior incomplete or refusal of TB treatment, memory impairment, dementia)
- Patient is able to prepare his/her TB medications and can accurately identify each medication
• Patient is not a child or adolescent
• Patient is able to demonstrate how to properly use the equipment
• Patient is able to provide TB staff with picture identification to keep on file in his/her chart to confirm identity
• Patient owns a smartphone, laptop, or desktop with a data plan

NOTE: If TB staff feel strongly about a clients’ need for VDOT despite he/she not meeting all eligibility requirements outlined in this section, contact the TB State Program to determine patient’s ability to begin VDOT.

REASONS TO STOP VDOT ONCE STARTED INCLUDE:
• Patient has an adverse reaction to TB medication
• Patient is no longer in stable housing
• Patient misses one or more health department calls and/or ingests less than 80% of scheduled VDOT medication doses
• Patient defaults on other aspects of adherence (missing medical appointments, not being truthful)
• Patient no longer consents to participating in VDOT and prefers traditional (face-to-face) DOT
• Patient receives American Lung Association (ALA) benefits

ADMINISTRATIVE REQUIREMENTS FOR VDOT
The following administrative requirements must be met prior to placing TB suspects or confirmed cases on VDOT:
• Signed Patient Consent and Release of Liability form
• Signed Active TB Treatment Plan Form 3144 (Appendix F)
• Patient has completed the required 40 (forty) doses of the initial phase of TB therapy over a minimum of 8 weeks
• Paperwork has been submitted to the State TB Office for approval

PROCEDURE FOR PERFORMING VDOT
Prior to performing VDOT, staff must ensure that consents are signed by patient and TB staff and that a mutual time has been established for calls to occur. VDOT will be performed as follows:

1. TB staff (outreach worker, RN, or LPN) calls the patient at a prearranged time via smartphone, desktop, or laptop using Skype.
2. Patient displays his/her face on the video screen and confirms identity by stating first and last name as well as password. (The patient may also wish to have a code word to let the TB staff know he/she is in a situation where confidentiality is compromised and he/she cannot continue with the call. If this occurs, the patient needs to agree on a different time on the same day to complete VDOT with TB staff. The patient and VDOT staff can also wear ear buds to maintain confidentiality).
3. TB staff inquiries about any problems, medications side effects (as outlined in Policy 5.19 DOT Screening Questions Checklist), or concerns before the patient takes their medications. Medications are held, if indicated, per existing protocols.
4. Using appropriate lighting, patient clearly displays the medication bottle or blister pack.
5. Patient describes the medication by name, shape, size, and/or other identifying qualities. Patient identifies the number of each type of medication to be taken.

6. Patient holds medication in front of video camera before placing them in their mouth.

7. Patient swallows medication in full view of camera.

8. Patient repeats the same procedure for each medication to be taken.

9. Prior to disconnecting, TB staff confirms date and time of the next VDOT to be observed.

After completing a VDOT session, the TB staff will document the date/time and medications observed as per standard DOT protocols on the MAR; the letter “V” must be circled after staff’s initials on the MAR next to the date for each dose administered using VDOT. A recorded demonstration of VDOT is available on SABA at http://learningdevelopment.dph.ga.gov/Saba/Web/Cloud search for Video Directly Observed Therapy.

CONFIDENTIALITY
Health departments must conform with the provisions regarding protection of personal health information contained in the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Currently, web-based service providers like Skype are not considered secure. This information is included in the Consent and Release of Liability Form that the patient and nurse will sign.

DIRECTLY OBSERVED THERAPY (DOT) EDUCATION
All training must be verified and documented. These documents are to be kept at the local level and are to be available to the state office upon request.

SECTION A: The public health employee or contractor whose primary duty is to provide DOT

1. Complete the current CDC Self Study Modules on Tuberculosis available online at http://www.cdc.gov/tb/pubs/ssmodules/default.htm. These modules can be completed either online or using hard copies. The Supervisor must verify completion of each module and assess knowledge retained.
   • Introduction to course # SS3035
   • Module 1: Transmission and Pathogenesis of Tuberculosis
   • Module 2: Epidemiology of Tuberculosis
   • Module 3: Targeted Testing and Diagnosis of Latent TB Infection and Tuberculosis Disease
   • Module 4: Treatment of Latent TB Infection and Tuberculosis Disease
   • Module 5: Infectiousness and Infection Control
   • Introduction to course #SS3036
   • Module 6: Contact Investigation for Tuberculosis
   • Module 7: Confidentiality in Tuberculosis Control
   • Module 8: Tuberculosis Surveillance and Case Management in Hospitals and Institutions
   • Module 9: Patient Adherence to Tuberculosis Treatment

2. Complete a DOT class provided by the state office, district or local personnel.

3. Demonstrate a skills check to include (but not limited to) the following:
• Be issued and fit-tested for correct N-95 respirator. Describe when and how to replace issued masks.
• Demonstrate the correct procedure for donning an N-95 Respirator.
• Demonstrate correct procedure for a self-check of fit of an N-95 mask.
• Describe when an N-95 respirator must be worn during a visit for DOT.
• Identify an N-95 mask and a surgical mask.
• Correctly name and identify each TB medication after visual inspection.
• Correctly confirm the number of pills needed for the following dosages of each TB medication they will deliver:
  i. Isoniazid 300 mg; 900 mg  
  ii. Rifampin 600 mg  
  iii. Pyrazinamide 1000 mg; 1500 mg; 2000 mg; 3000 mg; 4000 mg
  iv. Ethambutol 800 mg; 1200 mg; 1600 mg; 2000 mg; 2800 mg; 4000 mg
  v. Pyridoxine (B6) 25 mg; 50 mg
• Explain the difference between a medication side effect and an adverse reaction.
• Describe side effects of the medications and possible actions to take.
• Describe adverse reactions to the medications and actions to take.
• Identify when to call the TB Nurse Case Manager and how to reach him/her.
• Accurately and legibly complete a DOT sheet (form 3130 or comparable).
• Describe process of turning in DOT sheets and where they are to be kept.
• Be knowledgeable and able to provide basic education on the following 12 Points of Tuberculosis (TB) Patient Education (Appendix F) which includes:
  1. Transmission of TB
  2. Differences between LTBI and Active TB disease
  3. Progression of LTBI to Active TB
  4. Signs and symptoms of disease
  5. Importance of HIV testing
  6. Respiratory isolation and use of masks
  7. Infectious period
  8. Importance of chemotherapy as prescribed
  9. Side effects and adverse medication reactions
  10. Directly Observed Therapy
  11. Importance of regular medical assessments
  12. Importance of contact investigation

4. Complete a minimum of 2 weeks of observation in the field of a qualified DOT worker.
5. Complete a minimum of 2 weeks of performance in the field supervised by the DOT worker's supervisor.
6. Sign a DOT Provider Agreement.

SECTION B: The DOT worker who is not a public health employee or contractor, but is a mutually agreed upon person by the patient and the health department OR a public health employee whose regular job does not involve providing DOT, but who is acting as a lay DOT
worker. All training must be verified and documented. These documents are to be kept at the local level and are to be available to the state office upon request.

1. Attend a one-on-one educational session with the TB Nurse Case Manager or District TB Coordinator. Review the following:
   a. 12 Points of Tuberculosis (TB) Patient Education
   b. Review the specifics of case.
   c. Show the medications and dosages.
   d. Discuss the DOT Screening Questions Checklist and actions, side effects and adverse reactions, how to reach the TB Nurse Case Manager and when to seek help.
   e. Review, demonstrate and discuss the applicable skills needed from the following list:
      • Be issued and fit-tested for correct N-95 respirator.
      • Describe when and how to replace issued masks.
      • Demonstrate the correct procedure for donning an N-95 Respirator.
      • Demonstrate correct procedure for self-check of fit of an N-95 mask.
      • Describe when an N-95 respirator must be worn during a visit for DOT.
      • Identify an N-95 mask and a surgical mask.
      • Correctly name and identify each TB medication after visual inspection.
      • Correctly confirm the number of pills needed for the dosages of each TB medication they will deliver. Repeat this each time the medication changes.
      • Explain the difference between a medication side effect and an adverse reaction.
      • Describe side effects of the medications and possible actions to take.
      • Describe adverse reactions to the medications and actions to take.
      • Identify when to call the TB Nurse Case Manager and how to reach him/her.
   f. Show how to document on the DOT sheet. Set up the process to turn in the sheets each month.

2. Arrange to have the DOT worker observe several DOT visits with the patient and then have the DOT worker perform the visits under supervision until all parties feel comfortable.

3. Discuss where and how the medications will be stored.

4. Have the DOT worker sign the DOT Provider Agreement and the DOT consent with the patient.

5. Complete the DOT Instruction Sheet (Appendix F) and give to DOT Worker. Update as needed.

6. Allow plenty of time for questions and encourage questions. 7. Make sure the DOT Worker knows how to reach the TB Nurse Case Manager or designated person.

PROCEDURE

1. Obtain the medication bag for each patient from the TB Nurse Case Manager or Medication Nurse. Look at each bottle inside the bag to verify that the name matches the name on the outside of the bag and that there is enough medication to cover the day’s dosage. Don’t borrow medications from other patient’s bottles.
Tell the nurse if medications are needed. Make sure DOT sheet, form #3130-R has the right patient’s name on it and is in the right medication bag. Place all labeled medication bags in a carrying container.

2. Obtain information regarding isolation and the need for masks for each patient from the TB Nurse Case Manager. Make sure you have your N95 mask and a supply of surgical masks for the patients, if needed for clinic appointments.

3. Provide the clinic with an itinerary of your DOT visits for the day before leaving the clinic. Observe field safety rules. Follow local procedures for maintaining contact throughout the day.

4. Place the carrying container in your car where the medications are not visible from the windows. Place them in the cooler section of the car out of direct sunlight. During the summer keep the air conditioner on. Never put medication in the trunk. Follow local procedures to insure the proper sanitation, temperature, light, ventilation, moisture control, segregation and security. Lock the car doors whenever you exit the vehicle.

5. When you arrive at the DOT site, greet the person. Verify the identity of the patient and that you have the right medication for that patient.

6. Put on N95 mask, if needed.

7. Ask the patient how he/she is doing. Administer the DOT Screening Questions Checklist and take actions as indicated. If you identify any adverse reaction, hold the medication and immediately call the TB Nurse Case Manager. If you are the RN, assess the patient, hold the medication and call your District contract physician. Document on the DOT sheet (form #3130-R).

8. If no adverse reactions are reported, proceed with the DOT visit. Make sure the patient has something to drink and a snack if needed. Give the patient the medication bag with all the medication bottles in them.

9. Observe the patient taking the pills from each bottle and verify he/she has the correct number of pills for each medication. Once the patient has removed the pills from the bottles, maintain visual contact with the pills. Avoid the patient leaving your sight, answering the phone, picking up a child or clothing.

10. Watch the patient take and swallow the medication. Make sure the patient actually swallows the medication and does not “cheek” it or hide the pills in his/her hand, clothing or furniture. Do not leave the pills with the patient to take at a later time. The first line anti-TB medications should be taken together as a single oral dose rather than divided doses. This leads to a higher and potentially more effective peak serum concentration. It is preferable for the medications to be taken on an empty stomach if tolerated. However, if the patient experiences epigastric distress or nausea when taking the medication, dosing with a snack or food is recommended. If the patient (or child) cannot swallow the pills, he/she (or parent) can crush the pills and empty the capsules into one or two teaspoons of non-sugary liquid or food. Follow with the ingestion of non-medicated food or liquid.

11. It is recommended that the DOT Provider remain with the patient at least 5 minutes after the medication has been ingested, to assure that there is no
regurgitation of the medication. During this time, build rapport and trust with the patient by engaging in interaction. Listen and try to understand the patient's knowledge, beliefs, and feelings about TB disease and treatment. Adopt and reflect a nonjudgmental attitude about behaviors that the patient may participate in that you may not agree with (e.g., drug use).

Identify potential barriers to adherence and involve the patient in identifying possible solutions. Note any items or ideas that could be used as incentives or enablers for your patient.

12. Reinforce TB education from the 12 Points of Tuberculosis (TB) Patient Education and answer any questions the patient has regarding the disease or treatment. Prepare the patient for the next step in treatment. The 12 Points of Tuberculosis (TB) Patient Education:

1. Transmission of TB
2. Differences Between LTBI and Active TB Disease
3. Progression of LTBI to Active TB
4. Signs and Symptoms of Disease
5. Importance of HIV Testing
6. Respiratory Isolation and Use of Masks
7. Infectious Period
8. Importance of Chemotherapy as Prescribed
9. Side Effects and Adverse Medication Reactions
10. Directly Observed Therapy
11. Importance of Regular Medical Assessments
12. Importance of Contact Investigation

13. The DOT worker is expected to be alert for information concerning anything out of the ordinary (additional contact identification, social circumstances, and emotional status) and to communicate this information to the TB Nurse Case Manager promptly. For example, in casual conversation the patient may mention participating in a hobby at a previously undisclosed location. The DOT worker could probe a little bit and find out when the last time the patient participated in the hobby and which friends were there. It would be important to relay this information to the TB Nurse Case Manager for follow-up in the contact investigation.

14. After the patient has completed taking all of his/her medication, have the patient initial on the DOT sheet/Form 3130 and place your initials beside them.

15. Have the patient put the medication bottles back into his medication bag and hand it to you. Place the completed DOT sheet in the bag with the patient's medications.

16. Confirm the next DOT appointment, the next clinic appointment and transportation to the clinic. Answer any questions or concerns of the patient.

17. Offer words of support and encouragement to the patient for his/her involvement in treatment and getting better. Offer any incentive or enabler and thank the patient for the visit.
18. Take the medication bag with you and leave the DOT site.
19. Return to your vehicle and complete any notes and documentation about the DOT visit and observations made.
20. Place the notes and DOT sheet in the patient’s medication bag and place bag into carrying container.
21. When you get back to the clinic, return the medications to designated person in designated area. **DO NOT KEEP IN CAR.** Place DOT sheets in designated place.
22. Communicate with the TB Nurse Case Manager about the patients you observed today. Coordinate any new interventions or strategies with the TB team.
23. Complete any computer documentation or other patient record documentation.

**DOSE COUNTING**

Dose counting is a method to count and document TB medication doses. It is helpful in determining if a patient is on track to complete treatment within the recommended time frame and it aids in determining when a patient has completed treatment. Dose counting to determine completion of treatment is only definitive when the patient is on Regimen 1 or Regimen 2. These are the only treatment regimens allowed under nurse protocol. All other regimens require the contract physician’s clinical judgment to determine when treatment is complete. Dose count for the month and dose count to date should be placed on each DOT sheet as it is completed.

Weekend self-administered medications do not count in the final dose tally. Self-administered doses during short vacations and out of town trips do not count in the final tally.

Weekly and intermittent dosing can be counted together. Five (5) weekly doses equal two (2) twice weekly doses equal three (3) thrice weekly doses. Convert weekly and intermittent doses to follow the guidelines below.

The initial phase of treatment is counted first to determine completion of the intensive period of treatment. This count must be complete before moving on to the continuation phase of treatment. Ethambutol doses do not need to be counted and the Ethambutol may be dropped from the regimen as soon as the drug susceptibilities show no resistance.

<table>
<thead>
<tr>
<th>Regimen 1</th>
<th>Regimen 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial phase</strong></td>
<td><strong>Initial phase</strong></td>
</tr>
<tr>
<td>• (INH + RIF + PZA + EMB) 5 days/week</td>
<td>• (INH + RIF + PZA + EMB) 5 days/week</td>
</tr>
<tr>
<td>• 40 doses over 8 weeks</td>
<td>• 10 doses for 2 weeks <strong>PLUS</strong></td>
</tr>
<tr>
<td>• Should be completed within 3 months</td>
<td>• (INH + RIF + PZA + EMB) 2 days/week</td>
</tr>
<tr>
<td>Continuation phase</td>
<td>Continuation phase</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>(INH + RIF) 2 days/week X 36 doses over 18 weeks should be completed within 9 months</td>
<td>(INH + RIF) 2 days/week X 36 doses over 18 weeks should be completed within 9 months</td>
</tr>
</tbody>
</table>

### INTERRUPTIONS IN TREATMENT

Interruptions in treatment can lengthen the time of treatment or may cause the patient to have to start treatment over.

### INITIAL PHASE

The initial phase of treatment is considered the first two months when the patient is receiving four medications. During this intensive time, if the interruption lasts more than 14 days, the patient must start treatment over. If it is less, then time must be added to the treatment to assure the correct number of doses for the initial phase.
CONTINUATION PHASE
The continuation phase is after the patient completes the intensive portion of treatment and the drug susceptibilities are known. During this time, if the interruption is more than three months, the patient will have to start treatment over. If it is less than three months, then time will have to be added to the treatment to assure the correct numbers of doses are taken to complete treatment.

Determine the total percentage of doses completed.

Is the percentage of doses less than 80%?

If the duration of interruption is less than 3 months, continue treatment if:

The treatment can be completed within the required time for the regimen, complete treatment.

If the duration of interruption is 3 months or greater, start initial phase 4-drug regimen from the beginning.

Is the percentage of doses 80% greater?

If sputum smear was AFB negative at baseline, additional treatment may be necessary.

If sputum smear was AFB positive at baseline, continue treatment to complete planned total number of doses warranted.
# Contact Investigation

## Table of Contents

<table>
<thead>
<tr>
<th>Contact Investigation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions and Background</td>
<td>54</td>
</tr>
<tr>
<td>Children Less than 5 Years of Age</td>
<td>56</td>
</tr>
<tr>
<td>Patients with Extra-Pulmonary TB</td>
<td>58</td>
</tr>
<tr>
<td>Patients with Active TB</td>
<td>59</td>
</tr>
</tbody>
</table>

Georgia Tuberculosis Policy and Procedure Manual
CONTACT INVESTIGATION

DEFINITIONS AND BACKGROUND
Contact investigations serve as an important means of preventing further TB transmission. The evaluation of contacts of cases of infectious TB is one of the most productive methods of identifying adults and children with LTBI who are at high risk for progression to TB disease and persons already in the early stages of TB disease.
The TB cases we have identified are just the tip of the iceberg. Each infected person is what lies underneath the surface, waiting to emerge and become our next case. Every single TB case began as someone’s contact. On average, 10 contacts are identified for each person with infectious TB in the U.S.; 20-30 percent of contacts have latent TB infection and one percent of contacts have active TB disease. Of those contacts who develop disease, approximately onehalf will do so within the first two years after exposure.

Below are common terms used during contact investigations:

**Suspect:** A person believed to have active TB, but has not been confirmed to have TB disease

**Case:** A person diagnosed with active TB disease

**Index patient:** The first TB suspect or active TB case reported to the health department around whom a contact investigation is done

**Source case:** The person who infected another person with M. tuberculosis; this may be referenced when a child less than age five is reported to the health department and a source case investigation is done to look for the person who infected the child

**Secondary case:** Any additional suspects or cases found during the course of a contact investigation

**Exposure:** The condition of being vulnerable or susceptible to infection due to proximity to an infectious person; not every person who is exposed to TB becomes infected with TB

**Infectious period:** Time frame when exposure may have occurred. Starts three months prior to TB diagnosis or onset of symptoms

**Contact:** A person who has been exposed to an infectious case of TB

**Elicitation:** The naming and identifying of a person who has been exposed

**Evaluation:** Complete evaluation for a contact consists of a symptom screen, an initial tuberculin skin test (TST)/interferon gamma release assay (IGRA), a follow-up TST/IGRA 8-10 weeks later if initial TST/IGRA is negative, and a chest x-ray after any positive reaction of 5mm or more.

**TST/IGRA:** Tests to determine is a person is infected with M.tb

**NAAT:** (Nucleic Acid Amplification Test) a rapid test to determine whether M.tb is present in a specimen sample
The national and state goals for contact investigation per the Grant-in-Aid annex are below:

- Ensure that 100% of TB patients with positive acid-fast bacillus (AFB) sputum smear have contacts identified.
- Ensure that 93% of contacts to sputum smear AFB positive TB patients be completely evaluated for TB infection and disease.
- Ensure that 88% of contacts to sputum smear AFB positive TB patients with newly diagnosed LTBI start LTBI treatment.
- Ensure that 79% of contacts to sputum smear AFB positive TB patients with newly diagnosed LTBI who started LTBI treatment complete treatment.
- Ensure that 75% of immigrants and refugees have documented complete evaluation within 90 days of arrival.
- Ensure that 80% of immigrants and refugees diagnosed with LTBI start treatment.
- Ensure that 70% of immigrants and refugees who started treatment for LTBI complete treatment.

While there are specific steps in a contact investigation, information is obtained at inconsistent rates which may alter the sequence of events; however, all steps will be covered in a complete investigation. The steps are as follows:

1. Medical record review (Pre-interview preparation)
2. Index patient interviews
3. Field investigation
4. Risk assessment for *M. tuberculosis* transmission
5. Identification of priority contacts
6. Evaluation of contacts
7. Treatment and follow-up of contacts
8. Determining the need to expand the investigation
9. Evaluation of contact investigation activities

For in depth information about each step, refer to the following resources:


NTNC’s *Tuberculosis Nursing: A Comprehensive Guide to Patient Care* located in each health department.


A contact investigation plan is a work in progress and will change as more information is obtained. Who needs a contact investigation plan?

- Children less than five years old with LTBI
- Clients with extra-pulmonary TB
- Clients with active TB disease
CHILDREN LESS THAN AGE FIVE WITH LTBI
In Georgia, LTBI in children younger than five years old is reportable to public health authorities. Health departments must conduct a source case investigation, which entails looking for the person who may have infected the child. We know that infection had to be fairly recent (within the child’s life). Most often, the child is infected by a household member. A contact investigation for these children should be completed within a week in order to prevent further transmission of TB. The investigation consists of inquiring of the parents about any caretaker or family member who has signs and symptoms of TB and to placing and reading one TST/IGRA on each household member. A positive IGRA or a TST result of 5 mm or more is followed with a chest x-ray (CXR). If the CXR is normal or negative, then the initiation and completion of LTBI treatment is encouraged. Any pediatric TB suspect under 5 years of age should be IMMEDIATELY reported to the State Medical Consultant for evaluation. Any pediatric suspect for LTBI under 5 years of age should be IMMEDIATELY reported to the State Medical Consultant for evaluation as well.

PATIENTS WITH EXTRAPULMONARY TB
TB patients that do not have pulmonary, laryngeal, or pleural disease are considered to have extra-pulmonary TB and are not infectious. However, sometimes a person will have pulmonary TB along with extra-pulmonary TB. Pulmonary TB must be ruled out by collecting three diagnostic sputum specimens and performing a CXR. A limited contact investigation should be done within 30 days. This investigation consists of asking the patient if they have a household member with signs and symptoms of TB. If not, no further action is needed. If a household member is identified with signs and symptoms of TB, that person should be completely evaluated for TB. The household members would then receive one TST/IGRA. A positive IGRA or a TST result of 5mm or more is followed with a CXR. If the CXR is normal or negative, then treatment initiation for LTBI and treatment completion is encouraged. NOTE: Nurses can only dispense TB medications for conditions outlined in the TB Nurse Protocols. Please refer to current TB Nurse Protocols for further guidance.

PATIENTS WITH ACTIVE TB DISEASE
Clients with active TB disease will have the most comprehensive contact investigations. The first question to be answered is “what is the site of the disease”? 
Indications that a patient is infectious include the following:

- Symptoms of TB (cough that lasts three weeks or longer, fever, weight loss, night sweats, coughing up blood, weakness or fatigue)
- A positive AFB sputum smear
- A positive NAAT
- Cavitary disease
- An abnormal chest x-ray consistent with TB
Once a contact investigation is initiated, certain time frames must be met.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Suspects with indications of infectiousness</th>
<th>Suspects without indications of infectiousness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Index Patient:</strong> In-person interview</td>
<td>Less than or equal to 1 working day from notification</td>
<td>Less than or equal to 3 working days from notification</td>
</tr>
<tr>
<td><strong>Residence Visit:</strong> Visit the place of residence of the index patient</td>
<td>Less than or equal to 3 working days after the first interview</td>
<td>3 working days after the first interview</td>
</tr>
<tr>
<td><strong>Field Investigation:</strong> Visit all potential settings for transmission (school, work, church, leisure, etc.)</td>
<td>5 working days after the start of the investigation</td>
<td>5 working days after the start of the investigation</td>
</tr>
<tr>
<td><strong>Index Patient Re-interviews:</strong> Re-interview the index patient one or more times for clarification and additional information</td>
<td>1 or 2 weeks after the first interview</td>
<td>1 or 2 weeks after the first interview</td>
</tr>
</tbody>
</table>


For additional information on interviewing the index patient, please see the following resources: TB Interviewing for Contact Investigation: A Practical Resource for the Healthcare Worker (New Jersey Medical School Global Tuberculosis Institute Web site at http://web.njms.rutgers.edu/ntbcweb/downloads/products/tbinterviewing.pdf


CONTACT PRIORITY
The following is adapted from NTCA/NTNC Tuberculosis Nursing: A Comprehensive Guide to Patient Care, Appendix III, Priority of Exposed Contacts (Washington State):

Contacts are classified into three groups (High, Medium, and Low) according to the priority of their need for followup. Priorities may change as you learn more information about the case and/or the contact and/or the environment. Remember: No matter what their category, always prioritize the follow-up of contacts. First address the persons who are considered a medical risk. These are defined as those who are at particularly high risk of developing TB disease once infected with *M. tuberculosis*. These contacts include the following in Georgia:
• Immunosuppressed, e.g., HIV infection, prolonged corticosteroid therapy, organ transplant, TNF blockers • Less than 5 years of age
• Have diabetes mellitus, silicosis, end stage renal disease, gastrectomy, jejunoileal bypass, leukemia, lymphoma or cancer of the head or neck.

An initial encounter needs to be made with each identified contact in order to assess the person for signs and symptoms of tuberculosis.

EXPOSURE CATEGORY 1
The County Health Department (CHD) should focus on the highest priority contacts:

• Those exposed to persons with acid-fast bacilli (AFB) sputum smear positive or cavitary tuberculosis.

Contacts to these cases are categorized as follows:

• High = Case is sputum smear positive or cavitary chest x-ray and contact is:
  1. A household member
  2. Less than 5 years of age
  3. Has medical risk factors (i.e., HIV)
  4. Was exposed during a medical procedure (i.e., bronchoscopy)
  5. Was exposed in a congregate setting
  6. Exceeds duration environment limits

• Medium = Case is sputum smear positive or cavitary chest x-ray and contact is:
  1. 5 - 15 years of age
  2. Exceeds duration environment limits

• Low = Case is sputum smear positive or cavitary chest x-ray and contact is:
  1. All other contacts that do not fall under the preceding categories (e.g. individual visiting outdoors once or twice a week during the infectious period)

<table>
<thead>
<tr>
<th>Category 1 Time Frames for Contact Evaluation and Treatment Initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>High priority without medical risk</td>
</tr>
</tbody>
</table>
### Category 2 Time Frames for Contact Evaluation and Treatment Initiation

<table>
<thead>
<tr>
<th>Priority</th>
<th>Working days from listing of a contact to initial encounter</th>
<th>Working days from initial encounter to completion of initial medical evaluation</th>
<th>Considered for presumptive LTBI treatment during window period</th>
<th>Working days from completion of medical evaluation to treatment initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>High priority</td>
<td>3 working days after being listed as a contact</td>
<td>5 working days</td>
<td>Yes</td>
<td>Continue treatment for a full course if infected.</td>
</tr>
<tr>
<td>Medium priority</td>
<td>3 working days after being listed as a contact</td>
<td>10 working days</td>
<td>No</td>
<td>10 working days</td>
</tr>
<tr>
<td>Low priority</td>
<td>10 working days after being listed as a contact</td>
<td>30 calendar days</td>
<td>No</td>
<td>10 working days</td>
</tr>
</tbody>
</table>

### EXPOSURE CATEGORY 2

- Those exposed to persons with acid-fast bacilli (AFB) sputum smear negative tuberculosis or,
- Those exposed to persons suspected of having TB disease due to an abnormal chest x-ray that is consistent with TB disease.

Contacts to these cases are categorized as follows:
- **High** = Case is sputum smear negative and contact is:
  1. Less than 5 years of age
  2. Has medical risk factors (e.g., HIV)
  3. Was exposed during a medical procedure (e.g., bronchoscopy)
- **Medium** = Case is sputum smear negative and contact is:
  1. A household member
  2. Was exposed in a congregate setting
  3. Exceeds duration environment limits
- **Low** = Case is sputum smear negative and contact is:
  1. All other contacts that do not fall under the preceding categories
<table>
<thead>
<tr>
<th>EXPOSURE CATEGORY 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>The CHD should provide follow up on these contacts according to resource availability (time, staff, etc.):</td>
</tr>
<tr>
<td>- <strong>Those exposed to persons with suspected TB with abnormal chest x-rays not consistent with TB disease</strong></td>
</tr>
</tbody>
</table>

### CONTACT EVALUATION
The evaluation of a contact is much more than simply administering a tuberculin skin test. The contact must be completely evaluated based on good decision making and best practices. The following format for the evaluation and monitoring of TB patients is used to be consistent within this document. This format can assist the nurse in charting and in determination of correct CPT evaluation and management codes.

### CHIEF COMPLAINT
Patient has been exposed to an active TB case. This person may be a named contact by the index case or may be discovered during the course of the investigation. Not everyone who is exposed to an active case of TB becomes infected or progresses to disease.

### HISTORY OF PRESENT COMPLAINT
It is important to gather a pertinent history from contact/patient to perform a thorough evaluation, but it will also aid in conducting a thorough contact investigation.
CONTACT TO A CASE
When eliciting the details about the exposure, document all of the following:

- Location and environment of the exposure – Where did the exposure take place? Was it at school or work? If so, document the name of the workplace or school and describe the exact location of the exposure. Describe the environment.
- Amount of time spent with TB case – How much time is spent with the TB Case?
- Frequency of time spent with TB case – How often do the contact and the TB Case spend time together? Is it every day, once a week?
- Physical space between contact and TB case – What is the physical proximity of the contact and the TB Case? Six inches? 20 feet?

For example, “Ms. Smith and the TB Case share a 45 minute lunch break together in the ABC company break room. The break room is a 12 foot by 14 foot room with one table which seats 10 people. Ms. Smith states she sat at the same table with the TB case approximately 18 inches apart. They would eat lunch together at least 4 days a week.”

PREVIOUS TB HISTORY
It is very important to know if the contact/patient has ever been diagnosed with active TB disease or latent TB infection before because this will impact how he/she is evaluated for this exposure. Document dates of diagnosis or testing, location where the diagnosis or testing took place and what treatment was offered or completed. Also document date, and location of any BCG vaccination given to the patient.

PERTINENT MEDICAL HISTORY
It is necessary to determine if there is any medical history or condition that may indicate the contact would be at a high risk of progression to TB disease if infected with TB. Document the history of any of the following:

- HIV infection*
- Prolonged corticosteroid therapy
- Organ transplant
- Tumor necrosis factor (TNF) blockers
- Diabetes mellitus
- Silicosis
- End stage renal disease
- Gastrectomy
- Jejunoileal bypass
- Leukemia
- Lymphoma
- Cancer of the head or neck
- Less than 5 years of age

*CDC recommends HIV testing all contacts, no matter the HIV status of the case. However, if the index TB case is HIV+, then it is vital to have the adult contacts tested for HIV.

Any of the above conditions would make the contact a high priority contact with a medical risk. This means the healthcare provider will need to assess the need to place the contact on presumptive latent TB infection treatment during the window period.
REVIEW OF SYSTEMS
A limited review of systems is done to assess whether the patient has any signs and symptoms of active TB disease and whether there is any contraindication to performing a TST.

CONSTITUTIONAL
Does the patient have any unexplained weight loss, fever, chills, weakness or fatigue, night sweats, and/or loss of appetite?

SKIN
Does the patient have a rash, itching, scaring or tattoos on arm?

RESPIRATORY
Does the patient have any shortness of breath, cough or sputum?

ALLERGIC/IMMUNOLOGIC
Does the patient have asthma? Has he/she had hives or anaphylaxis as a result of exposure to anything? Does he/she have an allergic response to materials, foods or animals?

PHYSICAL EXAMINATION
A very limited physical examination is made. Observe characteristics of breathing; note any coughing or shortness of breath. Observe overall skin texture. Examine skin of arm for scarring, tattoos, veins, turgor.

DECISION MAKING
Use all of the information obtained during the history, review of systems and physical examination to make your decision on how to handle this patient.

ARE THERE ANY SIGNS OR SYMPTOMS OF POSSIBLE ACTIVE TB?
Does the patient need a complete evaluation for active TB?
Does the patient need a referral for a physician, chest x-ray, etc.?
Does the patient need to be isolated?
Dose the patient need a mask?
Do sputum specimens need to be collected?

WHAT METHOD OF EVALUATION IS BEST?
Is a TST or IGRA needed?
Is there any contraindication to placing a TST, IGRA?
Is the patient able to return to the clinic in 48-72 to have the TST read? Does the patient need a chest x-ray instead of a TST, IGRA?

WHAT IS THE PRIORITY OF THE PATIENT?
Is this patient at high risk of progression to TB disease if infected?
Does the patient need a chest x-ray along with a TST, IGRA?
Will the patient need any follow-up after this test? Does this contact need to be placed on presumptive latent TB infection treatment?

COUNSELING/CARE COORDINATION

GENERAL EDUCATION OF A CONTACT
Regardless of the method of evaluation for the patient, any contact to a case is bound to have questions and the healthcare provider needs to be able to educate the contact on the following:

- The difference between exposure, infection and disease
  - Purpose of an evaluation and the methods (TST, IGRA, Chest X-Ray)
  - Limitations of testing
  - Discuss follow-up testing in 8 – 10 weeks. Emphasize the significance of the follow-up TST/IGRA. Discuss best way to remind patient of follow-up test. Obtain alternative contact information for the patient.
  - Explain the need for HIV status and the relationship between HIV and TB
  - Discuss the patient’s risk factors and why the test was chosen

TUBERCULIN SKIN TEST

- Do not rub, scratch or pick at injection site
- Do not cover injection site with a Band-Aid
- It is alright to get the injection site wet
- Set appointment for the patient to return in 48-72 hours to have the test read

CHEST X-RAY

- For previous positive patients, explain why a TST is not indicated and why a chest x-ray is being done
- For patients with a medical risk, explain why a chest x-ray is needed regardless of the TST or IGRA result
- Set appointment for chest x-ray
- Complete referral forms
- Give instructions to patient as to where to go, what time and what will occur
- Set appointment for follow-up to review the results of the chest x-ray

HIGH PRIORITY CONTACTS WITH A MEDICAL RISK

- Explain how the medical risk can lead to a progression to disease if the contact is infected
- Discuss window period and presumptive latent TB infection treatment

PROCEDURES

Chose the appropriate procedures needed to evaluate the patient. Identify and take credit for everything you do. All procedures need to be coded accurately.
Administer a TST
- QFT
- T-Spot
- HIV
- Screening for HIV
- Venipuncture
- Handling / Conveyance of specimen
- Chest X-Ray
- Risk Reduction Interventions (15 min.)
- Risk Reduction Interventions (30 min.)

EVALUATION AND MANAGEMENT
The evaluation and management is sometimes referred to as the office visit code. Be sure to select the most appropriate evaluation and management code.
LPN: TST reading; no follow-up
RN: straightforward
RN: arrange for CXR; high risk for progression

This same procedure should be followed in 8 – 10 weeks when the follow-up evaluation is done.

PRESumptive Latent TB Infection Treatment
Presumptive LTBI treatment is the practice of providing window period prophylaxis treatment for presumed M. tuberculosis infection to high-risk contacts of infectious TB cases, when the contact has an initial TB skin test reaction of less than 5mm or initial negative IGRA result and the testing was performed less than 8 weeks from the contact’s last exposure to the source case.

Contacts at particularly high risk of developing TB disease once infected with M. tuberculosis include: children less than 5 years of age and persons with immune systems compromised by HIV infection, immunosuppressive medications (prednisone, cancer chemotherapy, anti-rejection drugs for cancer therapy, tumor necrosis factor alpha agents antagonists) and certain medical conditions (diabetes mellitus, silicosis, end stage renal disease, cancer of the head and neck, reticuloendothelial diseases [e.g., lymphoma, leukemia], gastric or jejunoileal bypass surgery).

Candidates for presumptive LTBI who would benefit from a full course of LTBI treatment are immunosuppressed due to the following conditions:
- HIV infection.
- Prolonged corticosteroid therapy.
- Persons with organ transplants.
- Persons on TNF-alpha inhibitors
Candidates for presumptive LTBI who can stop treatment after the window period if the follow-up TST/IGRA is negative include contacts that are children less than 5 years of age and persons with any of the following conditions:

- Diabetes mellitus.
- Silicosis.
- End stage renal disease
- Gastrectomy
- Jejunoileal bypass
- Leukemia
- Lymphoma
- Cancer of the head or neck

**TREATMENT OF INFECTED CONTACTS**

All contacts diagnosed with LTBI will be offered treatment unless contraindicated. Contacts will be encouraged to start and complete LTBI treatment. The TB Coordinator should review the contact investigation forms on a regular basis. All contacts will be entered into SENDSS according to the time frames stated in the Medical Records/ Surveillance Section. The following codes are to be used:

<table>
<thead>
<tr>
<th>CODES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason LTBI treatment stopped</td>
</tr>
</tbody>
</table>

1. Completed therapy  
2. Death  
3. Moved  
4. Active TB developed  
5. Adverse reaction  
6. Chose to stop/Lost to follow-up  
7. Provider decision  
8. \  
9.  
10. Other  

1. Still following up  
2. No second TST/IGRA because first TST/IGRA performed 8-10 weeks after exposure  
3. No second TST/IGRA because extra-pulmonary source case  
4. No second TST/IGRA because sputum/culture negative source case  
5. Refused/uncooperative  
6. Moved  
7. Lost to follow-up  
8. Died  
9. Other  

1. Contact investigation not done  
2. Case died or too ill to interview. No surrogate interviewee available.  
3. Case uncooperative/refused to identify contacts. No surrogate interviewee available.  
4. Case moved/lost to follow-up. No surrogate interviewee available.  
5. Contacts identified but cannot be located.  
6. Contacts uncooperative/refused  
7. Contacts moved/lost to follow-up  
8. Shares same contacts with an index case whose contacts have already been entered  
10. Other  

INVESTIGATIONS ACROSS JURISDICTIONS

CONTACT INVESTIGATIONS ACROSS HEALTH DISTRICTS
District TB Coordinators should notify other district TB coordinators of cross-district contact investigations and continue to monitor follow-up to ensure all contacts of cases from their district are identified and evaluated. Local health department TB nurses should complete the contact investigation form with full name and location information. This form should be forwarded to the receiving county health department for evaluation who in turn should return the completed form to the originating health department. The district of the source case for the contacts is ultimately responsible for entering the contact investigation results in SENDSS, but may request help from other districts or the state epidemiology unit if the data entry task overwhelms their district’s capacity to enter all contact information.

1. Requesting County should send a letter of notification to the identified contact which informs them of the exposure, refers them to their local health department, and lets them know that a health department employee may be contacting them.
2. Requesting County completes Form 3126 with the following information:
   • Index patient
     information o Patient’s
     clinic number o State
     registry number o
     Patient’s county o
     Disease site
       o Infectious period
       o Initial sputum results and date collected
   • Contact information o
     Exposure environment
       o Name, phone number, complete address
       o Race o Sex
       o Date of birth and age o Relationship to index patient o Last exposure date o Priority

3. Fax with a copy of the letter sent to the contact to the Receiving County and to the state office

4. Receiving County needs to act within stated time frames for evaluating contacts:
   • **HIGH PRIORITY** Initial encounter within 3 or less days after notification with medical evaluation completed within 5 days of initial encounter (10 days if smear negative)
   • **MEDIUM PRIORITY** Initial encounter within 3 days after notification with medical evaluation completed within 10 days of initial encounter
   • **LOW-PRIORITY** Initial encounter 10 days after notification with medical evaluation completed within 30 days.

5. Receiving County completes Form 3126 with documentation and faxes back to Requesting County by the timeframes indicated for the priority of the contact so first TST can be entered into SENDSS.

6. Requesting County telephones Receiving County at the time when the 2nd TST is due to give a friendly reminder. Remember, it is the Requesting County who is responsible.

7. Receiving County completes Form 3126 with documentation and faxes back to the Requesting County and to the state office.

**CONTACT INVESTIGATIONS ACROSS STATES**
Contacts to Georgia cases that move out of state should be referred to that state for follow-up by submitting an interjurisdictional notification form to the State TB Program, which will notify the new state. When the follow-up information is received from the new state, the TB Program will forward the information to the District TB Coordinator. When the Georgia TB Program is notified of contacts entering Georgia from other states, the information is forwarded to the appropriate District TB Coordinator. When follow-up information is returned to the TB Program, it is forwarded to the original state that submitted the contact information.
EXPANDING THE INVESTIGATION
A contact investigation may need to be expanded if there is evidence of recent and/or continuing transmission.

- Unexpectedly large rate of infection in high priority contacts
- Evidence of a secondary case of TB disease
- Infection in any contact less than 5 years of age
- Contacts with change in TST status (converters)

EXAMPLE OF INFECTION RATE
Eleven high priority contacts were identified for a reported TB case. One contact had a documented previous positive skin test. The other 10 contacts did not have documented previous skin tests. These 10 contacts were recently tested in connection with the contact investigation with the following results: 7 had a positive reaction and 3 had a negative reaction.

Summary:
11 contacts were identified
1 contact had a documented previous positive skin test
10 contacts had no documented previous skin test
7 of the 10 contacts had a newly identified previous positive skin test
3 of the 10 contacts had a newly identified negative skin test

1. **Determine the number of contacts with a newly identified positive skin test.**
   Subtract the number of contacts with a documented previous positive skin test from the total number of contacts with positive skin tests (new or previously documented)

   8 contacts with positive skin tests (new or previously documented) - 1 contact with a documented previous positive skin test
   7 contacts with newly identified positive skin tests

2. **Next, determine the total number of contacts without a documented previous positive skin test.** Subtract the number of contacts with a documented previous positive skin test from the total number of contacts

   11 total number of contacts identified - 1 contact with a previous positive skin test
   10 contacts without a documented previous skin test

3. **Finally, determine the infection rate.**
   Divide the number of contacts with a newly identified positive skin test by the total number of contacts without a documented previous positive skin test
   Multiply by 100; the resulting percentage is the infection rate for the group of contacts
7 contacts with a new positive skin test

10 contacts without a documented previous skin test \( \times 100 = 70\% \) Infection rate

4. Decide on expansion of testing.
   *Yes, you would expand testing since our background infection rate = 2-3%*

EXAMPLE OF SECONDARY CASE
During the course of your investigation, 14 contacts are evaluated. One of those contacts has signs and symptoms of active TB. This contact becomes a TB suspect and has a complete evaluation for a TB case. A contact investigation will now begin around this second suspect/case. At this point, it cannot be determined if the index case transmitted the disease to the contact or if the contact is the source case. Either way, recent transmission has taken place and now there is a secondary case of TB. The investigation of the index case should now be expanded.

EXAMPLE OF LATENT TB INFECTION IN PERSON LESS THAN 5 YEARS OF AGE
The contact investigation includes the household members. The index case has a wife, an eight-year old son and a three-year old toddler. The wife and the son have a 0 millimeter TST (negative), but the three-year old has a 6 mm TST (positive). This indicates recent transmission and calls for an expansion of the investigation.

EXAMPLE OF TST CONVERTER
An index case has exposed 22 co-workers. There is an annual TB screening in the workplace and each of the 22 contacts had a TST within the last year that was 0 mm (negative) at that time. When tested after the exposure, one co-worker had a result that was 12 mm. This co-worker is said to have converted from a negative result to a positive result. The definition of conversion is an increase of 10 mm within a two year period.

SUMMARY
In the absence of evidence of recent transmission, an investigation should not be expanded to lower priority contacts. When program-evaluation objectives are not being achieved, a contact investigation should be expanded only in exceptional circumstances, generally those involving highly infectious persons with high rates of infection among contacts or evidence for secondary cases and secondary transmission. Expanded investigations must be accompanied by efforts to ensure completion of therapy.

Decisions about expanding contact investigations should be made by clinical and supervisory staff, the TB coordinator, and sometimes the state office.
# Evaluation and Monitoring

## Table of Contents

<table>
<thead>
<tr>
<th>Evaluation and Monitoring</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation for TB Screening</td>
<td>73</td>
</tr>
<tr>
<td>Evaluation for Treatment</td>
<td>74</td>
</tr>
<tr>
<td>Monthly Treatment Monitoring</td>
<td>76</td>
</tr>
<tr>
<td>Lab Quick Reference</td>
<td>76</td>
</tr>
<tr>
<td>Telephone Nurse Monitoring Program</td>
<td>77</td>
</tr>
<tr>
<td>Patient Education</td>
<td>80</td>
</tr>
</tbody>
</table>
Each TB patient is to have a physical evaluation according to these programmatic guidelines prior to receiving services. Regardless of which service is provided, there are components that will remain the same. Each patient will have to give a medical history, have a review of systems and a physical examination. Whether these components are limited or in-depth depend on why the patient is being evaluated.

The evaluation of a patient needing a TB screening would be limited and focused in scope. A patient who is beginning treatment for active TB disease would need a very detailed and in-depth evaluation. A patient beginning treatment for LTBI would have an evaluation similar to the TB suspect/case but not quite as detailed.

**EVALUATION FOR TB SCREENING**

**PREVIOUS TB HISTORY**
It is very important to know if the patient has ever been diagnosed with active TB disease or latent TB infection before because this will impact how he/she is evaluated. Document dates of diagnosis or testing, location where the diagnosis or testing took place and what treatment was offered or completed. Also document date, and location of any BCG vaccination given to the patient.
PERTINENT MEDICAL HISTORY
It is necessary to determine if there is any medical history or condition that may indicate the patient would be at a high risk of progression to TB disease if infected with TB. Document the history of any of the following:

- HIV infection
- Prolonged corticosteroid therapy
- Organ transplant
- TNF blockers
- Diabetes mellitus
- Silicosis
- End stage renal disease
- Gastrectomy
- Jejunoileal bypass
- Leukemia
- Lymphoma
- Cancer of the head or neck
- Less than 5 years of age

REVIEW OF SYSTEMS
A limited review of systems is done to assess whether the patient has any signs and symptoms of active TB disease and whether there is any contraindication to performing a TST.

CONSTITUTIONAL: Does the patient have any unexplained weight loss, fever, chills, weakness or fatigue, night sweats, and/or loss of appetite?

SKIN: Does the patient have a rash, itching, scaring or tattoos on arm?

RESPIRATORY: Does the patient have any shortness of breath, cough or sputum?

ALLERGIC/IMMUNOLOGIC: Does the patient have asthma? Has he/she had hives or anaphylaxis as a result of exposure to anything? Does he/she have an allergic response to materials, foods or animals?

PHYSICAL EXAMINATION
A very limited physical examination is made. Observe characteristics of breathing; note any coughing or shortness of breath. Observe overall skin texture. Examine skin of arm for scarring, tattoos, veins, and turgor.

EVALUATION FOR TREATMENT
PERTINENT HISTORY
A thorough and complete medical and social history needs to be taken. The Tuberculosis Services form (3121-R) can be used to record much of the information obtained.
DEMOGRAPHICS
Certain demographic information is needed to help direct the focus of the contact investigation and the case management of the patient. Some of the demographic information is for reporting purposes to CDC.

SOCIAL HISTORY
A social history is helpful in determining any special needs that may need to be addressed in order to provide prompt and continuous treatment to completion. Living arrangements, transportation and employment information is needed to provide comprehensive case management. Substance use is a major cause of treatment interruption and needs to be addressed throughout treatment. One way is to perform a Screening, Brief Intervention and Referral to Treatment (SBIRT) for Substance Use:

1. **Screen**: How many times in the past year have you had X drinks or more in a day? X = 5 drinks for men, 4 for women. How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?
2. **Provide feedback**: “What connection (if any) do you see between your drinking and this visit?”
3. **Provide a brief intervention to enhance motivation, discuss pros and cons, assess patient readiness** 4. **Referral to treatment**

More information can be found here:
The patient can be referred to the state Social Worker for an in-depth assessment and intervention if needed.

MEDICAL HISTORY
A thorough medical history is needed to determine if there are any complicated acute or chronic medical conditions including (but not limited to): diabetes, renal insufficiency with estimated creatinine clearance less than 50 ml/min., end-stage renal disease on hemodialysis that will impact treatment. An alcohol and substance abuse assessment is needed. If HIV status is not documented, a test is indicated. Current prescriptions and over the counter medications need to be listed. Note any allergies and current immunization status.

PREVIOUS TB HISTORY
It is very important to know if the patient has ever been diagnosed with active TB disease or latent TB infection before. Document dates of diagnosis or testing, location where the diagnosis or testing took place and what treatment was offered or completed. Document whether this patient was named as a contact to another TB case. Was he/she a contact to a known drug resistant case? Also document date, and location of any BCG vaccination given to the patient.
REVIEW OF SYSTEMS
A review of systems is indicated when a patient is starting on medication for active TB disease or latent TB infection. A clear picture of the patient’s current health status is needed. This is necessary to provide a baseline for later assessment of possible adverse drug reactions. It is important for the patient to be able to describe a change from his/her “normal” baseline. In TB disease, it is also to determine the severity of symptoms and establish how ill the person is as a baseline for documenting clinical improvement with treatment.

CONSTITUTIONAL: Does the patient have any unexplained weight loss, fever, chills, weakness or fatigue, night sweats, and/or loss of appetite? How severe are they?

HEENT: Does the patient have any vision loss, blurred vision, double vision or trouble distinguishing colors? Does he/she wear glasses? Does the patient have any hearing loss or ringing in the ears? Does he/she wear a hearing aid?

SKIN: What is the normal color of skin? Are there any rashes or itching? If so, what is the cause? Is there any bruising? Does the patient bruise easily?

CARDIOVASCULAR: Does the patient have any chest pain, chest pressure/chest discomfort, palpitations or edema?

RESPIRATORY: Is the patient experiencing any shortness of breath, cough or sputum? Is this something new or is this a chronic condition? Is the patient coughing up blood?

GASTROINTESTINAL: Does the patient have anorexia, heartburn, nausea, vomiting or diarrhea or abdominal pain? Does anything relieve it? Does anything precipitate it? What color are his/her stools? Is there any blood in the stool?

GENITOURINARY: What color is the patient’s normal urine? Does he/she have bladder or kidney infections? Have they ever had a problem with kidney function?

NEUROLOGICAL: Does the patient have headaches? What kind and what relieves them? Does he/she have dizziness, syncope, paralysis, ataxia, numbness or tingling in the extremities? Is there any problem with memory or cognition?

MUSCULOSKELETAL: Does the patient have muscle and/or back pain? Does he/she have any arthritis, joint pain or stiffness? Is there any weakness in his/her limbs or any problem with gait and movement? Have they ever had signs of gout?

HEMATOLOGIC: Does the patient have anemia, bleeding or bruising? Are they on aspirin therapy?

LYMPHATICS: Has the patient ever had enlarged nodes or a history of splenectomy?
PHYSICAL EXAMINATION
A nursing physical examination will establish how ill the person is as a baseline for documenting clinical improvement with treatment. It also serves as a baseline to assess adverse drug reactions.

VITAL SIGNS: Temperature, Pulse, Respiration, blood pressure, height, current weight (compare to normal weight), BMI

EYES: Check color of sclera. Check pupils for size and reaction to light. Perform a vision test for acuity and color discrimination (especially for patients who will be taking Ethambutol).

SKIN: Observe the overall color of skin. Check trunk and back for bruising or rash. Check turgor and examine extremities for bruising.

GASTROINTESTINAL: Check abdomen for tenderness.

RESPIRATORY: Collect sputum specimens. Observe characteristics of cough (if any).

MUSCULOSKELETAL: Observe the patient’s movements and gait. Check for joint swelling or redness.

NEUROLOGICAL: Observe for dizziness, syncope, paralysis, ataxia when moving, or getting up and down. Check for any memory difficulty or change in cognition.

MONTHLY TREATMENT MONITORING
Every TB patient receiving treatment through the health department, whether active or latent should have a monthly Review of Systems and Physical Examination as outlined above. Patients should also be closely monitored for adverse drug reactions and response to treatment. Is there anything preventing optimal treatment? What can you do to improve treatment? For active TB suspects/cases, review DOT (Section 5) and contact investigation (Section 6).

LAB QUICK REFERENCE SHEET  Class 3: TB Disease Class 4: Old TB Disease Class 5: TB Suspect
These patients are usually started on a four-drug regimen of Isoniazid, Pyrazinamide, Ethambutol and Rifampin. When the initial four-drug regimen is used, it is important to perform the following monthly lab assessments for the duration of the four-drug treatment.

Isoniazid - monthly hepatic/liver function test
Pyrazinamide - monthly uric acid levels and creatinine
Ethambutol - monthly vision/color exam
Rifampin - monthly CBC with differential

In addition to the above labs, a baseline serum glucose should be drawn. If the results are abnormal, a Hgb A1C should be drawn at the next visit.

The hepatic/liver function test, the serum glucose and creatinine levels can be ordered as a comprehensive metabolic panel instead of ordering each individual lab in an effort to save money.
On all known diabetic patients, obtain a Hgb A1C with baseline labs.
**The above labs are sent for processing to the lab provider for your county.**

HIV testing should be done on all patients. TB patients *may* qualify for Oraquick, if not, do venipuncture for HIV.
Hepatitis C ab should be drawn on all adults initially. Hepatitis B profile should be drawn on all adults and anyone less than 18 years old who is foreign-born. **The above three labs are sent for processing to the state lab.**

During the initial phase of treatment assess the patient monthly for any signs or symptoms of gout or change in kidney function. If any signs or symptoms are present, continue to draw uric acid levels for gout and creatinine for kidney function. If the patient is asymptomatic for gout or kidney issues, then these labs do not have to be drawn every month.

During the continuation phase of treatment while the patient is on Isoniazid and Rifampin, monthly hepatic/liver function test and CBC with differential will be drawn monthly and **sent for processing to the lab provider for your county.**

**Class 2: Latent TB Infection, no disease**
If the patient is on Isoniazid, baseline hepatic/liver function test is done. Then monthly (if indicated by protocol) hepatic/liver function test is done.
If the patient is on Rifampin, baseline hepatic/liver function test and CBC with differential is done. Then monthly CBC differential is done and monthly (if indicated by protocol) hepatic/liver function test is done. **The above labs are sent for processing to the lab provider for your county.**

HIV testing should be done on all patients. TB patients *may* qualify for Oraquick, if not, do venipuncture for HIV and send for processing to the state lab.

**TELEPHONE NURSE MONITORING PROGRAM (TNMP)**
**OBJECTIVE**
1. To facilitate latent TB infection treatment adherence by making the medications available at minimum inconvenience to the patient.
2. To leverage existing technology to facilitate treatment adherence despite decreases in resources 3. To improve completion rates for latent TB infection treatment.

CONCEPT

- Patients being treated for latent TB infection with self-administered isoniazid for nine months, and who are at low risk for hepatic complications may be considered for the telephone nurse monitoring program.
- Patients will have baseline laboratory tests done at the initial clinic visit.
- Patients will have the initial clinic visit and the first three follow-up monthly clinic visits monitored by the nurse at the health department clinic and will pick-up their monthly supply of isoniazid at the clinic.
- If no adverse side effects to isoniazid are identified during the first three clinic visits, telephone monitoring may begin after the third follow-up visit to the health department clinic and a 90-day supply of medication will be issued.
- Follow-up monitoring by telephone calls interspersed with in-person clinic visits.

Refer to the Guidelines for Public Health Nurses Practicing in Telehealth/Telenursing/Telemedicine, January 2013” https://dph.georgia.gov/sites/dph.georgia.gov/files/GuidelinesTelemedicineTelenursingFINALRevisedMarch122013.pdf. Nurses must have read the above guidelines, have practiced under the TB Nurse Protocol for two years or more, have demonstrated mastery of communication skills and have been endorsed by their supervisor to participate in TNMP.

CLIENT ELIGIBILITY
- Be age eighteen years or older
- Has been on LTBI treatment for at least two months, has not missed a clinic appointment and states compliance with taking medication
- Identified as being at low risk for hepatic complications while receiving anti-TB medications (e.g., does not consume alcohol, does not have any liver problems, does not have hepatitis, does not have HIV)
- Baseline laboratory tests are at normal levels
- Able to communicate by telephone with the nurse directly or with translation assistance through the language line
- Able to have a stable telephone number where they can be reached
- Able to read instructions on the medication label
- Able to demonstrate knowledge about the side effects and adverse reactions to the medications
- Able to demonstrate understanding about the signs and symptoms of active TB disease
- Able to demonstrate when and how to call the nurse should adverse reactions occur

PROCEDURE

NOTE: All encounters will follow the same format outlined under Telephone Call Process.
1. The initial evaluation will be face-to-face at the health department clinic. Baseline laboratory tests will be done. If there is no contraindication to isoniazid, a 30-day supply of isoniazid will be ordered and dispensed.  2. The first follow-up evaluation (end of month one) will be face-to-face at the health department clinic. If there is no adverse reaction to isoniazid and the baseline laboratory tests were within normal limits, a 30-day supply of isoniazid will be ordered and dispensed to the patient. If adverse reactions are identified, the medication will be stopped and follow-up actions taken according to the Standard Nurse Protocols for latent TB Infection.  3. The second follow-up evaluation (end of month two) will be face-to-face at the health department clinic. If there is no adverse reaction to isoniazid, a 30-day supply of isoniazid will be ordered and dispensed to the patient. If adverse reactions are identified, the medication will be stopped and follow-up actions taken according to the Standard Nurse Protocols for latent TB Infection.  4. The third follow-up evaluation (end of month three) will be face-to-face at the health department clinic. If there is no adverse reaction to isoniazid, the patient has not missed any clinic visits and has missed minimal pills, the patient may be considered for enrollment in the TNMP. If adverse reactions are identified, the medication will be stopped and follow-up actions taken according to the Standard Nurse Protocols for latent TB Infection.

- Verify the patient’s eligibility to enroll in TNMP
- Describe the TNMP and explain the benefits to patients deemed eligible
- Explain criteria for enrollment
- Discuss importance of having access to a stable working telephone where he/she can be reached
- Explain the TNMP follow-up schedule and that medication would be issued in 90-day supplies.
- Discuss the following logistics with the patient: o Verify the ability to receive and/or make telephone calls in private o Verify and record the telephone numbers to be used by patient and nurse
  - The need to have both patient and nurse in the state of Georgia at the time of the telephone calls.
  - The privacy of the patient’s information and the need to verify the identity of both the patient and nurse when the telephone calls are made. Mutually decide on a code name/phrase and response.
- Continue to conduct patient education on the signs and symptoms of adverse reactions. Demonstrate to the patient how to articulate degree and severity of possible findings.
- Have the patient demonstrate how to completely and accurately describe the reactions.
- Instruct the patient on adverse reactions to the medications which need to be reported immediately to the health department. Explain that the patient will need to be seen in the clinic for any adverse reaction. • A 90-day supply of isoniazid will be ordered and dispensed to the patient.
5. The first Telephone Nurse Monitoring Program (TNMP) call will be made 25-30 days (end of month four) after the third follow-up clinic visit. If there is no adverse reaction to isoniazid, the patient will be instructed to continue with the medication. If there is an adverse reaction, the patient is to stop the medication immediately and come to the clinic for further evaluation.

6. The second TNMP call will be made 30 days (end of month 5) after the first TNMP call. If there is no adverse reaction to isoniazid, the patient will be instructed to continue with the medication. If there is an adverse reaction, the patient is to stop the medication immediately and come to the clinic for further evaluation.

7. The fourth follow-up visit will occur in the health department clinic for a face-to-face evaluation (end of month six). If there is no adverse reaction to isoniazid, a 90-day supply of isoniazid will be issued to the patient. If adverse reactions are identified, the medication will be stopped and follow-up actions taken according to the Standard Nurse Protocols for latent TB Infection.

8. The third TNMP call will be made 25-30 days (end of month 7) after the clinic visit. If there is no adverse reaction to isoniazid, the patient will be instructed to continue with the medication. If there is an adverse reaction, the patient is to stop the medication immediately and come to the clinic for further evaluation.

9. The fourth TNMP call will be made 30 days (end of month 8) after the third TNMP call. If there is no adverse reaction to isoniazid, the patient will be instructed to continue with the medication. If there is an adverse reaction, the patient is to stop the medication immediately and come to the clinic for further evaluation.

10. The fifth and final follow-up visit will occur in the health department clinic for a face-to-face evaluation (end of month nine). If there is no adverse reaction to isoniazid and the patient has finished taking his medication, then the patient’s treatment is considered complete and closed out.

TELEPHONE CALL PROCESS
1. Review the patient’s record before the call and keep the record open to document the call as you progress.
2. Call the patient at or within 15 minutes of the scheduled time.
3. Request to speak to the patient.
4. Ask the agreed upon security question to verify the identity of the patient and ask where the patient is currently located (must be within the borders of the state of Georgia).
5. Ask the patient whether the time is still appropriate.
   • If no, arrange another time with the patient (preferably within 30 to 60 minutes, but at least within 24 hours) and give the patient the option of initiating the call within this time frame
   • If yes, continue with the call
6. Following the format outlined in the previous section, complete a brief present history including asking about any missed pills.
7. Complete a pertinent history.
8. Perform a review of systems and document all answers in the patient record.
9. Identify any adverse reactions and discuss any change in the review of systems and the actions to be taken by the patient in response to the changes.
10. Discuss whether the patient is to continue or discontinue the medication.
11. Discuss any concerns identified by the patient.
12. Perform counseling/care management as indicated.
13. Verify the date and time of the next monitoring call.
   - Telephone assessment and management (5 – 10 min.)
   - Telephone assessment and management (11 – 20 min.)
   - Telephone assessment and management (21 – 30 min.)
15. Include the following documentation in the patient record:
   - The time and outcome of the TNMP call
   - Who initiated the call—the nurse or the patient
   - The date and the time for the next TNMP call
16. If the patient was not reached, then document the following actions and responses:
   - If the patient does not answer, make 2 to 3 additional attempts to reach the patient within the 30 minute period of time.
   - Document failed attempts in the patient’s chart.
   - Make an attempt to reach patient by telephone each day until contact is made.
   - If contact is not made by telephone within one week, make a home visit to the client to re-evaluate placement in TNMP.
   - At the discretion of the nurse, the patient may be discontinued from TNMP for lack of telephone availability.

Nurses may telephone patients not enrolled in TNMP for missed appointments, counseling and follow-up of referrals and education. The same CPT codes would apply.

DISCONTINUING TELEPHONE MONITORING SERVICE
Conditions under which a patient should be discontinued from the TNMP and returned to regular monthly clinic monitoring are as follows:
   - Patient no longer has a working telephone
   - Patient missed several TNMP calls and has not been reached in 15 days of the first missed scheduled contact
   - Patient developed side effects that need closer monitoring
   - Patient developed active disease and is placed on multiple drug treatment
   - Patient requests to be discontinued from TNMP

PATIENT EDUCATION
Nurses should provide counseling and education at every encounter. The patient needs to understand the disease process of tuberculosis and their individual treatment plan. The 12 Points of Tuberculosis Patient Education and the Tuberculosis Education Record are excellent tools to use for content and documentation. These are located on the TB website.
It is imperative that the client be thoroughly educated on the potential side effects of TB medications and the symptoms of adverse reactions. It is also vital that the patient know how to describe each symptom and that the nurse understand each description.

Side effects of medications are those things which are anticipated to happen to people taking certain medications. Most of the side effects are manageable and do not require stopping the medication. Adverse reactions of medications are those things which are severe and may indicate harm to the patient. Adverse reactions warrant stopping the medication and consulting the contract physician. Refer to the Standard Nurse Protocols and the 12 Points of Tuberculosis Patient Education for drug specific information and actions.

Use the patient education sheets (located at the end of this section) as you go through the review of systems. Demonstrate how to use the rating scales for each question for assessment during the first three months. This will assist the nurse and the patient understanding each other's vocabulary and what each other mean. This type of communication will carry over to the telephone and assist the nurse in making her assessment if the patient becomes enrolled in the TNMP.

On the patient education sheets, a scale is used with each symptom. Most of the scales are labeled from 0 to 10 with 0 being “none” of the symptom and 10 being “severe” symptom.

Example 1: Rudy and the nurse go over the patient education sheets about GI disturbances and Rudy denies having any nausea and vomiting. They rate this as 0 and discuss that if he feels nausea, he might rate it as 1, but if he begins to vomit dark, coffee ground material, then he would need to immediately alert the nurse and describe it as 10.

Example 2: When asked what color his urine is, Tom points to the orange urine. The nurse and Tom discuss how the medication rifampin turns secretions orange in color. They compare the normal yellow and the rifampin orange to the dark, maple syrup colors. Together they agree that if Tom’s urine begins to look dark like that, he will immediately alert the nurse and describe it as 8 – 10.

Example 3: Jeri states she had some nausea and vomiting. The nurse would discuss the number of events (Jeri states one time); the color of the vomit (Jeri states it looked like her dinner) and when the events took place (Jeri vomited shortly after eating) and when the last dose of medication (she had taken her pill that morning, 6 hours earlier). Together the patient and the nurse would discuss if there were any lingering feelings and how the patient feels at this moment. If Jeri states she felt better after vomiting and did not have any other problems at the time and that she feels great today, then they would discuss that “2 or 3” could describe this event and that it is unlikely to be related to medication. The nurse explains that if Jeri
continues to vomit in the next couple of days or if she begins to vomit dark, coffee ground material, then she would need to immediately alert the nurse and describe it as 10.

There are numerous patient education materials available for use in addition to what is covered here. People learn in different ways, so having information presented in writing, by speaking, in pictures, in video and by demonstration all assist in retaining what is learned.

Georgia TB Laws and Court-Ordered Treatment
ADHERENCE

For in-depth information on adherence, please read Chapter VII in *Tuberculosis Nursing: A Comprehensive Guide to Patient Care* and Module 9 of CDC’s *Self Study Modules on Tuberculosis*.

*Adherence* means "sticking to" or "being faithful to," such as your adherence to your diet even when chocolate cake is around, or patients’ adherence to TB treatment — they continue to take medication even when they are feeling better. TB treatment takes at least six months and could last for up to two years. Most patients begin to feel better early in the treatment. This makes it
difficult for them to continue to take medication that may make them feel bad. It can be challenging for the public health staff to help keep the patient on treatment.

Understanding how the patient feels about TB disease and treatment will help the healthcare worker begin to support the patient. Accepting different perceptions while presenting valid health information can be challenging. All education and information must be tailored to the patient’s knowledge and readiness to accept new information. The 12 Points of Patient Education can be presented using videos, pictures, written material or through conversation. The patient education section in this manual contains pictures that can be used as well as the 12 Points of Patient Education. The county health departments have DVDs and videos. Web presentations and other patient resources can be found online on the DPH TB Program’s web site at https://dph.georgia.gov/tb-educational-resourcesclinicians-and-healthcare-providers

From the first encounter, the patient needs to understand what is expected during the course of TB treatment and the consequences if those expectations are not met. Tell the patient about non-adherence and why it might occur. Explain the consequences of non-adherence are treatment failure and continued TB transmission. Set the expectation that public health is here to support the patient in completing a full course of therapy until treatment completion. The expectations should be reinforced at each encounter with the patient until they are fully understood. This can best be done by the health care worker listening carefully to the patient and quickly identifying any possible barriers to adherence. Once identified, the barriers need to be addressed and mutually resolved.

During the first visit, the consent to treatment form/3609.TB and the treatment plan/3144 should be explained and agreements signed. In addition, a DOT agreement/603 DOT needs to be negotiated and signed. At every patient encounter, adherence should be checked and documented. The TB Case Manager should analyze the patient’s adherence rate during monthly evaluation sessions and more frequently as needed. Episodes need to be dealt with promptly and efforts and results of efforts need to be documented as they occur. All forms mentioned above can be found in Appendix F

The local clinic staff must assess how the patient is adhering to treatment, quickly recognize when a patient is not on course and make rapid interventions to minimize interruptions in treatment. It is important for the staff to identify the specific reasons a patient is not adherent and address them with the patient. An individualized plan to overcome the barriers to treatment needs to be made and negotiated with the patient. At times, an additional agreement may need to be written and signed by the patient.

The following are some examples of non-adherent episodes:

• Patient on five day per week DOT and misses three DOT appointments in a two-week period.
• Patient on twice weekly DOT and misses two DOT appointments in a two-week period.
• Patient misses a clinic appointment
• Patient breaks isolation while still infectious
• Failure to disclose adequate information to identify contacts
• Substance abuse during treatment causing interruption in TB treatment

Each episode of non-adherence must be documented in the patient record. All actions taken and the results of those actions must be thoroughly documented in the patient record.

It is important be as pro-active as possible when dealing with patients. Break down the length of treatment into manageable steps and use individualized incentives for reaching set milestones. Provide positive reinforcement for keeping appointments. Make DOT appointments that fit into the patient’s lifestyle and are easy to keep. Send reminders for clinic appointments. Help the patient identify a buddy that can provide additional support during treatment.

Negotiation and assisting the patient to come up with solutions before small incidents become major issues can help to avoid having to take a patient to court. Listening carefully to the patient and acting on clues during conversation can decrease episodes of non-adherence. For instance, during the course of a conversation, the patient may mention leaving town to visit with a family member. The public health staff should act on that information and get details about the possible visit. Answer questions of who, when, where and work with the patient to work out a mutually satisfactory way to make sure the patient continues treatment without interruptions while visiting the family.

Adherence should methodically be assessed and documented on a monthly basis at a minimum. Results should be discussed during the regular case reviews with the staff and/or TB Coordinator. Strategies to address issues should be discussed, implemented, evaluated and documented before they become a major problem.

ASSESSMENT TOOL

1. Take the actual number of events and divide by the scheduled number of events then multiply by 100 to get percentage of adherence for each of the following:
   • DOT doses in a month
   • Clinic visits to date
   • Referrals made for social services or medical care to date

Examples:

<table>
<thead>
<tr>
<th></th>
<th>65 scheduled DOT visits, showed up for 42 visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOT</td>
<td>42 divided by 65 = .646 X 100 = 64.6% DOT adherence</td>
</tr>
<tr>
<td>Clinic appointments</td>
<td>5 scheduled clinic visits, showed up for 2 visits</td>
</tr>
<tr>
<td></td>
<td>2 divided by 5 = .4 X 100 = 40% clinic appointment adherence</td>
</tr>
</tbody>
</table>
Referrals

<table>
<thead>
<tr>
<th>Referrals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Referred to HIV clinic for testing, substance abuse counselor &amp; social security disability. Showed up for HIV testing 1 divided by 3 = .33 X 100 = 33% referral adherence</td>
</tr>
</tbody>
</table>

2. Review the number of episodes of non-adherence to date. Have the methods to address those episodes been effective? Are there other steps that need to be taken?

3. Is the patient on track to complete treatment within one year? Do a current dose count and project treatment completion. Minimum amount of time is 26 weeks and maximum time is 52 weeks.

4. Assesses patient’s TB knowledge, attitudes, and beliefs concerning drug efficacy and severity of TB disease; reviews patient education progress on the Tuberculosis Education Record.

ESCALATION OF ISSUES
Unfortunately, patient situations can be complex and timeliness of interventions is needed. Below are guidelines for bringing potential problems to resolution in a prompt manner so that interruptions to treatment are minimized. Remember, documentation is key in these matters.

LOCAL TB NURSE
- Assesses for potential conflicts in approach to TB treatment and naming of exposed persons; identifies nature of differences and addresses patient-centered approach with patient and in written plan
- Outlines, verbally and in writing, patient and provider responsibilities so that each understands important details about how patient’s TB will be managed: legal parameters, method of treatment administration, methods of airborne infection control, methods of communication (e.g., phone numbers)
- Assesses for potential treatment barriers; selects, with patient’s input, mutually acceptable enablers to overcome barriers;
- Negotiates incentives to reward successful accomplishment of treatment milestones
- Performs initial telephone calls, home visits, and certified letters to gain cooperation and compliance

DISTRICT TB COORDINATOR
- Assists TB nurse with follow up actions, field visits, and location strategies for missing patients
- Supports TB Nurse in negotiation and information sessions with patient to stress patient care plan; adherence; and strategies to overcome barriers
- Discusses with State Office developing situations and possible strategies

DISTRICT TB HEALTH DIRECTOR
- Issues Health Director Orders for compliance
• Notifies county attorney of possible court action; works with attorney through the court process

STATE TB OFFICE
• Support TB Coordinator in strategies to overcome issues
• Support district staff through the court process
• Liaison to CorrectCare if confinement is needed

COURT-ORDERED TREATMENT AND/OR CONFINEMENT OF NON-ADHERENT TB PATIENTS
All court proceedings should be through the District TB Coordinator. The state office TB Program is to be notified immediately of any pending legal issue with a TB case. The county attorney, the client’s attorney and all associated court fees are to be paid by the county health department.

The state office TB Program is to be notified immediately of any pending confinement case. Approval must be obtained from the TB Program Director. The health district is expected to pay the confinement facility. Paid invoices can then be submitted to the state office TB Program for reimbursement.

Typical Court-Ordered Treatment Process:
1. District Health Officer or TB Coordinator sends a certified letter to non-adherent patient with specific instructions on TB treatment and isolation, e.g., wear a surgical mask in public.
2. If no letter has been sent, but the County Health Department (CHD) has documentation that they gave specific instructions to the patient, patient agreed and signed a treatment plan, patient did not comply with these instructions and is a public health threat because of potential disease transmission, the District or CHD can proceed to ask for court-ordered compliance with CHD instructions.
3. CHD should contact the county attorney’s office for an Emergency Commitment Hearing Order (Form 3 in Court Order Templates). The county attorney will have a judge sign the order.
4. With this order, a court hearing is scheduled within 7 days from the day the order is signed. The county sheriff will pick-up the patient and confines him in a jail or hospital with respiratory isolation facilities until the court hearing. The sheriff’s office can contact other counties to confine the patient if their county jail or local hospital does not have an appropriate isolation room.
5. The patient is assigned a lawyer, the county attorney represents the CHD, and CHD health providers appear in court to testify.
6. The judge can order the patient to follow very specific instructions, e.g., wear a mask in public until sputum smear negative 3x and until he has taken 2 weeks of medicines, and comply with DOT. The judge can state that if patient does not comply, he will be in contempt of court and can be detained/committed by court order to a facility approved by
the state TB program like a county jail with respiratory isolation units or CorrectCare in South Carolina.

7. If the county attorney does not have a lot of experience with these kinds of orders, s/he can consult with the county attorneys from Fulton, DeKalb, Gwinnett or Cobb, who are experienced with such procedures.

The Georgia Department of Public Health and CorrectCare Inc. in South Carolina have a memorandum of understanding (MOA) regarding court-ordered non-adherent TB patients referred by county health departments to CorrectCare for detention. The MOA has the following stipulations:

FUNDING FOR ADMISSION OF GEORGIA TB PATIENTS AT CORRECTCARE:
Charges incurred by clients involuntarily committed will be invoiced to the client’s county health department. The DPH TB Program will provide allocations to the respective district for charges incurred by the client(s) admitted to CorrectCare. These allocations will be made within 30 days of receipt of an invoice.

- Services under this MOA will be invoiced to each district at a daily per person rate of $260.00 while in isolation and $189.00 out of isolation (2012 rates).
- After the first year of this MOA, on the anniversary date, the price will adjust for each additional year, in an amount equal to the most recently available annual change in the Bureau of Labor Statistics Consumer Price Index for the South, Medical Care Component, which is the most accurate measure of the cost increases CRCC experienced delivering services.
- The DPH TB Program will assist CorrectCare, when requested, in collecting past due invoices from respective districts.

RESPONSIBILITIES OF THE DPH TB PROGRAM FOR CORRECTCARE REFERRALS:
- The DPH TB Program will ensure that all clients referred for admission to CorrectCare have a legal commitment order prior to admission.
- The DPH TB Program will ensure that CorrectCare receives a completed Medical Data Summary Sheet on each pending admission.
- The DPH TB Program will ensure that each client will arrive with a signed Medical Care Plan, a copy of his/her current medical record.
- The DPH TB Program will ensure that the balance of prescribed TB medications to complete the client’s treatment regimen will be provided.
- The DPH TB Program will routinely monitor the care, treatment and clinical status of each TB client committed from Georgia. • The DPH TB Program will provide technical assistance, guidance, educational materials as requested.

RESPONSIBILITIES OF CORRECTCARE REGARDING SERVICES AND DELIVERABLES:
• CorrectCare agrees to provide rooms that are secure and ensure safety at all times and that are appropriate for clients involuntarily committed to the facility for failure to adhere to a treatment regimen.
• CorrectCare agrees to follow the Medical Care Plan which accompanies the client from Georgia.
• CorrectCare agrees to consult the DPH TB Program Medical Consultant prior to any change in the prescribed treatment plan.
• CorrectCare agrees to obtain prior approval from the DPH TB Program Medical Consultant or a designee before any referral to another facility for services, with the exception of a medical or life-threatening emergency. The DPH TB Program will be notified as soon as possible after the occurrence.
• CorrectCare will provide monthly x-rays as ordered.
• CorrectCare will provide all TB medications when the patient arrives at their facility.
• CorrectCare will provide Monthly Medical Status Reports to the DPH TB Program and local county health department.
• CorrectCare will provide Airborne Infection Isolation (AII) rooms/special negative pressure rooms for the specific purpose of isolating persons who might have suspected or confirmed infectious TB disease.
• CorrectCare will provide three nutritious meals along with snacks daily.
• CorrectCare will provide opportunities for recreation in the courtyard.
• CorrectCare will provide transportation for external medical appointments, if required.

SPECIAL CIRCUMSTANCES:
• In the event of the death of the TB client committed from Georgia, CorrectCare shall notify the state TB Program Manager or designee as soon as possible after the event.
• The DPH TB Program will notify the county health department of the client’s death.
• The DPH TB Program will discuss any burial plans with the respective county health department and with family members, if available.
• If the TB client is deemed homeless and after due diligence to identify family none is found, the client will be buried in accordance with the procedures of CorrectCare.
• A statement to the effect of the above item will be faxed to the CorrectCare General Manager.
• The cost of burial will be included in the client’s last invoice.

REPORTING REQUIREMENTS:
• CorrectCare will submit monthly invoices for each client’s charges to the respective District TB Coordinator by the 15th of each month for the preceding month.
• CorrectCare will submit a Monthly Medical Status Report to the DPH TB Program’s State Office for each TB client in their custody. Reports should be received by the 15th of each month for the preceding month.
• CorrectCare will provide the DPH TB Program with a thorough Discharge Summary within two weeks after the client’s discharge from their facility. The Discharge Summary will be
inclusive of a synopsis of the hospital course, special procedures performed, consultations performed, abnormal laboratory studies and a complete list of medications prescribed at discharge.

- CorrectCare will provide a 7-day supply of TB medications, if the patient is still under treatment at the time of discharge from the facility.

**DELINQUENT REPORTS:**
- CorrectCare will submit reports/client updates as required by the DPH TB Program by the designated due dates as outlined in this MOA.
- DPH TB Program reserves the right to withhold payments for services performed under this MOA, after notice to CorrectCare and an opportunity for a meeting with a DPH TB Program representative.

**Sample Medical Care Plan for CorrectCare Referral** (Type the Medical Care Plan on your County Health Department’s letterhead/stationery)

**Current Date:**

**Patient’s Name:**

**Patient’s Date of Birth:**

**Patient’s Social Security Number:**

**Diagnosis:** Laboratory-confirmed, active pulmonary TB

**Medications:**
(Provide detailed directions. For PRN medications, add reason for administration)

- **Initial TB drug regimen** (for current weight = xx lbs.)
  - Isoniazid 300 mg daily for 56 doses by DOT
  - Rifampin 600 mg daily for 56 doses by DOT
  - Ethambutol xxxx mg daily for 56 doses by DOT
  - Pyrazinamide xxxx mg daily for 56 doses by DOT
  - Pyridoxine 25 mg daily for 56 doses by DOT

- **Continuation TB drug regimen**
  - Isoniazid 900 mg twice weekly for 36 doses by DOT
  - Rifampin 600 mg twice weekly for 36 doses by DOT
  - Pyridoxine 50 mg twice weekly for 36 doses by DOT

**Chest x-ray frequency:** Only if indicated

**Laboratory Testing:** (Frequency of sputum examination, liver enzymes, vision tests, etc.)
- Monthly hepatic function panel, or as needed if signs or symptoms of hepatic toxicity
- Sputum AFB smear/culture daily x 3 then weekly until sputum conversion, then monthly **Miscellaneous:** (ID consult, negative pressure isolation room, frequency of recording patient’s weight, social services referral if substance abuse counseling/drug rehabilitation is indicated, etc.)
  - Baseline and monthly visual acuity testing and red/green color discrimination
  - Negative pressure room needed until 3 consecutive negative sputum smears collected on different days, 2 weeks of TB medication and signs of clinical improvement
• Biweekly weight checks
• Refer to social services related to substance abuse **Interchange:** Please send monthly reports of normal findings re:
  • Medical evaluation
  • Laboratory results
• General condition and miscellaneous Please notify us as soon as possible re:
  • Abnormal laboratory findings
  • Adverse reactions to medications
  • Any other pertinent abnormal findings

**Physician’s signature and date signed needed at end of sheet** Type physician’s name and title underneath signature.

**REFERENCES**

CDC. *Core Curriculum on Tuberculosis: What the Clinician Should Know, 2011.* Each district health office was sent a copy in 2012. It can also be ordered from CDC or downloaded at [http://www.cdc.gov/tb/education/corecurr/](http://www.cdc.gov/tb/education/corecurr/)


CDC. “Plan to Combat Extensively Drug-Resistant Tuberculosis.” 2009. *(MMWR)* 2009; 58 (RR-03). Available at [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5803a1.htm?s_cid=rr5803a1_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5803a1.htm?s_cid=rr5803a1_e)

CDC. “Recommendations for Use of an isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent *Mycobacterium tuberculosis* Infection.” *(MMWR)* 2011;60(48); 1650-1653. Errata: 60(48) February 3, 2012 / 61(04); 80. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)


CDC, ATS, IDSA. “Diagnostic Standards and Classification of Tuberculosis in Adults and Children” (Am J Respir Crit Care Med 2000;161[4 Pt 1]). Available at: http://www.thoracic.org/statements/resources/archive/tbadult1-20.pdf

CDC, ATS, IDSA. “Treatment of Tuberculosis” (MMWR 2003;52 [No. RR-11]). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf

CDC, NTCA. “Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC” (MMWR 2005; 54 [No. RR-15]). Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf


NTCA, NTNC. *Tuberculosis Nursing: A Comprehensive Guide to Patient Care, Second Edition*. 2011. Published and distributed by the National TB Controllers Association and the National Tuberculosis Nurse Coalition. Each district health office and county health department was sent a copy in 2012. Additional copies may be purchased by contacting the National TB Controllers Association at [http://tbcontrollers.org/](http://tbcontrollers.org/)


Mission: To promote health and quality of life by preventing, controlling, and eventually eliminating tuberculosis (TB) from the United States, and by collaborating with other countries and international partners in controlling global tuberculosis.

Goals for Reducing TB Incidence$^{1,2,5}$

<table>
<thead>
<tr>
<th>Goal Description</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Incidence Rate</td>
<td>Reduce the incidence of TB disease. 1.4 cases per 100,000</td>
</tr>
<tr>
<td>U.S.-Born Persons</td>
<td>Decrease the incidence of TB disease among U.S.-born persons. 0.4 cases per 100,000</td>
</tr>
<tr>
<td>Foreign-Born Persons$^6$</td>
<td>Decrease the incidence of TB disease among foreign-born persons. 11.1 cases per 100,000</td>
</tr>
<tr>
<td>U.S.-Born Non-Hispanic Blacks or African Americans$^6$</td>
<td>Decrease the incidence of TB disease among U.S.-born non-Hispanic blacks or African Americans. 1.5 cases per 100,000</td>
</tr>
<tr>
<td>Children Younger than 5 Years of Age</td>
<td>Decrease the incidence of TB disease among children younger than 5 years of age. 0.3 cases per 100,000</td>
</tr>
</tbody>
</table>

Objectives on Case Management and Treatment$^{1,2,5}$

<table>
<thead>
<tr>
<th>Objective Description</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Known HIV Status</td>
<td>Increase the proportion of TB patients who have a positive or negative HIV test result reported. 98%</td>
</tr>
<tr>
<td>Treatment Initiation</td>
<td>For TB patients with positive acid-fast bacillus (AFB) sputum smear results, increase the proportion who initiated treatment within 7 days of specimen collection. 97%</td>
</tr>
<tr>
<td>Recommended Initial Therapy</td>
<td>For patients whose diagnosis is likely to be TB disease, increase the proportion who are started on the recommended initial 4-drug regimen. 97%</td>
</tr>
<tr>
<td>Sputum Culture Result Reported</td>
<td>For TB patients ages 12 years or older with a pulmonary or a pleural or a respiratory site of disease, increase the proportion who have a sputum culture result reported. 98%</td>
</tr>
<tr>
<td>Sputum Culture Conversion</td>
<td>For TB patients with positive sputum culture results, increase the proportion who have documented conversion to negative results within 60 days of treatment initiation. 73%</td>
</tr>
<tr>
<td>Completion of Treatment</td>
<td>For patients with newly diagnosed TB disease for whom 12 months or less of treatment is indicated, increase the proportion who complete treatment within 12 months. 95%</td>
</tr>
</tbody>
</table>

August 2015

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
For TB patients with cultures of respiratory specimens identified with M. tuberculosis complex (MTBC), increase the proportion reported by the laboratory within 25 days from the date the specimen was collected. 78%

NOTE: 25 days includes 21 days for culture to grow and 4 days for specimen collection and delivery to lab.

Turnaround Time — For TB patients with respiratory specimens positive for MTBC by nucleic acid amplification (NAA), increase the proportion reported by the laboratory within 6 days from the date the specimen was collected. 92%

NOTE: 6 days includes 2 days for detection and 4 days for specimen collection and delivery to lab.

Drug-Susceptibility For TB patients with positive culture results, increase the proportion who have 100% initial drug-susceptibility results reported.

Universal For TB patients with a positive culture result, increase the proportion who have a MTBC genotyping result reported.

For TB patients with positive AFB sputum-smear results, increase the proportion who have contacts elicited.

For contacts to sputum AFB smear-positive TB cases, increase the proportion who are examined for infection and disease.

For contacts to sputum AFB smear-positive TB cases diagnosed with latent TB infection, increase the proportion who start treatment.

For contacts to sputum AFB smear-positive TB cases who have started treatment, increase the proportion who complete treatment.
For immigrants and refugees with abnormal chest radiographs (X-rays) read examination overseas as consistent with TB, increase the proportion who initiate a medical examination within 30 days of notification.

<table>
<thead>
<tr>
<th>Medical Examination</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiating within 30 days of notification</td>
<td>84%</td>
</tr>
<tr>
<td>Completing within 90 days of notification</td>
<td>76%</td>
</tr>
</tbody>
</table>

For immigrants and refugees with abnormal chest X-rays read overseas examination as consistent with TB, increase the proportion who complete a medical examination within 90 days of notification.

<table>
<thead>
<tr>
<th>Medical Examination</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiating within 30 days of notification</td>
<td>84%</td>
</tr>
<tr>
<td>Completing within 90 days of notification</td>
<td>76%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Examination</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiating within 30 days of notification</td>
<td>84%</td>
</tr>
<tr>
<td>Completing within 90 days of notification</td>
<td>76%</td>
</tr>
</tbody>
</table>

Objectives on Data Reporting

Ensure the completeness of each core Report of Verified Case of
- RVCT Tuberculosis (RVCT) data item reported to CDC, as described in the TB cooperative agreement announcement.

Increase program evaluation activities by monitoring program

Ensure the completeness of each core Aggregate Reports for
- ARPE Tuberculosis Program Evaluation (ARPE) data items reported to CDC, as described in the TB cooperative agreement announcement.

Increase program evaluation activities by monitoring program

Ensure the completeness of each core Electronic Disease Notification
- EDN (EDN) system data item reported to CDC, as described in the TB cooperative agreement announcement.
• Evaluation Activities progress and tracking evaluation status of TB cooperative agreement recipients.

Increase the percent of TB cooperative agreement recipients that

• Evaluation Focal Point have an evaluation focal point.

Objectives on Human Resource Development

Increase the percent of TB cooperative agreement recipients who submit a program-specific human resource development plan (HRD)

• Development Plan and a yearly update of progress, as outlined in the TB cooperative agreement announcement.

Increase the percent of TB cooperative agreement recipients that

• Training Focal Point have a TB training focal point.

Footnotes:

1. Indicator calculations for measuring progress are established by the National TB Indicators Project (NTIP).

2. Targets for incidence rates and objectives on case management and laboratory reporting are established on the basis of performance reported in NTIP using 2000-2013 data from the National TB surveillance system.

3. Targets for objectives on contact investigation are established on the basis of performance reported in NTIP using 2000-2011 data from the Aggregate Reports for Tuberculosis Program Evaluation (ARPE) for contacts.

4. Targets for objectives on the examination of immigrants and refugees are established on the basis of performance reported in NTIP using 2008-2012 data from the Electronic Disease Notification (EDN) system. The latest year with data available for treatment outcome of immigrants and refugees diagnosed with TB infection is 2011.

5. Targets are based on a statistical model that uses data to find trends from 2000 through 2013 (or the latest year with data available). TB programs with fewer than 150 cases from 2011-2013 were excluded. For each objective, we used a quantile regression model to estimate the 90th percentile for each year, and extrapolated the fitted model to predict the estimated 90th percentile in the year 2020, which served as the target for 2020. The “90th percentile” values reflect the projected performance of the top 10% of TB programs in the United States in 2020. The quantile regression serves to establish a smooth trend over time, which is useful since the actual percentiles in any given year (e.g. the final year of available data) may not be representative of the overall trend.

6. Jurisdictions with a foreign-born population or U.S.-born non-Hispanic black or African American population less than an average of 100,000 persons per year in 2011-2013 are also excluded in the statistical model for TB incidence rates for foreign-born persons and U.S.-born non-Hispanic blacks or African Americans.

7. Report of Verified Case of Tuberculosis (RVCT) is the standard surveillance data collection form for reporting tuberculosis cases.

8. Aggregate Reports for Tuberculosis Program Evaluation (ARPE) is the standard form for reporting contact investigation activities.
RE  “Public Health” Exceptions to HIPAA

Dear Colleague:

From time to time, we receive questions from physicians and other health care providers who are concerned that federal privacy regulations prevent them from reporting patient information to local health departments or to the Department of Public Health.

The “Health Insurance Portability and Accountability Act” (HIPAA), enacted by Congress in 1996, protects the confidentiality of the patient’s personal health information. However, HIPAA and its accompanying regulations strike a balance between a health care provider’s duty of confidentiality and the need to protect the public health. Federal HIPAA regulations provide that patient health information may be provided to state public health authorities, with or without the patient’s consent, in many different circumstances. Those circumstances include the following:

- A health care provider “may disclose protected health information for the public health activities and purposes described in this paragraph to a public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions,” 45 C.F.R. § 164.512(b)(1)(i); and

- A health care provider “may, consistent with applicable law and standards of ethical conduct, use or disclose protected health information, if the [provider] in good faith believes the use or disclosure is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public, and is to a person or persons reasonably able to prevent or lessen the threat, including the target of the threat,” 45 C.F.R. § 164.512(j)(1)(ii).

I hope this information will facilitate your support of our unwavering efforts to protect the public health. If you have any questions, please feel free to contact our legal department.

With best regards, I am

Yours very truly,

Brenda Fitzgerald, M.D.
Commissioner of Public Health
State Health Officer

Equal Opportunity Employer
Interjurisdictional TB Notification (IJN) Form

Type of Referral: □ Active/Suspect TB - See Section 1
□ TB Contact - See Section 2
□ Class A/B - See Section 3
□ TB Infection - See Section 4

Date of Expected Arrival

Online directory of state and big city TB programs:
www.tbcontrollers.org/community/statecityterritory

Referring Jurisdiction Information:

City ___________________________________________ County ___________________________________________ State ____________

Person Completing Form

Phone ___________________________________________ Fax ___________________________________________

Form Sent to:

Date _______________  IJN Form Sent

Name ___________________________________________ Phone ___________________________________________ Fax ___________________________________________ Location ____________

Name ___________________________________________ Phone ___________________________________________ Fax ___________________________________________ Location ____________

Return Follow-Up Form To:

Follow Up Requested

Name ___________________________________________ Jurisdiction ___________________________________________ Location ____________

Phone ___________________________________________ Fax ___________________________________________
<table>
<thead>
<tr>
<th>Referred Person’s Name</th>
<th>DOB</th>
</tr>
</thead>
</table>

### SECTION 1: Active/Suspect TB Disease

<table>
<thead>
<tr>
<th>RVCT Number</th>
<th>Site of Disease</th>
<th>Most Recent Respiratory Smear</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Treatment Status</th>
<th>Most Recent Respiratory Culture</th>
</tr>
</thead>
</table>

**Results Attached:** Please attach all applicable results
**SECTION 2: TB Contact Investigation**

<table>
<thead>
<tr>
<th>Date of Last Exposure</th>
<th>Contact Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial TB test</td>
<td>Date</td>
</tr>
<tr>
<td></td>
<td>Results: attach results</td>
</tr>
<tr>
<td>8-12 week post exposure</td>
<td>Date</td>
</tr>
<tr>
<td></td>
<td>Results: attach results</td>
</tr>
<tr>
<td>Radiology</td>
<td>Treatment Status</td>
</tr>
</tbody>
</table>

**SECTION 3: Immigrants & Refugees - Class A/B**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Alien #</th>
<th>EDN Transfer Complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>TST/IGRA</td>
<td>US Radiology</td>
<td>Sputa</td>
</tr>
<tr>
<td>Treatment Status</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SECTION 4: TB Infection - Non-Contact of Class A/B**

**Results Attached:** TST/IGRA Radiology Sputa Treatment Status

**SECTION 5: TB Treatment Summary**
**Note:** This form contains confidential patient information. Please comply with HIPAA regulations when sending this form.

### Interjurisdictional TB Notification Form (IJN)
**Revision:** May 2015

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Therapy Admin</th>
<th>Date Started</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Treatment Summary for:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Therapy Admin</th>
<th>Date Started</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Estimated Date of Completion**

<table>
<thead>
<tr>
<th>Last DOT dose administered on:</th>
<th># of doses given for travel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Prescription Given**

<table>
<thead>
<tr>
<th>Side Effects or Adherence Problems</th>
<th>MAR/DOT Log Attached</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Comments:**

---

**www.tbcontrollers.org/resources/interjurisdictional-transfers**
INTERNATIONAL TUBERCULOSIS NOTIFICATION FORM

TO: **Health Officer, Physician, or Tuberculosis Control Personnel of:**

<table>
<thead>
<tr>
<th>Country</th>
<th>Province</th>
<th>District</th>
<th>City or Village</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The individual named below has **active tuberculosis** and was treated in the USA. He or she **has not completed treatment**. This form is to notify you so that treatment can be completed.

Tuberculosis Patient’s Name:_______________________________________________________

Date of Birth:____________ Place of Birth:_________________________ Sex:________

This patient informed us that he/she was going to the following location:

<table>
<thead>
<tr>
<th>Patient’s Address</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>City or village</td>
<td></td>
</tr>
<tr>
<td>District, Province</td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td></td>
</tr>
<tr>
<td>Telephone if available</td>
<td></td>
</tr>
<tr>
<td>e-mail address if available</td>
<td></td>
</tr>
<tr>
<td>Contact person at this location</td>
<td></td>
</tr>
</tbody>
</table>

If you have any questions, contact the following person who treated this patient in the United States:

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td></td>
</tr>
<tr>
<td>City, State, Zip Code</td>
<td></td>
</tr>
</tbody>
</table>
Date of diagnosis of current illness ____________________

This illness was a: [ ] New episode of TB
(check one) [ ] Treated for TB in the past, before the current episode

If previously treated, describe the patient’s prior history of tuberculosis and treatment.

Site(s) of disease: [ ] Pulmonary [ ] Extra-pulmonary (specify) ____________________

Initial and most recent laboratory and radiographic test results (microscopy, cultures, drug susceptibility test results, radiographs, and other critical lab tests) (use additional pages as needed)

<table>
<thead>
<tr>
<th>Date</th>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Current Medications (generic name), Dose, Frequency, Route of Administration, Start Date

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Frequency</th>
<th>Route</th>
<th>Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Treatment Plan. Our treatment plan for this patient is specified below. This may differ from TB treatment in your country. *Please insure this patient completes a full course of treatment.*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Frequency</th>
<th>Route</th>
<th>Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Any Other Comments

Revised 08 June 2011, Page 2 of 2

Appendix E
CureTB Binational Notification

Telephone: (619) 542-4013
Fax: (619) 692-8020

¹Referring Jurisdiction: ________________________________ ¹Date sent: ____

City Count County State

¹Contact person: ___________________________ ¹Telephone: (___) _____ Ext. ___ Fax (___) __________

Referring Agency: ________________ E-Mail Address: ________________________________
1. Fields required to initiate the referral process
2. Whenever possible send CXR reports and laboratory reports as attachments to this referral.

<table>
<thead>
<tr>
<th>Date of collection</th>
<th>Specimen type</th>
<th>Smear</th>
<th>Culture</th>
<th>Susceptibility</th>
<th>Chest X-ray</th>
<th>Other tests/results</th>
</tr>
</thead>
</table>

Comments:

County of San Diego
Health and Human Service Agency  Public Health Services • TB Control
E-Mail: curetb.hhsa@sdcournty.ca.gov
curetb.org

Migrant Clinicians Network Business Phone: (512) 327-2017 PO Box 164285  Confidential Fax: (512) 327-6140
Austin, Texas 78716  Confidential Phone: (800) 825-8205
Migrant Clinicians Network
ENROLLMENT IN THE MCN HEALTH NETWORK

Enrolling Clinic                              Clinic phone number(s)
E-mail address                               Clinic fax number(s)
Contact person at Clinic                     

Security Question #1:  Patient’s city of birth?
Security Question #2:  Patient’s father’s first name?

Please indicate the health area(s) for which the participant is being enrolled. If the participant’s health status changes during enrollment in the Health Network, additional areas may be added with the participant’s verbal consent.

- Tuberculosis
- Prenatal Care
- Cancer
- Diabetes
- HIV
- General Health

CONSENT FOR RELEASE OF MEDICAL INFORMATION

First Name                                   Last Name(s)
Alias, Nicknames, Etc                        Birth Date (Month / Day / Year)

The Health Network currently helps with continuity of care for people with infectious chronic illnesses or other healthcare concerns. (i) MCN is a non-profit company coordinating my enrollment in the Health Network at no cost to me; (ii) MCN may not be able to obtain health care providers that are available to care for my condition at no cost to me; (iii) the health care providers who will be providing my treatment are independent and not employees of MCN; and (iv) MCN does not provide, and is not responsible for, any health care treatment, or the outcomes of such treatment, in connection with any or all of the Health Network projects.

I agree to participate in the Health Network, and I understand that my protected health information and personal information will only be released for the purposes of my medical treatment, healthcare operations, payment, or pursuant to my authorization.

I do NOT authorize MCN or future health care providers to have access to my medical records around issue(s) listed here:

(attach additional page if needed)

I agree to notify my future health care providers of my enrollment in the MCN Health Network to help facilitate the transfer of my medical records. I understand and consent to MCN maintaining records for me containing sensitive health information (examples: HIV status and/or information about mental health issues) if my health care provider believes this information is needed for my treatment. I authorize MCN and future health care providers to have access to those medical records that my health care providers feel are necessary for my medical treatment and/or continued screening.

Authorized individuals from MCN may contact me by phone, mail or in person regarding follow up and referral for my treatment for these conditions. These individuals will adhere to federally mandated confidentiality, privacy and security procedures. This consent form will remain in effect for two years (24 months) from the date signed or until my participation in the Health Network has ended for another reason. I can submit a written request any time to leave the Health Network or to limit the health issues that MCN is authorized to address. I also understand that I have a right to receive a copy of my medical records on file with MCN upon written request.

I HEREBY RELEASE MCN, ITS EMPLOYEES, OFFICERS, DIRECTORS, CONSULTANTS, REPRESENTATIVES, SUCCESSORS, AND ASSIGNS FROM AND AGAINST ANY AND ALL CLAIMS, CAUSES OF ACTIONS, DAMAGES, LOSSES, EXPENSES (INCLUDING ATTORNEYS' FEES), AND LIABILITIES OF ANY KIND WHATSOEVER ARISING OUT OF MY ENROLLMENT IN THE HEALTH NETWORK AND MY HEALTH CARE TREATMENT RESULTING FROM MY ENROLLMENT IN THE HEALTH NETWORK.
**PARTICIPANT SIGNATURE**
(or Signature of Legal Representative)  

<table>
<thead>
<tr>
<th>Relationship of Legal Representative to Patient</th>
<th>Witness Signature</th>
</tr>
</thead>
</table>

We recommend that, whenever possible, you provide the participant with a copy of this Consent for Release of Medical Records and MCN Health Network Enrollment form when it is completed.

**ENGLISH – THIS CONSENT FORM IS VALID FOR 2 YEARS AFTER DATE OF SIGNATURE**

*Please contact us at 512-327-2017 or www.migrantclinician.org/network for more information on the MCN Health Network.*

---

**PARTICIPANT INFORMATION SHEET | MCN HEALTH NETWORK**

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mother’s Maiden Name</th>
<th>Birth Date (Month / Day / Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Place of birth:</th>
<th>Gender:</th>
<th>Marital Status:</th>
</tr>
</thead>
<tbody>
<tr>
<td>City</td>
<td></td>
<td></td>
</tr>
<tr>
<td>State</td>
<td>Female</td>
<td>Single</td>
</tr>
<tr>
<td>Country</td>
<td>Male</td>
<td>Divorced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race/Ethnicity:</th>
<th>Language(s) Spoken:</th>
<th>Language you prefer to be contacted in:</th>
</tr>
</thead>
<tbody>
<tr>
<td>White – Non-Hispanic/Latino</td>
<td>English</td>
<td></td>
</tr>
<tr>
<td>Asian – Non-Hispanic/Latino</td>
<td>Creole</td>
<td></td>
</tr>
<tr>
<td>Black – Non-Hispanic/Latino</td>
<td>Spanish</td>
<td></td>
</tr>
<tr>
<td>Indigenous</td>
<td>Other:</td>
<td></td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Occupation(s) (from past two years):</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Farmworker</td>
<td></td>
</tr>
<tr>
<td>Homemaker</td>
<td></td>
</tr>
<tr>
<td>Student</td>
<td></td>
</tr>
<tr>
<td>Construction</td>
<td></td>
</tr>
<tr>
<td>Factory</td>
<td></td>
</tr>
<tr>
<td>Child care</td>
<td></td>
</tr>
<tr>
<td>Retired</td>
<td></td>
</tr>
<tr>
<td>Unemployed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Current Residence:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Farmworker Camp Housing</td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
</tr>
<tr>
<td>Jail</td>
<td></td>
</tr>
<tr>
<td>ICE Detention Center</td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
</tr>
</tbody>
</table>

**CURRENT CONTACT INFORMATION FOR PARTICIPANT:**

<table>
<thead>
<tr>
<th>Street / P.O Box</th>
<th>City</th>
<th>State</th>
<th>Zip/Country</th>
</tr>
</thead>
</table>

*PHYSICAL ADDRESS:*

<table>
<thead>
<tr>
<th>*MAILING ADDRESS:</th>
<th></th>
</tr>
</thead>
</table>
**Phone Number** (with Area Code)  
Home / Cell / Work:  
Is it ok if we talk to people that answer this phone about your personal health information? (If you do not check off either box, or you do not initial, your answer will be “No”)  
- Yes  
- No  
*Initials:*

**Other Contact Information for Participant (Place you normally move to):**

<table>
<thead>
<tr>
<th>Street / P.O Box</th>
<th>City</th>
<th>State</th>
<th>Zip/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Address:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mailing Address:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Phone Number** (with Area Code)  
Home / Cell / Work:  
Is it ok if we talk to people that answer this phone about your personal health information? (If you do not check off either box, or you do not initial, your answer will be “No”)  
- Yes  
- No  
*Initials:*

---

Additional Contact: Please list someone we can contact if we cannot reach you at either of the locations you provided. In doing this you give MCN permission to contact that family member or friend to assist you in receiving continued health care, which may require discussing your health condition(s) with this individual. You do not have to provide this additional contact information.

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Relationship to Participant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street / P.O Box</th>
<th>City</th>
<th>State</th>
<th>Zip/Country</th>
</tr>
</thead>
</table>
| Phone Number (with Area Code)  
Home / Cell / Work:  
Is it ok if we talk to people that answer this phone about your personal health information? (If you do not check off either box, or you do not initial, your answer will be “No”)  
- Yes  
- No  
*Initials:*

---

Please contact us at 512-327-2017 or www.migrantclinician.org/network for more information on the MCN Health Network.

Appendix F

Tuberculosis Services

#3121-R (Rev. 01/2016)

- Suspect  
- Case  
- LTBI  
- Presumptive LTBI  
- B1/B2 Refugee or Immigrant  
- MDR  
- Ryan White

Child less than 5 years  
Private Physician or Health Department:  

---------------------------- Refer to Report of Verified Case of Tuberculosis Instructions for Definitions  
----------------------------
### DEMOGRAPHICS

<table>
<thead>
<tr>
<th>Name, Address, City, State, Zip, Phone</th>
<th>Date of Birth</th>
<th>Age</th>
<th>Sex at Birth</th>
<th>Race</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within city limits: Yes No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Pediatric (less than 15 years old):

<table>
<thead>
<tr>
<th>Country of Birth for Primary guardian</th>
<th>Name</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lived outside the U.S. for more than 2 months: Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>If yes, specify countries:</th>
<th></th>
</tr>
</thead>
</table>

#### Immigration Status at 1st Entry to U.S.:

<table>
<thead>
<tr>
<th>N/A (U.S. born)</th>
<th>Immigrant visa</th>
<th>Family/Fiancé visa</th>
<th>Student visa</th>
<th>Employment visa</th>
<th>Tourist visa</th>
<th>Refugee</th>
<th>Asylee or Parolee</th>
<th>Other Immigration status</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U.S. born (born in 1 of 50 states, DC, U.S. territories, or to 1 parent of a U.S. citizen)</th>
<th>Yes</th>
<th>No</th>
<th>Country of Birth</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Any travel in the past 6 months?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>If yes, what countries (if outside the US) or states (if inside the US) and for how long:</th>
<th></th>
</tr>
</thead>
</table>

#### Primary Occupation Within the Past Year:

<table>
<thead>
<tr>
<th>Health Care Worker</th>
<th>Correctional Facility Employee</th>
<th>Migrant/Seasonal Worker</th>
<th>Retired</th>
<th>Not Seeking Employment (student, homemaker, disabled)</th>
<th>Unemployed, but seeking employment</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Employer</th>
<th>Last date worked</th>
<th>Return to work date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### MEDICAL HISTORY

#### EVER a resident of a correctional facility?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Location</th>
<th>Currently resident of correctional facility:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Resident of a Homeless Shelter?

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Homeless within past year</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Inadequate housing</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Inadequate income</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Inadequate transportation</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Domestic violence</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Domestic violence</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Child abuse</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Depression</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Suicidal/homicidal thoughts</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Paranoia</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Defiant</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Erratic behavior</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Uncooperative</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Low literacy</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Language barrier</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Primary Language</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Does not follow isolation</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unknown Misses appointments</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Misses DOT appointments</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Reluctant to identify contacts</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

| No | Unknown | |

<table>
<thead>
<tr>
<th>Unknown</th>
<th></th>
</tr>
</thead>
</table>
### Primary Care Physician

**diagnosed with or treated for:**

- Diabetes Mellitus
- Cancer (site)
- Leukemia
- Lymphoma
- Hodgkins
- Silicosis
- Asbestos Exposure
- Asthma
- Bronchitis
- Chest injury
- Chest surgery
- COPD
- End Stage Renal Disease
- Chronic liver disease
- Tumor necrosis factor alpha (TNF) antagonists
- Organ Transplant
- Corticosteroid Therapy
- Other immunosuppression (not HIV/AIDS)
- Hypertension
- Heart disease
- Bleeding
- Gastrectomy
- Intestinal Bypass
- Malabsorption syndrome
- Arthritis
- Bone/Joint disorder
- Hepatitis B: Yes No Test ordered
- Hepatitis C: Yes No Test ordered

### Ever received BCG vaccine?

- Yes
- No
- Packs of cigarettes smoke daily
- Ounces of beer drinks daily
- Ounces of wine drank daily
- Ounces of liquor drank daily
- Injecting drug use
- Non-injecting drug use
- Other

Recent hospitalization, specify details:

---

### Medical Complications:

<table>
<thead>
<tr>
<th>Disease</th>
<th>Date start treatment</th>
<th>Date stop treatment</th>
<th>Site of infection</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer (site)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silicosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asbestos Exposure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest injury</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End Stage Renal Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor necrosis factor alpha (TNF)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretrovirals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site of infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Care Physician</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ever</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TUBERCULOSIS HISTORY

- Expul = Extrapulmonary
- IGRA = Interferon-gamma release assay tests

**Primary reason for TB evaluation:**

- TB Symptoms (cough fever weight loss fatigue night sweats hemoptysis)
- Abnormal Chest Radiograph (consistent with TB)
- Contact Investigation
- Targeted testing

- Health Care Worker
- Employment/Administrative
- Immigration medical
- Incidental lab result

- Contact to MDR-TB Patient
- S+
- S-
- Expul*

- Contact to TB Patient
- S+ S- Expul*

- Missed Contact
- No Known exposure

#### Contact to

<table>
<thead>
<tr>
<th>Relationship</th>
<th>Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Contact to

<table>
<thead>
<tr>
<th>Disease</th>
<th>Date start treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB</td>
<td></td>
</tr>
</tbody>
</table>

#### Previous Diagnosis of TB

<table>
<thead>
<tr>
<th>Date start treatment</th>
<th>Date stop treatment</th>
<th>Site of infection</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Previous TST & Chest X-Rays

<table>
<thead>
<tr>
<th>Date start treatment</th>
<th>Date stop treatment</th>
<th>Site of infection</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Initial TST

<table>
<thead>
<tr>
<th>Date</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Follow-Up TST

<table>
<thead>
<tr>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
**INITIAL BACTERIOLOGY SUMMARY**

* (+) = Positive  **(-) = Negative

**INITIAL SPECIMEN:**

Date _____________________ Site _____________________ code _____________________

- Sputum Smear
- Smear/Pathology/Cytology of Tissue & other body fluids
- Public Health Laboratory
- Commercial Laboratory
- Other

**INITIAL RESULTS:**

<table>
<thead>
<tr>
<th>Test</th>
<th>(+)</th>
<th>(-)</th>
<th>Not done</th>
<th>Pending</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Culture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Nucleic Acid Amplification test:**

- (+)*
- (-)**
- Indeterminate
- Pending
- Not done
- Unknown

**INITIAL DRUG REGIMEN ORDERED BY NURSE PROTOCOL**

Case/suspect  Initial treatment: 4 Drug Regimen - Option 1 4 Drug Regimen Option 2

LTBI/presumptive Initial Treatment: Isoniazid 9 months Rifampin 4 months Rifampin 6 months Isoniazid/Rifapentine 12 weeks

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Form</th>
<th>Route</th>
<th>Frequency</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
<td>tab</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
<tr>
<td>Ethambutol</td>
<td></td>
<td>tab</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
<td>caps</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
<tr>
<td>Rifapentine</td>
<td></td>
<td>tab</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td></td>
<td>tab</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
<tr>
<td>Pyridoxine</td>
<td></td>
<td>tab</td>
<td>PO</td>
<td>x wk X mo #</td>
<td>(# doses)</td>
</tr>
</tbody>
</table>

Medication Start Date_________________________  DOT  Non-DOT

Comments:
Name of client____________________________________  DOB____________________  #3121-R, Tuberculosis Services  

Reason for Review:  
- Continuation/review  
- Follow up/Adverse Event  
- Window Period Prophylaxis  
- Treatment Completion  
- Other

Health Department: ________________________________________________________________
Phone:_________________________________

### CURRENT DRUG REGIMEN

<table>
<thead>
<tr>
<th>Drug</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td></td>
</tr>
<tr>
<td>Ethambutol</td>
<td></td>
</tr>
<tr>
<td>Rifapentine</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

### TREATMENT COURSE

<table>
<thead>
<tr>
<th>DOT</th>
<th>Non-DOT</th>
<th># Months on Therapy</th>
<th># Doses to date</th>
<th>Anticipated length of treatment</th>
<th>Anticipated completion date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Treatment interruptions:</th>
<th>Date stopped</th>
<th>Date re-started</th>
<th># Doses missed</th>
<th>Reason therapy stopped:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical adverse reactions</td>
<td></td>
<td></td>
<td></td>
<td>Liver Enzymes elevated</td>
</tr>
<tr>
<td>Patient non-adherence</td>
<td></td>
<td></td>
<td></td>
<td>Provider reasons</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comments:

Date Completed ____________________________  SIGNATURE ____________________________

CHEST RADIOGRAPHY & IMAGING STUDY
### INITIAL
- [ ] Not done
- [ ] Unknown

### Date
- [ ] Chest views
- [ ] CT scan/imaging

### Remarks:
- [ ]

### Interpretation
- [ ] Normal
- [ ] Not done
- [ ] Unknown
- Abnormal:
  - Pleural Effusion
  - Evidence of Miliary TB
  - Cavitary
  - Non-cavitary:
    - Consistent with TB
    - Inconsistent with TB

### FOLLOW-UP
- [ ] Chest views
- [ ] CT scan
- [ ] MRI

### Status
- [ ] Stable
- [ ] Improving
- [ ] Worsening
- [ ] Unknown

### Treatment:
- [ ] Do not treat
- [ ] Treatment complete
- [ ] Refer to private Physician for diagnosis and/or treatment
- [ ] Start or continue window period prophylaxis
- [ ] Discontinue window period prophylaxis
- [ ] Start or continue treatment for LTBI
- [ ] Discontinue treatment for LTBI
- [ ] Start or continue treatment for active TB disease
- [ ] Discontinue treatment for active TB disease
- [ ] Other:

### Site of TB Disease (select all that apply):
- [ ] Pulmonary
- [ ] Pleural
- [ ] Laryngeal
- [ ] Lymphatic: Cervical
- [ ] Lymphatic: Intrathoracic
- [ ] Lymphatic: Axillary
- [ ] Lymphatic: Other
- [ ] Lymphatic: Unknown
- [ ] Bone and/or Joint
- [ ] Genitourinary
- [ ] Meningeal
- [ ] Peritoneal
- [ ] Site not stated
- [ ] Other:

### Diagnosis:
- [ ] Latent TB Infection
- [ ] Laboratory confirmed TB case
- [ ] Clinical TB case
- [ ] Recurrent TB case within 12 months after completion of therapy
- [ ] Nontuberculous Mycobacterial Disease
- [ ] Other:

### Classification:
- [ ] 0 No exposure, not infected
- [ ] I Exposure, no infection
- [ ] II TB Infection, no disease
- [ ] III Current TB disease
- [ ] IV Previous TB disease
- [ ] V TB suspected

### PHYSICIAN RECOMMENDATIONS

#### Medication:
- [ ] Initial
- [ ] Continuation
- [ ] Change of medications
- [ ] Daily
- [ ] Twice weekly
- [ ] Other:
- [ ] Self administer

- Isoniazid 300 mg _____ tab(s) (_____mg) PO ____ days/wk X _____ doses
- Rifampin 300 mg _____ cap(s) (_____mg) PO ____ days/wk X _____ doses
- Pyrazinamide 500 mg _____ tab(s) (_____mg) PO ____ days/wk X _____ doses
- Ethambutol 400 mg _____ tab(s) (_____mg) PO ____ days/wk X _____ doses
- Pyridoxine 25 mg 1 tablet PO ____ days/wk X _____ doses
- Pyridoxine 50 mg 1 tablet PO BIW X _____ doses
- Other:

#### Recommendations:
- [ ] None
- [ ] Hospitalization
- [ ] Send old X-rays
- [ ] Send medical records
- [ ] Repeat TST (mo./yr. _____)
- [ ] Repeat Chest-X-ray (mo./yr. _____)
- [ ] Re X-ray as clinically indicated
- [ ] Sputum AFB Smear/Culture daily X3 then weekly until sputum conversion, then monthly
- [ ] Sputum culture sensitivity
- [ ] 2 month sputum conversion

Perform baseline labs:
- [ ] AST
- [ ] ALT
- [ ] Liver profile
- [ ] Bilirubin
- [ ] Alkaline phosphatase
- [ ] CBC with platelet count
- [ ] Serum uric acid
- [ ] Serum creatinine
- [ ] Hepatitis B & C profile
- [ ] HIV counseling & testing
- [ ] CD4+ count

Perform monthly labs:
- [ ] AST
- [ ] ALT
- [ ] Liver profile
- [ ] Bilirubin
- [ ] Alkaline phosphatase
- [ ] CBC with platelet count
- [ ] Serum uric acid
- [ ] Serum creatinine
- [ ] Baseline and monthly visual acuity testing and red/green color discrimination
- [ ] Other

#### Comments:

#### Date Review Completed

### SIGNATURE

---

GA DPH TB Unit

Form 3121-R (Rev. 01/2016)
INSTRUCTIONS FOR COMPLETELY EVALUATED CONTACTS

The ideal initial encounter with a contact is made within 3 days. Gather background information, make a face-to-face assessment of the person’s health and assign the appropriate priority.

Pulmonary/Laryngeal/Pleural Cases:

1. **High Priority** - Initial encounter 3 - 7 days from notification with medical evaluation completed within 5 days of initial encounter (10 days if smear negative)
   - Medical history, exposure history and a physical assessment
   - Initial IGRA/TST within 7 days or less if not done during initial encounter
   - Any positive IGRA/TST with induration 5mm or greater followed up with a chest x-ray
   - HIV Counseling, Testing and Referral **specimens obtained as part of the evaluation** – regardless of [ ] Follow-up IGRA/TST 8-10 weeks later **assigned priority** or IGRA/TST result.
   - Place on LTBI treatment if indicated Some contacts may have a false negative reaction to IGRA/TST due to
   - Those contacts who are considered a medical risk* HIV/AIDS, treatment with steroids or immunosuppressive drugs, old age, or should have the following regardless of initial TST/IGRA status: tuberculosis disease. If such is suspected, the contact should have a chest x-ray.
     1. Chest x-ray
     2. Place on INH if their chest x-ray is negative for active TB disease
     3. See list below to determine if window period treatment or a full course of treatment is recommended

2. **Medium Priority** – Initial encounter 14 days or less with medical evaluation completed within 10 days of initial encounter [ ] Medical history, exposure history and a physical assessment
• Initial IGRA/TST 14 days or less if not done during initial encounter
• Any positive IGRA/TST with induration 5mm or greater followed up with a chest x-ray
• HIV Counseling, Testing and Referral
• Follow-up IGRA/TST 8-10 weeks later
• Place on LTBI treatment if indicated

2. High-Priority – Initial encounter 14 days or less after notification
   • Medical history, exposure history and a physical assessment
   • IGRA/TST 8-10 weeks later
   • Any positive IGRA/TST result should be followed up with a chest x-ray
   • Place on LTBI treatment if indicated

3. Low-Priority – Initial encounter 30 calendar days or less after notification
   • Medical history, exposure history and a physical assessment
   • IGRA/TST 8-10 weeks later
   • Any positive IGRA/TST result should be followed up with a chest x-ray
   • Place on LTBI treatment if indicated

Pulmonary/Laryngeal Cases - Sputum Smear AND Culture Negative and Source Case Investigations for children less than 5 years of age with active TB disease and Extrapulmonary cases:
1. Initial encounter 30 days or less after notification (household contacts only)
2. Medical history, exposure history and a physical assessment
3. Initial IGRA/TST, if negative then no further action is needed
4. Initial IGRA/TST, if positive then follow-up with a chest X-ray
5. Place on LTBI treatment if indicated

*Contacts who are considered a medical risk* are those who are at a particularly high risk of developing TB disease once infected with M. tuberculosis.

These contacts include the following:
• Immunosuppressed, e.g., HIV infection, prolonged corticosteroid therapy, organ transplant, TNF blockers (full course of preventive treatment beyond window period)
• Less than 5 years of age (Window period treatment)
• Have diabetes mellitus, silicosis, end stage renal disease, gastrectomy, jejunoileal bypass, leukemia, lymphoma or cancer of the head or neck (Window period treatment)

This contact investigation form should be forwarded to the district TB coordinator after the initial phase, but no later than 30 days. Update the district TB coordinator as determined by local policy. Initial information is to be entered into SENDSS within 30 days. Complete information is to be entered within 90 days. Do not send this form to the state office.

GA DPH TB Unit
Notification Date ________________  GEORGIA DEPARTMENT OF HUMAN RESOURCES INVESTIGATION REPORT

<table>
<thead>
<tr>
<th>CODES:</th>
<th>a) Reason LTBI Therapy Stopped:</th>
<th>b) Reason Why CI not completed for contact</th>
<th>c) Reason Why No contacts entered</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Completed Therapy</td>
<td>1. Still following up</td>
<td>1. Contact investigation was not done</td>
</tr>
<tr>
<td>2.</td>
<td>Death</td>
<td>2. No IGRA2/TST2 because 1st IGRA/TST done 8-10 weeks after exposure</td>
<td>2. Case died or too ill to interview. No surrogate interviewee available.</td>
</tr>
<tr>
<td>5.</td>
<td>Adverse Reaction</td>
<td>5. Refused/uncooperative</td>
<td>5. Contacts identified but can not be located</td>
</tr>
<tr>
<td>7.</td>
<td>Lost to Follow-Up</td>
<td>7. Lost to follow up</td>
<td>7. Contacts moved/lost to follow-up. Shares same contacts with an index case whose contacts have already been entered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10. Other</td>
</tr>
</tbody>
</table>
PLEASE REPORT ALL CONTACTS TO SUSPECTED OR CONFIRMED CASES OF TUBERCULOSIS TO THE

TUBERCULOSIS PROGRAM 2 PEACHTREE STREET, NW, 12TH FLOOR, ATLANTA, GEORGIA 30303-3142

* If case is child less than 5 years, name source case:_______________________________ Code for Reason Why NO Contacts Entered c) __________

Reviewed By: ________________ Date: __________ Signature of Person Completing 1st Interview: __________________________ Date: __________ Telephone _________
### SCREENING DONE IN CONNECTION WITH TB CASE

Location of Screening ____________________________ Title ____________________________ Date ____________________________

Contact Person ___________________________________________ Title ____________________________ Telephone ____________________________

Case Cross-Reference Identifier ____________________________________________

<table>
<thead>
<tr>
<th>Environment</th>
<th>Name / Telephone</th>
<th>Address, City, State, Zip</th>
<th>Race/SEX</th>
<th>Date of Birth</th>
<th>Known Exposure to case</th>
<th>IGRA/TST Date</th>
<th>IGRA/TST Date Result</th>
<th>Document/Comments:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Work</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Work</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Referrals
- Recommendations
- Follow-Up
### CONTACT INVESTIGATION SUMMARY

<table>
<thead>
<tr>
<th>Household</th>
<th>School / Work</th>
<th>Social</th>
<th>Additional persons screened</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total contacts screened</td>
<td>Total number of previous positive IGRA/TST</td>
<td>Initial IGRA/TST Results</td>
<td>Chest x-ray</td>
</tr>
</tbody>
</table>

- + P: Abnormal
- - N: Normal

GA DPH TB Unit
Form 3126 (Rev. 10/2014)
**DOT MEDICATION SHEET**

**Name:** ____________________________  **DOB:** ______________  **Race:** ______________  **Sex:** M / F  **Date medication started:** __________

**Address:** __________________________________________  **Telephone:** (home)______________________ (work) ______________  **Month/Year** ______________

<p>| Medication          | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 |
|---------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Isoniazid ______mg PO x wk |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Rifampin ______mg PO x wk |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| Pyrazinamide ______mg PO x wk |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |</p>
<table>
<thead>
<tr>
<th></th>
<th>Ethambutol</th>
<th>Pyridoxine</th>
<th>Rifamate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>mg PO x wk</td>
<td>mg PO x wk</td>
<td>mg PO x wk</td>
</tr>
</tbody>
</table>

**Time of DOT**

**# of doses this month**

**# weeks of treatment this month**

**Side effects:** If present write √ and write F/U under comments. If absent, write Ø

<table>
<thead>
<tr>
<th>Side Effect</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea/vomiting/abdominal pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice/dark urine/yellow eyes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache/skin rash/weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue/flu-like symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unsteady gait/behavioral change</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual problems/change in hearing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tingling in extremities/bleeding problems/joint pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of appetite/weight loss</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coughing/coughing up blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever/chills/night sweats</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total doses to date**

**Initials**

**Signature of Person Observing Medication**

**Sputum Date:**

**Special Instructions/Comments:**
Active Tuberculosis (TB) Treatment Plan

Health care provider will check the appropriate instructions. The client will initial checked instructions.

☐ I understand I (may have / have) active tuberculosis disease and that I need to take TB medications for an extended period of time. I may need to take medications longer than initially told if my clinical condition changes ________

☐ I agree to take my medication as ordered. I will call the health department if I am unable to take my medication for any reason. Directly Observed Therapy (DOT) has been explained to me and I have signed a DOT agreement ______

☐ The side effects of my medication have been explained to me and I agree to call the health department immediately at __________________ if I develop any of the side effects ______

☐ I agree to keep all clinic appointments. If I am unable to keep an appointment, I will call the health department and reschedule another appointment within 7 days ______

☐ I agree to provide sputum, urine or blood specimens as requested ______

☐ I agree to tell the health department of any changes in my health ______

☐ I agree to tell the health department if I move or change my phone number. I agree to tell the health department how to reach me in person and by telephone ______

☐ I am infectious and can spread the disease to others ______

☐ I will remain at home on isolation. As much as possible, I will stay away from other people in my house by staying in my room or wearing a surgical mask when I leave the room. I understand separate bedrooms or beds are highly recommended ______

☐ I will cover my mouth and nose with a tissue when I cough or sneeze. These tissues should be flushed, burned or placed in a sealed leak proof bag before disposal ______

☐ I understand that my activities are limited. I will not travel, go to work, go to school, go shopping or participate in any other activity where I will be in contact with other people ______

☐ I agree not to leave my home except to keep medical appointments. I agree to wear a surgical mask to the clinic and doctor’s offices ______

☐ I will not allow anyone, other than those living with me or those individuals providing care to me, into my home and I will stay away from young children ______

☐ I understand these isolation instructions remain in effect until I am told by the health department that I no longer have to stay in isolation ______

☐ I understand these isolation instructions may become effective again after I have been told I am no longer infectious should my clinical situation change ______

☐ I agree to help with the contact investigation by sharing the places I have been and names of the people I have been around to prevent my family, friends or co-workers from developing this disease ______

☐ I understand the reasons I need to complete my treatment and that legal action can be taken against me if I fail to follow my treatment plan ______
I have received a copy of this treatment plan. It has been explained to me and all my questions have been answered. I agree to follow this treatment plan.

Signature of Client______________________________________________________     Date _____________

Signature of Public Health Representative _____________________________________ Date ______________

Consent and Treatment Plan
Latent Tuberculosis Infection (LTBI)

I, _________________________________________________, have been advised and counseled by
(Client’s name)

________________________________________________
(Public Health Representative/Title)

that based on available information, I (may have

I have) latent tuberculosis infection (LTBI). The following has been explained to me:

1. LTBI means I have been infected by the TB germ *M. tuberculosis*. My immune system has walled off the
germs to keep them dormant (sleeping). I have no symptoms and can not spread the germ to others.

2. I know that without treatment, I can get sick with active TB disease and have symptoms such as cough,
fever, night sweats, weight loss or extreme tiredness. If any of these symptoms appear, I agree to call the
health department at ___________________ immediately.

3. I understand the link between TB and HIV and therefore I agree to be tested for HIV.

4. I agree to follow this treatment plan. I agree to come to the health department for medical evaluations and
pill refills as ordered and to cooperate in my treatment. If I am unable to keep a scheduled appointment, I
will call the health department at once and reschedule another appointment within 7 days.

5. I agree to take my TB medication as ordered for the entire length of treatment. I will notify the health
department if I am unable to take my medication for any reason.

6. The side effects of the medication I am taking have been explained to me. I agree to call the health
department at ___________________ immediately if I develop any of these side effects.

7. I agree to tell the health department if I move or change my phone number. I agree to tell the health
department how to reach me in person and by telephone.

8. My treatment plan has been explained to me and all my questions have been answered. I have a copy of
this plan.

______________________________________  __________________________
(Client’s Signature)                    (Date)
I, ________________________________, have been advised and counseled by ________________________________.

I understand the link between TB and HIV and therefore I agree to be tested for HIV.

I agree to take my TB medication, as ordered via DOT for the entire length of treatment. I agree to cooperate with the supervised DOT program to help remind me to take my medicine and to make sure I complete my treatment. In this program, a designated public health employee or a trained DOT worker is authorized as my agent to maintain possession of my medication and to be present when I take my TB medicine.

I will be at: ___ home ___ work ___ clinic/lhd ___ other (specify) ____________________________ between the hours of ______ and ______ for my DOT visit. If I cannot meet at the agreed place/time, I will call ____________________________ at ____________________________ to change the visit. If I do not call in time to change the visit, I know that I may have to go to _____________ between _____________ for my DOT visit.
6. I will notify the health department if I am unable to take my medication for any reason.

7. The side effects of the medication I am taking have been explained to me. I agree to call the health department at ___________________ immediately if I develop any of these side effects.

8. I agree to tell the health department if I move or change my phone number. I agree to tell the health department how to reach me in person and by telephone.

9. My treatment plan has been explained to me and all my questions have been answered. I have a copy of this plan.

___________________________________  ____________________________________________  
Client’s Signature                   Date                                    Public Health Representative/Title Signature 
                                                                                     Date

___________________________________  ____________________________
Witness/Interpreter’s Signature       Date

Affix Patient label or complete:      Name _____________________________________________

Address _____________________________________________

City, State, Zip ________________________                  Patient ID# ________________________
Telephone ____________________________________________

GA DPH TB Unit                                         Form 603.LTBI (3/2015)

Consent to Treatment

Active TB Case/Suspect

I, ________________________________________________, have been told by
(Client’s name)

_____________________________________________ that based on available information, I (may have
(Public Health Representative/Title)

/ have) active tuberculosis (TB) disease. The following has been explained to me:

1. TB is an infectious disease that can be spread to others. I know that I need to be away from other people until I can not spread the disease to them. I know that untreated TB can lead to drug resistant disease or may be fatal. I need to take TB medicines for many months to get well.

2. I agree to be treated for TB and to help with the contact investigation to prevent my family, friends or co-workers from getting sick.

3. I understand the link between TB and HIV and therefore I agree to be tested for HIV.
4. I agree to follow the treatment plan given to me by my health care provider and the health department.

5. If I don't follow my treatment plan, legal action can be taken against me.

6. I have a copy of my treatment plan and all my questions have been answered.

______________________________________                        ___________________________
(Client’s Signature)                        (Date)

______________________________________                        ___________________________
(Public Health Representative/Title)                        (Date)

______________________________________                        ___________________________
(Witness/Interpreter’s Signature)                        (Date)

Affix Patient label or complete:

Name _____________________________________________
Address ___________________________________________
City, State, Zip __________________________________
Telephone _______________________________________  
Patient ID# _______________________________________ 

GA DPH TB Unit

Enter County Board of Health
Information/Letterhead Here
(Enter Region, Address, City, State, Zip)

______________________________________                        ___________________________
(Patient Name)                        (Date)

______________________________________
Patient Address, City, State, Zip Code

I __________________________, consent to use a personal smartphone with video capability ____ (initial) or internet web camera ____ (initial) technology to ensure
compliance with Video Directly Observed Therapy (VDOT) for the treatment of Tuberculosis (TB).

I understand that if I choose to use a webcam for VDOT that a secure connection over the Internet cannot be guaranteed. I understand that the webcam is to be used only for observation of taking the prescribed TB medications. I will immediately contact the (insert Local Health Department name here) or the Department of Public Health for other concerns and/or questions regarding my treatment.

I understand that the video transmission will occur over the internet, that the transmission is not secure or encrypted, and that (enter County Board of Health name here) cannot guarantee that third parties will not gain access to the transmission. I release the (enter County Board of Health name here) of liability for the access to the transmission by third parties. I understand that use of this video technology is voluntary and may be stopped at any time should I choose to use face-to-face Directly Observed Therapy. VDOT can also be stopped if:

- I miss more than one scheduled VDOT in one week
- I miss a scheduled clinic appointment
- I have any reaction(s) during my treatment and require a physician evaluation
- I have any adverse reactions to my medication
- My equipment (smartphone/desktop/laptop) is lost, stolen, or damaged
- My condition worsens
- I am physically unable to perform VDOT

☐

______________________________
Patient’s signature

______________________________
Nurse’s signature

______________________________
Witness’s signature

______________________________
Date

______________________________
Date

______________________________
Date

GA DPH TB Unit
Form 3610 (Created 12/2014)

DOT INSTRUCTION SHEET

Date medication started _______________________________

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Main phone</th>
<th>Cell phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOT Worker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication name and dosage</td>
<td>Picture of medication</td>
<td>Number of Pills take</td>
<td>Number of Days / week</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Isoniazid _______________ mg</td>
<td><img src="image" alt="Isoniazid" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampin _______________ mg</td>
<td><img src="image" alt="Rifampin" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide ____________ mg</td>
<td><img src="image" alt="Pyrazinamide" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol _____________ mg</td>
<td><img src="image" alt="Ethambutol" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyridoxine (B6) _________ mg</td>
<td><img src="image" alt="Pyridoxine" /></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DOT Days (circle):** Monday Tuesday Wednesday Thursday Friday

**DOT Time:** ______________________  
**Mask Needed?** No Yes

**DOT Documentation Sheet**
**DOT Screening Questions**
**Medications**

**Check in with nurse (day and time):** ______________________  
**Phone:** ______________________

**Next Clinic appointment for client:** ______________________

**Additional Instructions:**

**Directly Observed Therapy (DOT)**

**Agreement for Tuberculosis (TB) Treatment**

**Name** ______________________  
**DOB** __________  
**Home phone:** ______________________

**Address** ___________________________________________________________  
**Work phone:** ______________________
I, _______________________________ understand and agree that

(Name of Client)

1. The only way to get well is by taking my TB medicine exactly as my nurse or doctor tells me. If I do not follow these directions, my illness could come back worse than before. Then it could be harder to treat, take longer to treat and could spread the disease to others.

2. I will be taking several medications for a long time (6 months or more) in order to kill the TB germs.

3. I agree to cooperate with the supervised DOT program to help remind me to take my medicine and to make sure I complete my treatment and get well. In this program, a designated public health employee or a trained DOT worker is authorized as my agent to maintain possession my medication and to be present when I take my TB medicine.

4. I will be at: ____ Home _____ Work _____ Clinic/LHD _____ Other (specify) _______________________________ between the hours of _______________ and _______________ for my DOT visit.

5. If I cannot be at the agreed place and time, I will call _______________________________ at _______________ to change the visit.

6. If I do not call in time to change the visit, I know that I may have to go to ____________________________ between _____________ for my DOT visit.

7. I will tell my DOT worker if I have any problems. I may be asked to go to ____________________________ to meet with a doctor or nurse and/or to have tests during my treatment.

8. I know that if I miss my visits and do not take my treatment as scheduled, legal action may be taken.

I, _______________________________ understand and agree that

(Name of Health Dept./Case Manager)

1. If I cannot be at the agreed place and time, I will call _______________________________ at _______________ to change the visit.

2. I will keep the client’s health data private.

3. I will answer questions and concerns of the client. I will help link the client to other services as needed.

4. I will promptly tell the doctor or nurse of anything out of the ordinary. I will give reports as needed.

__________________________  ________________  ______________________
Client                      Nurse                      DOT Provider

GA DPH TB Unit

Form 603 DOT (Rev. 12/2011)

Second Line Therapy
Authorization Form

The items listed on this page are for complicated Tuberculosis (TB) cases only and require consultation with the TB Program Medical Consultant, Dr. Susan Ray. Please fax to (404)463-3460 the following documentation:

1. Copy of the prescription for ALL TB medications
2. List of ALL TB medications in patient’s drug regimen (including 2nd line medications) as well as any other prescription medications the patient may be taking
3. Progress Note stating why the need for alternate regimen
4. This completed form

To contact Dr. Ray call 404-657-2634 or email sray02@emory.edu (sray[zero]2@emory.edu)

Name of patient: ____________________________________________

District: ___________________________________________________

Requestor Name (print): __________________________________________

Date of original request: __________________________

Signature: ___________________________________________________

Approved: ___________________________________________________

Date of Approval: __________________________

Approval good until: __________________________

Fax signed form to: ___________________________________________

Fax number: ___________________________________________________

Medication requested for: ☐ New Patient
☐ Continued drug treatment

☐ Levofloxacin (tablets) 500mg, 50 in bottle
☐ Levofloxacin (tablets) 750mg, 50 in bottle
☐ Moxifloxacin (tablets) 400mg, 30 in bottle
☐ Streptomycin 1gram, vial (refrigerate)
☐ Kanamycin (vial) 1gram, 3mL vial
☐ Capreomycin (vial) 1gram, 10mL vial
☐ Amikacin (vial) 500mg, 2mL vial
☐ Amikacin (vial) 1gram, 4mL vial
☐ Ethionamide (tablets) 250mg, 100 in bottle
☐ Cycloserine (capsules) 250mg, 40 in bottle
☐ Clofazimine (capsules) 50mg, 100 in bottle
☐ Para-aminosalicylic acid (packets) 4grams, 30 packs in carton (refrigerate)
☐ Rifampin (vial) 600mg, 10mL vial
☐ Prednisone 5mg ☐ Prednisone 10mg
**Transmission of TB**

- TB is a disease caused by the TB germ. The disease is mainly in the lungs (pulmonary TB), but the germ can travel to other parts of the body (extrapulmonary TB) and sometimes can be in multiple parts of the body (miliary or disseminated TB).
- TB is spread when someone who is sick with TB in his/her lungs coughs, sneezes, talks or sings and sprays the TB germ into the air. When someone spends time with that person, he/she can breathe in the TB germ and become infected. Usually have to be around an infectious person for a long time and share the same airspace.
- Infectiousness decreases after the person has been on treatment for a while. Can NOT get TB by sharing drinks, toys or personal items.
- When a person is exposed to the TB germ and becomes infected, the person's own immune system will usually build a wall around the TB germs, keeping them from growing and multiplying. This is called latent TB infection or LTBI. The germs can remain dormant in a person's body throughout his/her lifetime.
- A TB skin test (Mantoux) can be given to see if someone has been infected with the TB germ. If the skin test is positive, a chest X-ray and sputum test will be done to make sure the person does not have TB disease. The skin test only determines TB infection. A positive result does not necessarily mean the person has TB disease.
- Once TB disease is ruled out, the doctor may prescribe a preventive medicine called Isoniazid (INH). INH can prevent TB by killing the TB germs.

**Differences between LTBI & Active TB disease**

- Both can have a positive skin test.
- LTBI has no symptoms & the person feels fine, but in active TB disease, the person usually feels sick and has symptoms of TB.
- LTBI the chest x-ray is normal, in active TB disease, it is usually abnormal.
- LTBI can NOT transmit the germs to others, in active TB disease; the germs can be transmitted to other people.
- Both can be treated.

**Progression of LTBI to Active TB**

- A person who is exposed and becomes infected with TB has a 10% chance of developing active TB disease. The most critical time period is the first 2 years after becoming infected.
- When the body's immune system is weak, the wall around the TB germs begins to break down. The TB germs wake up and start multiplying; growing and attacking the body, making the person feel sick and develop symptoms.
Anyone can get TB, but some people are at greater risk than others. These include:
- Persons living with someone who has active TB of the lungs
- Persons who had TB disease in the past but didn’t receive or complete their treatment
- Persons who are elderly
- Persons with weakened immune systems

**Signs & symptoms of disease**
- The early signs and symptoms of TB develop slowly and may go unnoticed for a long time. These include:
  - Cough
  - Chest pain
  - Loss of appetite
  - Weight loss
  - Tiredness
  - Fever/chills/night sweats
- The symptoms should get better after the person is on medication for a couple of weeks. If they don’t or if they come back after getting better, the nurse or physician needs to be notified.

**Importance of HIV testing**
- All patients in TB clinics should be tested for HIV. This includes TB suspects, patients, and contacts.
- People infected with HIV (the virus that causes AIDS) are more likely than uninfected people to get sick with other infections and diseases. Tuberculosis (TB) is one of these diseases.
- HIV infection weakens the immune system. If a person’s immune system gets weak, TB infection can activate and become TB disease. Someone with TB infection and HIV infection has a very high risk of developing TB disease. Without treatment, these two infections can work together to shorten the life of the person infected with both.
- HIV infection is the most important known risk factor for progression from latent TB infection to TB disease. Progression to TB disease is often rapid among HIV-infected persons and can be deadly. In addition, TB outbreaks can rapidly expand in HIV-infected patient groups.

**Respiratory isolation & use of masks**
- It is important for the patient to remain at home on isolation. As much as possible, he/she should stay away from other people in the house by staying in a separate room or wearing a surgical mask when leaving the room. Separate bedrooms or beds are highly recommended, if possible. The patient cannot travel, go to work, go to school, go shopping or participate in any other activity where there is contact with other people.
- The patient needs to cover his/her mouth and nose with a tissue when coughing or sneezing. These tissues should be flushed, burned or placed in a sealed leak proof bag before disposal.
- The patient cannot leave home except to keep medical appointments. He/she must wear a surgical mask to the clinic and doctor’s offices.
- The patient should not allow anyone, other than those living with him/her or those individuals providing care to him/her, into the home and should stay away from young children.
- These isolation instructions remain in effect until the patient is told by the health department that he/she no longer has to stay in isolation.
• These isolation instructions may become effective again after the patient has been told that he/she is no longer infectious should the clinical situation change.
• Keep doors and windows open as much as possible.
• DOT visits will be conducted outdoors, beside open windows and as efficiently as possible in order to reduce exposure time.
• The DOT worker will wear an N95 mask during the time the patient is considered infectious.
• Go outside to collect sputum specimens. The DOT worker should wear an N95 mask anytime sputum is being collected.

**Infectious period**

• The infectious period is the time when a patient sick with active TB can pass the germs to other people.
• The infectious period begins 3 months prior to the onset of symptoms or clinical sign of TB.
• The infectious period continues until all of the following criteria is met:
  o 3 consecutive smear negative specimens
  o The patient is on appropriate medications
  o The patient is getting better.
• The infectious period is important to determine in order to focus the contact investigation.

**Importance of chemotherapy as prescribed**

• Having TB should not keep someone from leading a normal life. When TB patients are no longer infectious or feeling sick, they can do the same things they did before they had TB. The medicine does not affect strength, sexual function or the ability to work. If the TB medicine is taken as directed, the medicine will kill all the TB germs and prevent the patient from becoming sick with TB again.
• It is necessary to take several different TB medications because there are many TB germs to be killed. Taking three to four different TB medications will stop the TB germs from becoming resistant to the medication.
• The most common medications are Isoniazid; Rifampin; Pyrazinamide & Ethambutol.
• The patient will usually take several tablets of 4 different medications every day (M-F) for the first 2 months. Then the patient may be able to take several tablets of just 2 medications twice a week until treatment is completed (another 4-7 months).
• TB is almost always curable if the patient adheres to the treatment regimen of taking several special medications for six to nine months. The medication must be taken continuously and uninterrupted for the duration of treatment.
• The treatment takes this long because the TB germs grow very slowly and are slow to die. The combination of these medications delivered by DOT can cure the disease in less than a year.
• Prolonged illness, disability or possible death is avoided.
• Risk of developing MDR-TB or XDR-TB is decreased.

**Side effects and adverse medication reactions**

*Side effects* of medications are those things which are anticipated to happen in people taking certain medications.

Most of the side effects are manageable and do not require stopping the medication.
<table>
<thead>
<tr>
<th>Medication</th>
<th>Side Effect</th>
<th>Action</th>
</tr>
</thead>
</table>
| Isoniazid  | Dizziness, tingling/numbness around the mouth or in the extremities  
GI distress; nausea when taking the pills but feels better later in the day | Proactively B6 is usually given; report any mild signs or symptoms to the nurse or physician  
Alter time of day pills are given; try giving pills with a small snack or food; report to nurse or physician |
| Rifampin   | Discoloration of bodily fluids; urine, sweat or tears may be orange or reddish  
Drug interactions; can interfere with birth control pills or implants; can alter effectiveness of methadone | Prepare the patient to see this; have him/her switch to hard contact lenses or glasses because staining can occur of soft contact lenses  
Counsel patient to use an alternative or back-up method of birth control (e.g., copper-bearing IUD such as ParaGard, condoms, diaphragm) when rifampin is prescribed, it reduces effectiveness (degree depending on method) of combined oral contraceptives, progestinonly oral contraceptives, levonorgestrel implants, Depo-Provera, patch and ring. Advise condom back-up. Make sure nurse & physician are aware of all medications the patient is taking.  
Counsel patient to avoid prolonged exposure to sun & to wear adequate sunblock  
Avoid bruising; do not take aspirin unless ordered by a physician; tell healthcare provider about medications prior to any procedure that might cause bleeding |
**Adverse reactions** to medications are unexpected reactions to medications that may be severe and warrant stopping the medications to avoid harm or damage to the patient.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adverse Reaction</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoniazid</strong></td>
<td>Dizziness; tingling/numbness around the mouth or in the extremities&lt;br&gt;Hepatitis: nausea; vomiting; yellowish skin or eyes; abdominal pain; dark, maple syrup or coffee colored urine; abnormal liver function tests; fatigue; fever &gt;3 days; flu-like symptoms; lack of appetite</td>
<td>Stop medication if severe or seems to be worsening; notify nurse or physician&lt;br&gt;Stop medication and notify nurse or physician</td>
</tr>
<tr>
<td><strong>Rifampin</strong></td>
<td>Easy bruising; slow blood clotting</td>
<td>Stop medication and notify nurse or physician&lt;br&gt;Stop medication and notify nurse or physician</td>
</tr>
<tr>
<td><strong>Pyrazinamide</strong></td>
<td>GI distress; nausea when taking the pills but feels better later in the day&lt;br&gt;Joint aches</td>
<td>Alter time of day pills are given; try giving pills with a small snack or food; report to nurse or physician&lt;br&gt;Cold packs or heat packs; report to nurse or physician</td>
</tr>
<tr>
<td><strong>Ethambutol</strong></td>
<td>Can cause blurred or changes vision; changes in color vision</td>
<td>Monitor &amp; test eyes monthly</td>
</tr>
<tr>
<td>Hepatitis: nausea; vomiting; yellowish skin or eyes; abdominal pain; dark, maple syrup or coffee</td>
<td>colored urine; abnormal liver function tests; fatigue; fever &gt;3 days; flu-like symptoms; lack of appetite</td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>Severe stomach upset; vomiting; lack of appetite</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stop medication and notify nurse or physician</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stop medication and notify nurse or physician</td>
<td></td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Any changes in visions noted</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stop medication and notify nurse or physician</td>
<td></td>
</tr>
</tbody>
</table>

**Other warnings to tell clients taking TB medications**

- Limit alcohol use when taking TB medication. Combining alcohol and TB medicine can cause liver damage.
- Tell the nurse if other medications are being taken. TB medication can interfere with certain prescription drugs.
- Report any concerns to the nurse.

**Directly Observed Therapy (DOT)**

- Most TB patients start feeling well after only a few weeks of treatment but the TB germs are still alive in the body.
- It is very dangerous for a TB patient to stop taking medicine early or not to take it regularly. The TB germs begin to grow again and patients may become infectious and remain sick much longer.
- Stopping treatment too early or taking treatment irregularly could cause the TB germs to become resistant to the TB medicine. If this happens, new and different medicines will be needed to kill the TB germs. These new medicines have to be taken for a longer time and usually have more serious side effects.
- DOT helps prevent these problems by making sure that treatment is complete.

**Importance of regular medical assessments**

- It is very important to have regular checkups at the clinic at least monthly.
- Blood tests can be done to make sure the medications are not harming the liver.
- Chest x-rays may be done to see if there is improvement.
- Sputum tests will be done to ensure medications are working. The sputum results also help decide when a
patient is no longer infectious and can return to his/her normal life.

**Importance of contact investigation**

- **When a patient has TB disease, they are doing the right thing by sharing the names of people they spent time with when they were able to pass TB germs to others (infectious period).** By helping the healthcare worker do a contact investigation, they are helping their family and friends stay well. And they are helping to make sure their community stays healthy.
- **The healthcare worker will ask for the names of contacts, people the patient spent time with before getting treatment—when the TB germs could be passed on to others.**
- **The healthcare worker will call or visit people to let them know they should be tested for TB.** Together the healthcare worker and patient make a list of all contacts. Contacts are family members, friends, neighbors, co-workers, and others who spent time with the patient when they were sick.
- **Give the names of the contacts to your healthcare worker.** Don’t let being embarrassed keep you from listing people you may have given TB germs. Think of how you are helping those around you stay well. Protect your family and friends.
- **Questions the healthcare worker may ask the patient:**
  - “How long have you been coughing? When did you first feel sick?”
  - “Where did you spend time when you were feeling sick and coughing? Where did you live? Did you go to school? Where did you hang out when you were not at home or working?”
  - “Who are the family members, friends, neighbors, and co-workers you spent time with while coughing?”
- **The healthcare worker will decide which people need to be contacted based on the information given.** It is important for the healthcare worker to be in touch with people who may have been given TB germs. These friends, family members, co-workers, or classmates may have TB infection. This means they have dormant (sleeping) TB germs in their body, so they may not feel sick. If they get treatment for TB infection, they won’t get sick with TB disease. If they already have TB disease, they will need treatment right away.
- **Some people with TB disease are afraid they will lose their job if others learn they passed TB germs to people at work. Others may be worried their friends and family will reject them.** What you need to know is that the information you share with the healthcare worker is kept private and personal.
- **The healthcare worker will call or visit the people named.** He/she may talk to a group of people at the patient’s work, school, or place of worship. The healthcare worker will suggest the contact get a TB skin test and will provide information on where to get tested.
### Medical Case Review

**Date of Birth:** ___________  
**Age:** ___  
**Race:** ___  
**Sex:** ___  
**HIV:** ___  

- [ ] US born  
- [ ] Foreign-born

- [ ] Contact to known case?  
- [ ] If case is < 18, source identified

**Physician or Health Department:**

**Occupation:** __________________________  
**Last date worked:** _______________  
**Return to work date:** ___________

#### DIAGNOSTIC INFORMATION

**Diagnosed at:**  
- [ ] Hospital  
- [ ] Physician’s Office  
- [ ] Health Dept.

**Health Dept. Status at Diagnosis:**  
- [ ] Alive  
- [ ] Dead  

**Major site of disease:**

**Additional site:**

**Fluid specimens**  
<table>
<thead>
<tr>
<th>Date(s) Collected</th>
<th>Smear Pos / Neg / Pend / Not done</th>
<th>Culture Pos / Neg / Pend / Not done</th>
<th>Biopsy specimens for hisopathology &amp; culture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Sputum</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>Bronchial Wash</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>Gastric Aspirate</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>Pleural Fluid</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ]</td>
<td></td>
</tr>
</tbody>
</table>

**Skin Test**

- [ ] Date
- [ ] Results
- [ ] Reason

**DRUG SUSCEPTIBILITY RESULTS:**

- [ ] No resistance  
- [ ] INH resistance  
- [ ] RIF resistance  
- [ ] Other

**SPUTUM CULTURE CONVERSION:**

- [ ] Date _________________  
- [ ] Occurred within 2 months of treatment?

- [ ] Yes  
- [ ] No

**BACTERIOLOGY SUMMARY:**

- [ ] Smear: Last Positive ___________  
- [ ] Negative ___________  
- [ ] Culture: Last Positive ___________  
- [ ] Negative ___________

**INITIAL CHEST RADIOGRAPHY FOLLOW-UP**
**Interpretation**
- Normal
- Not done
- Unknown
- Abnormal → Cavitary
- Non-cavitary → Consistent with TB
- Inconsistent with TB
- Pleural Effusion

**Remarks:**
- Date _______________
- Status
- Stable
- Worsening
- Improving
- Unknown

**CO-MORBID MEDICAL**
- HIV Test Offered
- Yes
- No
- Refused Testing
- Yes
- No
- Test done, results unknown

- Status Negative
- Status Positive → CD4
  - On Antiretrovirals
  - Yes
  - No
  - If Yes, List:
  - PCP Prophylaxis
  - Yes
  - No

- Diabetes Mellitus
- Cancer (site)
- Silicosis
- Chronic Liver disease
- End Stage Renal Disease
- Hepatitis B
- Hepatitis C
- Tumor necrosis factor alpha (TNF) antagonists
- Other

- Recent hospitalization, specify details:

- Medical Complications:

**INITIAL DRUG REGIMEN**
- Date RX Started:
- Daily
- Twice Weekly
- Other
- DOT
- Non-DOT
- Isoniazid
- Rifampin
- Pyrazinamide
- Ethambutol
- Other

**CURRENT DRUG REGIMEN**
- Date RX Started:
- Daily
- Twice Weekly
- Other
- DOT
- Non-DOT
- Isoniazid
- Rifampin
- Pyrazinamide
- Ethambutol
- Other

- # Months on Therapy
- # Doses to Date
- Est. length of treatment
- Anticipated completion date

- Describe clinical improvement

**RISK FACTORS**
- Within last 12 months:
- Homeless
- IV Drug Use
- Juvenile Correction Facility
- Non-IV Drug Use
- Excessive Alcohol
- Unknown
- Alcohol or drug treatment facility
- Mental health facility

- At time of Diagnosis:
- Previous LTBI history
- Did not complete therapy
- Completed therapy (date)
- Resident of correctional facility, if yes:
  - Federal Prison
  - State Prison
  - Local Jail
- Other Correctional Facility
- Unknown
- Resident of long term care facility, if yes:
  - Nursing home
  - Hospital based facility

**BARRIERS TO ADHERENCE**

**TREATMENT ISSUES**
- Homelessness
- Inadequate housing
- Inadequate nutrition
- Inadequate income
- Inadequate transportation
- Inadequate healthcare/insurance
- Unemployment
- Domestic violence/abuse
- Low literacy
- Language barrier
- Alcohol use
- Drug use
- Specify
- Depression
- Suicidal/homicidal thoughts
- Paranoia / Defiant / Erratic behavior
- Uncooperative
- Erratic behavior
- Does not follow isolation
- Misses Clinical appointments
- Misses DOT appointments
- Reluctant to identify contacts

<table>
<thead>
<tr>
<th>Treatment interruptions?</th>
<th>Yes</th>
<th>No</th>
<th>Date stopped</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical/adverse reactions</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Liver Enzymes elevated</td>
<td>Yes</td>
<td>No</td>
<td>Specify</td>
</tr>
<tr>
<td>Patient nonadherence</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Provider reasons</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Date re-started</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REFERRALS & ADHERENCE STRATEGIES (specify):

ADDITIONAL COMMENTS:

Date Report Completed ____________________
SIGNATURE ________________________________

RECOMMENDATIONS:
<table>
<thead>
<tr>
<th>Unexplained elevated temperature for three or more days</th>
</tr>
</thead>
<tbody>
<tr>
<td>0__l__l__l__l__l__l__l__l__l__l__10</td>
</tr>
<tr>
<td>98°</td>
</tr>
<tr>
<td>101°</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unexplained weight loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>0__l__l__l__l__l__l__l__l__l__l__10</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Severe</td>
</tr>
<tr>
<td>Symptom</td>
</tr>
<tr>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>Tired, don’t feel well, malaise, weakness</td>
</tr>
<tr>
<td>Chills and/or night sweats</td>
</tr>
<tr>
<td>Head, eyes, ears, nose, throat (HEENT)</td>
</tr>
</tbody>
</table>

### Tired, don’t feel well, malaise, weakness

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Severe</td>
</tr>
</tbody>
</table>

### Chills and/or night sweats

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Severe</td>
</tr>
</tbody>
</table>

### Vision changes

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Severe</td>
</tr>
<tr>
<td><strong>SKIN</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Color of sclera</strong></td>
<td></td>
</tr>
<tr>
<td><img src="image" alt="Eye with yellowish sclera" /></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Hearing loss, ringing in ears</strong></td>
<td></td>
</tr>
<tr>
<td><img src="image" alt="Person with hand on ear" /></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Yellowish skin</strong></td>
<td></td>
</tr>
<tr>
<td><img src="image" alt="Yellowish skin images" /></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Rash or itching</td>
<td>None to Severe (10)</td>
</tr>
<tr>
<td>Bruising</td>
<td>None to Severe (10)</td>
</tr>
<tr>
<td>Flushing</td>
<td>Avoid eating cheeses and meats, soy sauce, soy beans. Miso soup, fava beans, snow peas, sauerkraut, yeast, wine or beer</td>
</tr>
</tbody>
</table>

**CARDIOVASCULAR**
### Chest Pain

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### RESPIRATORY

#### Shortness of Breath

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Coughing

<table>
<thead>
<tr>
<th></th>
<th>10</th>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom</td>
<td>Scale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coughing up blood</td>
<td>0-10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of appetite</td>
<td>0-10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>0-10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GASTROINTESTINAL, 1**

- **Coughing up blood**
  - Rating: 0-10
  - None to Severe
- **Loss of appetite**
  - Rating: 0-10
  - None to Severe
- **Nausea**
  - Rating: 0-10
  - Small snack with pill or suck on hard candy
    - None to Severe
<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
<th>Scale</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea and Vomiting</td>
<td>Dark brown, coffee grounds material</td>
<td>0-10</td>
<td>None</td>
</tr>
<tr>
<td>Heartburn</td>
<td>Do not take antacids 1 hour before or 1 hour after your pill</td>
<td>0-10</td>
<td>None</td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td>0-10</td>
<td>None</td>
</tr>
</tbody>
</table>

GASTROINTESTINAL, 2
### Pale or clay-colored stools

- Pale or clay-colored: 1
- White: 0

### Abdominal Pain

- None: 0
- Severe: 1

### Right upper quadrant tenderness

- None: 0
- Severe: 1
<table>
<thead>
<tr>
<th>Normal</th>
<th>Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine is light yellow to a deep yellow in color</td>
<td>Persistently dark urine</td>
</tr>
<tr>
<td><strong>0_1_1_1_1_1_1_1_1_1_10</strong></td>
<td><strong>0_1_1_1_1_1_1_1_1_1_10</strong></td>
</tr>
</tbody>
</table>

**Light, clear** **deeper, cloudy**

<table>
<thead>
<tr>
<th>Normal</th>
<th>Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine is light to deep orange with Rifampin</td>
<td>Urine the color of maple syrup or coca cola</td>
</tr>
<tr>
<td><strong>0_1_1_1_1_1_1_1_1_1_10</strong></td>
<td><strong>0_1_1_1_1_1_1_1_1_1_10</strong></td>
</tr>
</tbody>
</table>

**Yellow** **Maple syrup**
### Change in kidney function

Lethargy, feeling of being unwell, flu-like feelings but no fever, weakness, shortness of breath, appetite loss, nausea, weight loss, itching, dry skin and generalized swelling may occur.

<table>
<thead>
<tr>
<th>Kidney function</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>No symptoms</td>
</tr>
</tbody>
</table>

### NEUROLOGICAL

#### Peripheral Neuropathy

- A burning or prickling sensation
- Tingling or numbness, skin crawling, or itching
- A feeling of "pins and needles"

Taking Vitamin B6 will help decrease symptoms.

<table>
<thead>
<tr>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

#### Headache

<table>
<thead>
<tr>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>
### Dizziness

<table>
<thead>
<tr>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

### Cognitive and memory problems

<table>
<thead>
<tr>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

### MUSCULOSKELETAL

#### Joint pain, Stiffness, Gout

<table>
<thead>
<tr>
<th>None</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Sore Muscles</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td>Weakness in legs or difference in walking</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

**Refusal of HIV Testing**

Name______________________________ Date of Birth ___________________
☐ I have been exposed to an active TB case
☐ I have been diagnosed with latent TB infection (LTBI)
☐ I have been diagnosed with an active case of TB or suspected case of active TB

CDC recommends HIV screening for all TB clients. This includes persons who have been exposed to an active case of TB (contacts), persons diagnosed with latent TB infection (LTBI) and those persons either suspected to have active TB or those persons confirmed to have active TB.

TB is particularly dangerous for people with HIV infection. Active TB can accelerate the progression of HIV in persons living with HIV. Having HIV infection when exposed or diagnosed with LTBI can increase the progression of the latent form of TB to an active case of TB.

After having the recommendations and risks explained to me, I have decided to refuse a test for HIV. I have been told the signs and symptoms of active TB are cough lasting more than 3 weeks, fever, night sweats, coughing up blood, chest pain, fatigue and unexplained weight loss. I understand that if I develop any signs and symptoms of active TB, I need to seek medical care immediately. I understand that TB is an infectious disease that can be passed to others. I also understand that legal steps can be taken if I develop active TB and I do not seek medical care, but expose others to becoming infected and/or sick.

________________________________________  _________________________
Client’s signature                              Date

________________________________________  _________________________
Public Health Representative Signature         Date
<table>
<thead>
<tr>
<th>Name:</th>
<th>Date of Birth:</th>
<th>Gender at birth: Male Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case/Suspect</td>
<td>Initial Treatment:</td>
<td>4 Drug Regimen - Option 1</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTBI/Presumptive LTBI</td>
<td>Initial Treatment:</td>
<td>Isoniazid 9 mo.</td>
</tr>
<tr>
<td>Med Start Date:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolation Ordered</td>
<td>□ YES</td>
<td>□ NO</td>
</tr>
<tr>
<td>Telephone Nurse Monitoring Program</td>
<td>Start Date:</td>
<td></td>
</tr>
<tr>
<td>KEY:</td>
<td>YES = √</td>
<td>NO = Ø</td>
</tr>
<tr>
<td>Date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adheres to treatment plan /Number of doses completed to date</td>
<td></td>
<td></td>
</tr>
<tr>
<td># missed doses/# missed appointments (make note)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last menstrual period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol Use/Substance Use (make note)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any travel since last visit? Plans to travel within the next month?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of Systems (Questions on back of flow sheet)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSTITUTIONAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SKIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARDIOVASCULAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GASTROINTESTINAL/GENITOURINARY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MUSCULOSKELETAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VITAL SIGNS: Temperature/Pulse/Respirations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current weight</td>
<td>(Initial weight at diagnosis _________)</td>
<td></td>
</tr>
<tr>
<td>HEENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision acuity test/Vision color discrimination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SKIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash (trunk = t, back = b, extremities = e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruises (trunk = t, back = b, extremities = e)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shortness of Breath</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough (note characteristics)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GASTROINTESTINAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal tenderness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memory loss/poor cognition/dizziness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MUSCULOSKELETAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain, swelling of joints/abnormal gait</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Tests Ordered</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Hepatitis B/Hepatitis C/HIV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Glucose/Hbg A1C
### Uric Acid/Serum Creatinine/Bilirubin
### AST/ALT/Liver Profile
### CBC with differential
### Pregnancy test (if applicable)
### Most recent date of sputum specimen
### Most recent sputum status (Positive, Negative, NA)

#### Medications Ordered and Dispensed

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosage</th>
<th>Form</th>
<th>Route</th>
<th>Frequency</th>
<th>Duration</th>
<th># of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>mg</td>
<td>tab(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td>mg</td>
<td>cap(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>mg</td>
<td>tab(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Ethambutol</td>
<td>mg</td>
<td>tab(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Pyridoxine</td>
<td>mg</td>
<td>tab(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Rifapentine</td>
<td>mg</td>
<td>tab(s)</td>
<td>PO</td>
<td>x wk X mo</td>
<td>#</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Next appointment date

Nurse’s Signature

---

**REFERENCE:** Review of Systems questions:

**CONSTITUTIONAL:** Does the patient have any unexplained weight loss, fever, chills, weakness or fatigue, night sweats, and/or loss of appetite? How severe are they?

**HEENT:** Does the patient have any vision loss, blurred vision, double vision or trouble distinguishing colors? Does he/she wear glasses? Does the patient have any hearing loss or ringing in the ears? Does he/she wear a hearing aid?

**SKIN:** What is the normal color of skin? Are there any rashes or itching? If so, what is the cause? Is there any bruising? Does the patient bruise easily?

**CARDIOVASCULAR:** Does the patient have any chest pain, chest pressure/chest discomfort, palpitations or edema?

**RESPIRATORY:** Is the patient experiencing any shortness of breath, cough or sputum? Is this something new or is this a chronic condition? Is the patient coughing up blood?

**GASTROINTESTINAL/GENITOURINARY:** Does the patient have anorexia, heartburn, nausea, vomiting or diarrhea or abdominal pain? Does anything relieve it? Does anything precipitate it? What
color are his/her stools? Is there any blood in the stool? What color is the patient’s normal urine? Does he/she have bladder or kidney infections? Have they ever had a problem with kidney function?

**NEUROLOGICAL:** Does the patient have headaches? What kind and what relieves them? Does he/she have dizziness, syncope, paralysis, ataxia, numbness or tingling in the extremities? Is there any problem with memory or cognition?

**MUSCULOSKELETAL:** Does the patient have muscle and/or back pain? Does he/she have any arthritis, joint pain or stiffness? Is there any weakness in his/her limbs or any problem with gait and movement? Have they ever had signs of gout?

---

**Tuberculosis (TB) Risk Assessment**

Please complete this form to help us decide if you fall into a high-risk group that requires a TB skin test.

Name: ______________________________

Date of Birth: ______________________
Please circle **YES** or **NO**.

1. Have you been around a person sick with active TB disease?  **Yes**  **No**
2. Have you had an organ transplant?  **Yes**  **No**
3. Within the last 5 years, have you lived in, traveled to or had a visitor from a country where TB is common? If yes, what country? ___________  **Yes**  **No**
4. Have you ever injected drugs?  **Yes**  **No**
5. Have you been in jail, prison or a nursing home?  **Yes**  **No**
6. Have you ever worked in a lab that processed TB samples?  **Yes**  **No**
7. Do you have?
   a. Diabetes  **Yes**  **No**
   b. Chronic kidney failure with dialysis  **Yes**  **No**
   c. Cancer of the blood or lymph system  **Yes**  **No**
   e. Cancer of the head, neck, or lungs  **Yes**  **No**
   f. Stomach surgery  **Yes**  **No**
   g. Immune problems (HIV or taken steroids like cortisone for longer than one month)  **Yes**  **No**
8. Are you starting a treatment for arthritis?  **Yes**  **No**
9. Have you ever been told you have an abnormal chest x-ray?  **Yes**  **No**
10. Have you had?
    a. A cough and/or hoarseness lasting more than 3 weeks  **Yes**  **No**
    b. A cough with a lot of mucous or blood  **Yes**  **No**
    c. Fever or night sweats for more than one week  **Yes**  **No**
    d. Weight loss without trying  **Yes**  **No**
    e. Tiredness or weakness  **Yes**  **No**
11. Have you ever had a positive TB skin test?  **Yes**  **No**

If you answered **NO** to all of these questions, you are not in a high-risk group and do not need a TB skin test.

If you answered **YES** to any of these questions, you fall into a high-risk group and should have a TB skin test or other tests for TB.

______________________________  ____________________
Signature/Title of Person Assessing the Client  Date

GA DPH TB Unit  Rev. 12/2011
Tuberculosis (TB) Symptom Screen

Name: ___________________________ M ____  F ____  Date of Birth: __________________________

Last skin test: ____________________________ (Name, address, city, state, zip, and phone number of place where test was given)

Test Date: __________  Results _____ mm  Positive ___ Negative ___  Chest X-Ray: Normal ___ Abnormal ___

Were you treated for: Latent TB infection (LTBI)? Yes __ No ___ #Months ___  TB Disease? Yes __ No ___ #Months ___

If yes, When? _______________ Where? _______________________________________________________________

Name of Medications: ________________________________________________________________

Today’s Date __________________________

Do you have a cough? Yes _____  No _____
If yes, how long have you had it? # Days _____  # Weeks _____  # Months _____
What color is the mucus? ________________  Are you coughing up blood? Yes _____  No _____

Do you have night sweats? Yes _____  No _____

Do you have fevers? Yes _____  No _____

Have you lost weight without trying? Yes _____  No _____  # Pounds _____

Have you been tired or weak? Yes _____  No _____
If yes, how long has it lasted? # Days _____  # Weeks _____  # Months _____

Do you have chest pain? Yes _____  No _____
If yes, how long has it lasted? # Days _____  # Weeks _____  # Months _____

Do you have shortness of breath? Yes _____  No _____
If yes, how long has it lasted? # Days _____  # Weeks _____  # Months _____

Do you know anyone who has these symptoms? Yes _____  No _____

Name _________________________ Address ____________________________________ Phone________________


**Appendix G**

**Hospitalization for Tuberculosis**

[Georgia Statutes current through 2016]

**O.C.G.A. § 31-14-1. Active tuberculosis; definition; declaration of policy**

(a) As used in this chapter, the term “active tuberculosis” means a diagnosis demonstrated by clinical, bacteriologic, or diagnostic imaging evidence, or a combination thereof. Persons who have been diagnosed as having active tuberculosis and have not completed a course of antituberculosis treatment are still considered to have active tuberculosis and may be infectious.

(b) Active tuberculosis is declared to be dangerous to the public health.

**O.C.G.A. § 31-14-2. Conduct of diseased person likely to expose others; petition for commitment**

When the county board of health or the Department of Public Health has evidence that any person has active tuberculosis and is violating the rules and regulations promulgated by the department or the orders issued by the county board of health and thereby presents a substantial risk of exposing other persons to an imminent danger of infection, after having been directed by the county board of health or the department to comply with such rules, regulations, or orders, the county board of health or the department shall institute proceedings by petition for commitment, returnable to the superior court of the county wherein such person resides or, if such person is a nonresident or has no fixed place of abode, in the county wherein such person may be found. The petition executed under oath shall state the specific evidence supporting the allegations, that the evidence has existed within the preceding 30 days, that the person named therein has active tuberculosis and is violating the rules and regulations of the department or the orders of the county board of health and presents a substantial risk of
exposing other persons to an imminent danger of infection, after having been directed by the county board of health or department to comply with such rules, regulations, or orders, and that the public health requires commitment of the person named therein. The petition must be accompanied by a certificate of a physician stating that the physician knows or suspects that the person named therein may have active tuberculosis, the evidence which forms the basis of this opinion, and whether a full evaluation of the person is necessary.

O.C.G.A. § 31-14-3. Hearing on petition; notice of hearing; physical examination; court costs; conduct of hearing

(a) Immediately upon the filing of a petition pursuant to Code Section 31-14-2, the judge of the superior court shall set the matter for a full and fair hearing on the petition. Such hearing shall be held no sooner than seven days and no later than 12 days, excluding Saturdays, Sundays, and holidays, subsequent to the time of filing of the petition. The court shall serve personal notice of the hearing upon the person named in the petition and upon the petitioner. The notice required by this Code section shall include the time and place of the hearing; notice of the person’s right to counsel, that the person may apply for court appointed counsel if the person cannot afford counsel, and that the court will appoint counsel unless the person indicates in writing that he or she does not wish to be represented by counsel; and notice that the person may waive his or her rights to a hearing under this Code section. A copy of the petition and physician’s certificate filed under Code Section 31-14-2 shall be attached to the notice. The judge shall, where prayed for in the petition, provide for the examination of the person named therein by a physician licensed under Chapter 34 of Title 43, which examination shall include sputum examinations by a laboratory approved by the department and a recent chest X-ray of good diagnostic quality interpreted by a physician licensed to practice under Chapter 34 of Title 43, as a part of the order setting the matter for hearing; the order shall require the person or persons named therein to make such examination. Any X-ray and accompanying report or any written report as to a sputum examination shall be admissible as evidence without the necessity of the personal testimony of the person or persons making such examination and report. A physician may rely upon this evidence as the basis for the diagnosis of active tuberculosis and the defendant may offer opposing evidence on this issue by testimony or otherwise. All court costs incurred in proceedings under this chapter, including costs of examinations required by order of court but excluding any examinations procured by the person named in the petition, shall be borne by the county wherein the proceedings are brought. The fee to be paid to an attorney appointed under this Code section to represent a person who cannot afford counsel shall be paid by the county board of health instituting proceedings for commitment.

(b) A full and fair hearing shall mean a proceeding before a hearing examiner under Code Section 31-14-8.1 or before the superior court in a proceeding under subsection (a) of this Code section. The hearing may be held in a regular court room or in an informal setting, in the discretion of the hearing examiner or the court, but the hearing shall be recorded electronically or by a qualified court reporter. The person named as defendant shall be provided with the opportunity for the assistance of counsel. If the defendant cannot afford counsel, the court shall appoint counsel for the defendant or the hearing examiner shall request that the court appoint such counsel; provided, however, that the defendant shall have the right to refuse in writing appointment of counsel. Both parties shall have the right to confront and cross-examine witnesses, to offer evidence, and to subpoena witnesses. Both parties shall have the right to require testimony before the hearing examiner or in court in person or by deposition from any physician upon whose evaluation the decision of the hearing examiner or the court may rest. The hearing
examiner and the court shall apply the rules of evidence applicable in civil cases, except as otherwise provided for in this chapter. The burden of proof shall be upon the party seeking commitment of the defendant. The standard of proof shall be by clear and convincing evidence. At the request of the defendant, the public may be excluded from the hearing. The defendant may waive his or her right to be present at the hearing. The reason for the action of the court or the hearing examiner in excluding the public or permitting the hearing to proceed in the defendant's absence shall be reflected in the record.

O.C.G.A. § 31-14-4. Service of copy of petition and order; contempt for failure to comply

A copy of the petition and order shall be served on the person named in the petition. Any failure of such person to comply with the order or with the notice by the persons appointed therein to make examination shall be enforceable by attachment for contempt.

O.C.G.A. § 31-14-5. Procedure where there is danger of diseased person absconding

Where a danger exists that the person named in the petition may abscond or conceal himself or herself or where the person is conducting himself or herself so as to present a substantial risk of exposing other persons to an imminent danger of infection, the court may, as a part of the order made pursuant to Code Section 31-14-3, direct the sheriff or the sheriff's deputies to take such person into custody pending hearing and impose such confinement as will not endanger other persons. An affidavit shall be attached to the petition containing the specific facts supporting the need for custody pending hearing.

O.C.G.A. § 31-14-6. Report of person making examination; service of copies

The person or persons appointed by the order to make the examination shall file a report thereof, in triplicate, in the court wherein the proceeding is pending. The clerk of the superior court shall forthwith make service of one copy on the agency instituting the proceeding and one copy on the party named as defendant therein and the defendant's attorney, which service shall be personal or by certified mail or statutory overnight delivery.

O.C.G.A. § 31-14-7. Order based upon hearing; commitment of patient to hospital; costs of transportation; dismissal of petition and release of defendant where standards not met; review of commitment order

(a) Upon the hearing set in the order, if the court finds that the person has active tuberculosis, is violating the rules and regulations promulgated by the department or the orders issued by the county board of health after having been directed by the county board of health or the department to comply with such rules, regulations, or orders, presents a substantial risk of exposing other persons to an imminent danger of infection, and there is no less restrictive available alternative to involuntary treatment at a hospital or facility approved by the department for the care of tubercular patients, then the court shall issue an order committing the defendant to
the custody of the sheriff of the county or the sheriff’s deputies to be delivered to the designated hospital or facility, where the defendant shall be admitted for care and treatment not to exceed two years. If the court does not find that the above standards are met, then the court shall dismiss the petition and the defendant shall be released from custody if taken into custody pursuant to Code Section 31-14-5. The costs of transporting such person to the hospital or facility shall be paid out of county funds.

(b) An order for commitment shall be subject to review at the instance of either party by appeal.

O.C.G.A. § 31-14-7. Order based upon hearing; commitment of patient to hospital; costs of transportation; dismissal of petition and release of defendant where standards not met; review of commitment order

(a) Upon the hearing set in the order, if the court finds that the person has active tuberculosis, is violating the rules and regulations promulgated by the department or the orders issued by the county board of health after having been directed by the county board of health or the department to comply with such rules, regulations, or orders, presents a substantial risk of exposing other persons to an imminent danger of infection, and there is no less restrictive available alternative to involuntary treatment at a hospital or facility approved by the department for the care of tubercular patients, then the court shall issue an order committing the defendant to the custody of the sheriff of the county or the sheriff’s deputies to be delivered to the designated hospital or facility, where the defendant shall be admitted for care and treatment not to exceed two years. If the court does not find that the above standards are met, then the court shall dismiss the petition and the defendant shall be released from custody if taken into custody pursuant to Code Section 31-14-5. The costs of transporting such person to the hospital or facility shall be paid out of county funds.

(b) An order for commitment shall be subject to review at the instance of either party by appeal.

O.C.G.A. § 31-14-8.1. Continued confinement; report of necessity; hearing

(a) If it is necessary to continue confinement of a committed patient beyond a period of two years ordered by a court or hearing examiner or authorized under subsection (d) of this Code section, the designated responsible physician of the tuberculosis inpatient unit shall review and update the patient's treatment plan and shall prepare a report giving evidence of the necessity of such continued confinement. The report shall be prepared so as to allow sufficient time for the hearing authorized by this Code section to be conducted before the expiration of the two-year period of confinement. The report shall specify that, based upon clinical or X-ray evidence:

(1) The patient is a person having active tuberculosis requiring continued commitment; or

(2) The patient is a person having active tuberculosis with a substantial likelihood of future noncompliance with a proposed treatment plan which will predictably lead to the development of infectious drug-resistant tuberculosis. The likelihood of noncompliance must be based upon a history of noncompliance with treatment.

(b) Such report shall be filed in the patient’s medical record. A copy of the report shall be personally served on the patient along with a statement that the patient may, within 15 days after service of the report, file a request for a hearing to be conducted in accordance with the procedure for contested cases under Chapter 13 of Title 50, the “Georgia Administrative Procedure Act,” except as otherwise provided in this chapter, that the patient has a right to counsel at the hearing, that the patient may apply immediately to the superior court in the county where the committed patient is confined to have counsel appointed if the patient cannot afford counsel, and that the
court will appoint counsel for the patient unless the patient indicates in writing that he or she does not desire to be represented by counsel or has made his or her own arrangements for counsel. Payment for such court appointed representation shall be made by the department. The hearing may be continued as necessary to allow the appointment of counsel.

(c) If a hearing is requested within 15 days of service of the report on the patient, the hearing examiner shall set a time and place for the hearing to be held within 15 days of the time the hearing examiner receives the request. The hearing examiner may set a hearing if a request is made later than 15 days after service of the report if good cause is shown for the delay in making the request. Notice of the hearing shall be personally served on the patient, the hospital or facility, and, when appropriate, on counsel for the patient. Such hearing shall be a full and fair hearing, as described in Code Section 31-14-3, before a hearing examiner. After such hearing, the hearing examiner may issue any order which the court is authorized to issue under Code Section 31-14-7.

(d) If a hearing is not requested within 15 days of service of the report on the patient, the department shall be authorized to continue confinement of the patient for an additional period not to exceed six months.

O.C.G.A. § 31-14-8.2. Appeal of order of superior court or hearing officer

[Text of section effective until Jan. 1, 2017.]

Either party may appeal any order of the superior court or hearing examiner in a proceeding under this chapter. An order of the superior court may be appealed to the Court of Appeals and the Supreme Court as provided by law but shall be heard as expeditiously as possible. The appeal of an order of a hearing examiner shall be to the superior court of the county in which the proceeding was held. The review shall be conducted by the superior court without a jury and shall be confined to the record. The court, upon request, may hear oral argument and receive written briefs. The patient must pay his or her costs upon filing any appeal authorized under this Code section or must make an affidavit that he or she is unable to pay costs. The parties shall retain all rights of review of any order of the superior court, the Court of Appeals, and the Supreme Court, as provided by law. The patient shall have a right to counsel on appeal or, if unable to afford counsel, shall have counsel appointed for the patient by the court. The appeal rights provided in this Code section are in addition to any other appeal rights which the parties may have.

O.C.G.A. § 31-14-8.2. Appeal of order of superior court or hearing officer

[This text becomes effective Jan. 1, 2017.]

Either party may appeal any order of the superior court or hearing examiner in a proceeding under this chapter. An order of the superior court may be appealed to the Court of Appeals or the Supreme Court as provided by law but shall be heard as expeditiously as possible. The appeal of an order of a hearing examiner shall be to the superior court of the county in which the proceeding was held. The review shall be conducted by the superior court without a jury and shall be confined to the record. The court, upon request, may hear oral argument and receive written briefs. The patient must pay his or her costs upon filing any appeal authorized under this Code section or must make an affidavit that he or she is unable to pay costs. The parties shall retain all rights of review of any order of the superior court, the Court of Appeals, and the Supreme Court, as provided by law. The patient shall have a right
to counsel on appeal or, if unable to afford counsel, shall have counsel appointed for the patient by the court. The appeal rights provided in this Code section are in addition to any other appeal rights which the parties may have.

O.C.G.A. § 31-14-9. Procedure to secure discharge; examination; hearing; limitation on frequency of applications; petition for writ of habeas corpus

(a) At any time after commitment and not more often than once every six months, the patient or any friend or relative having reason to believe that the patient no longer has active tuberculosis or that the patient’s discharge will not endanger the public health may institute proceedings by petition in the superior court of the county wherein the confinement exists, whereupon the judge shall set the matter for a hearing to occur within 15 days requiring the person or persons to whose care the patient was committed, or their duly authorized agents, to show cause on a day certain why the patient should not be discharged. The judge shall also require that the patient be allowed the right to be examined prior to the hearing by a licensed physician of the patient’s own choice and at the patient’s own personal expense. Thereafter all proceedings shall be conducted in the same manner as are proceedings for commitment.

(b) In addition to the above procedure for securing discharge, the patient or a friend or relative on behalf of such person may petition, as provided by law, for a writ of habeas corpus to question the cause and legality of detention and to request a court of competent jurisdiction to issue a writ for release, provided that a copy of the petition along with the proper certificate of service shall also be served upon the presiding judge of the court ordering such detention and upon the county board of health or the Department of Public Health which initiated the petition for commitment pursuant to Code Section 31-14-2, which service shall be made by certified mail or statutory overnight delivery.

O.C.G.A. § 31-14-10. Enforcement of rules and regulations by county boards of health

The county boards of health or their duly authorized agents shall, within their respective limits, enforce rules and regulations adopted by the department for the protection of the public against active tuberculosis.

O.C.G.A. § 31-14-11. Taking into custody and return of committed person leaving hospital without authority

Any person who leaves a hospital or facility approved by the department for the treatment of tuberculosis to which he or she has been committed by court order, without having been discharged by the medical staff of the tuberculosis inpatient unit or the community tuberculosis control unit, shall be taken into custody and returned thereto by the sheriff of any county where such person may be found, upon affidavit being filed with the sheriff by the designated responsible official of the hospital or facility to which such person has been committed.

O.C.G.A. § 31-14-12. No commitment for person having active tuberculosis who obeys rules and regulations

No person having active tuberculosis who, in his or her home or other place, obeys the rules and regulations of the department and county boards of health for the control of active tuberculosis or who voluntarily accepts care in a hospital or facility operated for the care of tuberculosis, in his or her home, or in another place and who obeys the
rules and regulations of the department and completes the prescribed course of therapy for the control of active
tuberculosis shall be committed as prescribed in this chapter.
Appendix H
COMMITMENT TEMPLATES

Commitment Order (p. 25)
Consent Commitment Order (p. 29)
Emergency Commitment Hearing Order (p. 31)
Emergency Petition for Confinement of Tuberculosis Client (p. 35)
Modification of Consent Commitment Order (p. 39)
Physician’s Certification for Tuberculosis Confinement (p. 41)
Verification (p. 43)
COMMITMENT FOR TUBERCULOSIS TREATMENT

IN THE SUPERIOR COURT OF _____________________ COUNTY

STATE OF GEORGIA

________________ COUNTY                     *
BOARD OF HEALTH                         *

Plaintiff,                                          *
_____________________,  *

v.                                                      *

_____________________,  *

Defendant,                                            *

COMMITMENT ORDER

The Plaintiff having filed a Petition for Commitment to a hospital of a client with active tuberculosis on ______, 200__, the Court having appointed a hearing officer to hear the Plaintiff’s Petition and counsel to represent the Defendant, the Plaintiff and the Defendant having agreed to the following Consent Order for Confinement and the hearing officer having agreed to this Consent Order; the hearing officer finds the following:

The Defendant, ___________, is a _____-year old male/female who has active tuberculosis as defined by O.C.G.A. 31-14-1. From 200__, the Defendant was under the supervision of the ________Board of Health’s Tuberculosis Clinic for treatment of his/her active tuberculosis.

During this time, the Defendant did not comply with Board of Health orders to consistently take his/her medication and remain confined so that he/she would not spread the disease. The inconsistent treatment of tuberculosis poses the risk to _______________________________ and the general public of creating a resistant tuberculosis strain that would not be treatable for the Defendant or for any person who might contract this resistant strain. Since the Defendant’s involuntary confinement on ________, 200__, at __________, the Defendant’s tuberculosis has
responded to treatment and the level of bacteria in his/her sputum has reduced dramatically. Although he/she shortly will become non-infectious for active tuberculosis, he/she would subject himself/herself to a relapse if the tuberculosis treatment were not confined for the length of time as prescribed by his/her physician, which could result in a resistant or multi-resistant tuberculosis strain.

Based upon the above-described facts, the hearing officer hereby finds that the Defendant should remain confined to a facility that will ensure he/she consistently takes his/her medication for active tuberculosis. The period of confinement shall be for six (6) months unless an extension of the confinement is granted pursuant to O.C.G.A 31-14-8.1. The place of confinement shall be __________, a facility that has been approved by the Department of Human Resources for the care of tubercular clients. The Defendant’s confinement at __________ shall begin only after the Defendant no longer has active tuberculosis as determined by his/her physician. While the client still has active tuberculosis, he/she shall remain confined at __________ under the __________ County Sheriff’s supervision. When it is determined that he/she no longer has active tuberculosis, the Sheriff of __________ County or his/her deputies will transport the client to __________ in __________, ________, and release him/her into the custody of and care of ___________________________.

SO FOUND this __________ day of ________, 200_____.

________________________________________

Hearing Officer appointed by

Superior Court Judge

______________________________ Consented
to and approved by:
The hearing officer that was appointed by this Court having approved a Consent Commitment Order for the confinement of the Defendant, this Court hereby approves the Commitment Order that was entered into by the hearing officer on the __________ day of ___, 200__.

THEREFORE, the Defendant is ORDERED to be confined pursuant to O.C.G.A 31-14-1, et seq., and to ______________ for a period of ______(______) months to ensure that he/she regularly takes his/her tuberculosis treatment. While at __________, the Defendant will comply with all the orders of ______________ for the treatment of tuberculosis, Board of Health orders regarding his/her treatment for tuberculosis, and the orders of medical professional whose care he/she is under. The Defendant’s confinement for the treatment and
care for his/her disease shall not exceed _______ (___) months, unless that time period is extended by hearing as provided in O.C.G.A. 31-14-8.1.

The Defendant’s confinement at ______________ shall begin only after he/she is negative for active tuberculosis. Until the Defendant is negative for active tuberculosis, he/she shall remain in the custody of the ________ County Sheriff or his/her lawful deputies at ________ Hospital.

SO ORDERED this _______ day of ____________, 200__.

____________________________________
Judge
Superior Court ________ County

Prepared and presented by:

________________________
Attorney for ______________________

Approved by:

_________________
Attorney for ______

___________________________________
Defendant

IN THE SUPERIOR COURT OF ________________ COUNTY
The plaintiffs’ Emergency Petition for Confinement of Tuberculosis Client having come before this Court, and after hearing ex parte evidence presented by the Plaintiff, the Court finds the following:

1. The Defendant, ______________, has active tuberculosis.

2. The Defendant has violated the ______________ County Board of Health orders to remain confined in the Defendant’s residence and has further defied the Board of Health orders to consistently take his/her medicine.

3. The Defendant poses a flight risk because (state documented basis for allegation – he/she does not have a stable address, has a drug problem, is used to living on the streets).

4. Based upon the above listed conclusions, the evidence presented to the Court and the Physicians Certificate attached to the Plaintiff’s Petition, and the verified Petition, the Court holds the following:
a. Because the Defendant may abscond or conceal himself/herself and because his/her violation of Board of Health orders makes him/her a substantial risk of exposing other person to an imminent danger of infection, the Court directs the Sheriff or his/her deputies to take the Defendant into custody pending the hearing that is required pursuant to O.C.G.A. 31-14-3. This shall be under the supervision of Board of Health personnel or other medical personnel to ensure the safety of the Sheriff’s deputies.

b. The Defendant shall remain in custody until he/she has a full and fair hearing on the Plaintiff’s Petition for Confinement. This initial confinement shall be at a facility appropriate for TB treatment.

c. The Court hereby sets a hearing date on the Plaintiff’s Petition for the _______ day of ________, 200_ at ________ ___. The hearing shall be conducted at _________________.

d. ________________ is entitled to appointed counsel. The Court will appoint counsel unless _____________ indicates in writing he/she does not want counsel. The Court will appoint counsel unless ____________ indicates in writing he/she does not want counsel. The Court hereby appoints _________________ as Counsel for the Defendant to represent him/her in this matter.

e. During the Defendant’s initial confinement pursuant to this Order, the Defendant shall remain confined so that he/she does not infect the general public with tuberculosis and he/she shall take his/her medications as directed by the Board of Health and any health professional whose care he/she is under.

f. The Defendant shall further submit himself/herself to appropriate medical examinations to determine whether and when the tuberculosis is no longer active.

SO ORDERED this ________ day of ____________, 200_.

_____________________
_________________, Judge

Superior Court of
IN THE SUPERIOR COURT OF ________________ COUNTY

STATE OF GEORGIA

______________ COUNTY

BOARD OF HEALTH

Plaintiff,

v.

Defendant,

FILE NO._______

EMERGENCY PETITION FOR CONFINEMENT OF TUBERCULOSIS CLIENT
COMES NOW, the __________ COUNTY BOARD OF HEALTH to file this Petition for
Commitment of a Person with Active Tuberculosis pursuant to O.C.G.A. 31-14-1, et seq., and shows the Court as follows;

1. The Defendant, ____________, resides at __________________________ in _____________ County, and is therefore subject to the jurisdiction of this Court.

2. The Defendant has active tuberculosis as defined in O.C.G.A. 31-14-1 (a).

3. The Defendant is violating orders of the Department regarding treatment of his/her active tuberculosis having missed ______ (________) out of his/her last _______ (_______) scheduled doses. The Defendant has also violated specific Board of Health orders by not confining himself/herself to his/her residence, thus exposing himself/herself to the general public. The Defendant, by violating these orders of the Board of Health presents a substantial risk of exposing other persons to an imminent danger of infection. The Defendant was released from ____________ Hospital on ____________, 200_, with active tuberculosis and was referred to the ____________ County Board of Health Tuberculosis Clinic for follow-up treatment.

5. The Defendant’s chest x-ray and medical examinations and sputum examination confirm that the Defendant has active tuberculosis. The state medical lab has confirmed the sputum test.

6. The general public’s health requires commitment of this person to prevent exposing the general public to tuberculosis.

7. The Defendant was formerly a homeless person, but since his/her release from ____________ Hospital, has resided with _______________ at _______________. This person may be unaware
of their risk for TB infection due to continued contact with the Defendant therefore screening may be necessary. Because he/she has no stable address, the Defendant presents a risk of concealing himself/herself from the ____________ County Board of Health. He/She has also conducted himself/herself in a manner to expose the general public by disregarding the Board of Health orders to remain confined in ____________ ’s house and to regularly take his/her medication.

8.

Because the Defendant is a flight risk and is conducting himself/herself in a manner to expose others to imminent danger of infection, emergency commitment is necessary to protect the general public.

WHEREFORE, the Plaintiff respectfully requests that this Court:

a. Direct the Sheriff or Sheriff’s Deputies to take the Defendant into Custody pending a hearing on the Petition for Confinement so he/she will not endanger other persons pursuant to O.C.G.A 31-14-5.

b. That the Court schedules a hearing no sooner than ________ (__) days and no later than ________ (__) days to determine whether the Defendant should be confined.

c. That the Court appoints the Defendant counsels to represent him/her at this hearing.

d. That the Court give the Plaintiff such further relief as the Court deems necessary.

Respectfully submitted,

__________________________

__________________________

Attorney for Plaintiff

Ga.Bar No._______

Address

Phone Number
IN THE SUPERIOR COURT OF ______________ COUNTY

STATE OF GEORGIA

________ COUNTY BOARD OF HEALTH, * CIVIL ACTION

Petitioner *

v. *

FILE NO. __________ *

________________________, *

Respondent. *

MODIFICATION OF CONSENT COMMITMENT ORDER

The Plaintiff and the Defendant having come before this Court with a Consent Modification of this Court’s Consent Commitment Order dated _____________, 200_, the Court hereby amends its Order of ________________, 200_, as follows:

1.

The _________ County Sheriff is relieved of his/her responsibility of maintaining the Defendant in his/her custody at _____________ Hospital until further order of this Court. The _________ County Sheriff or his/her lawful deputies are still responsible for transporting the Defendant to _____________ in __________, __________. No other terms of the Consent Commitment Order or the Commitment Order of the hearing officer is altered or amended or superseded by this amendment.

________________________

Judge, _____ County Superior Court
PHYSICIAN’S CERTIFICATION FOR TUBERCULOSIS CONFINEMENT

COMES NOW, ____________, M.D., who after being duly sworn states the following:

1. Affiant is a Physician licensed to practice medicine in the State of Georgia and is the Primary Physician for the Defendant.

2. The Defendant is a _______ year old man/woman with presumptive active Tuberculosis (TB). This diagnosis is based upon a physical examination of the client and reviewing ____________’s medical records, including his/her chest x-ray, which shows
an anomaly, and positive AFB sputum smears.

3.

The client should be strictly monitored to ensure that he/she takes his/her medication for the TB as prescribed to ensure his/her infection is not infectious and that he/she does not develop drug-resistant TB.

4.

Since ___________’s TB is contagious, he/she should be confined so he/she does not come into contact with the general public.

FURTHER AFFIANT SAYETH NOT.

___________________________
Print Physician Name

Sworn to and subscribed before me this ________ day of __________, 200__.

___________________________
NOTARY PUBLIC

[seal]
STATE OF ______________

COUNTY OF

VERIFICATION

____________________, DIRECTOR, TB CLINIC, _______________ COUNTY

BOARD OF HEALTH being first duly sworn on oath, deposes and say that he/she is the
Coordinator of the TB Clinic for the ____________ County Board of Health, that
he/she has read the foregoing Emergency Petition for Confinement of Tuberculosis
Client and knows the contents thereof, and that the contents of the Petition are true and
correct to the best of his/her knowledge.

____________________

DIRECTOR OF ______ COUNTY
BOARD OF HEALTH

Sworn to and subscribed
before me this ________ day
of ______, 200 __.

________________

NOTARY PUBLIC

[SEAL]
Appendix I

Alternative Housing Program-HOPWA AID
Atlanta for
Homeless Tuberculosis Patients

OPERATIONAL PROCEDURES

2452 Spring Road
Smyrna, Georgia 30080
(770) 434-5864

Revised
July 2015
TABLE OF CONTENTS

Overview .............................................. 3

Procedures ........................................... 4

Identify Housing Resources ...................... 5

Patient Assessment .................................. 5
  Eligibility .......................................... 6
  Financial Assistance .............................. 6
  Housing Placement without income .......... 7
  Housing Placement with income .............. 7

Administrative Procedures ....................... 8

Housing Facility Guidelines ....................... 10

Enablers and Incentives ......................... 11

Forms: ............................................... 12
  Social Service Referral ......................... 13
  HIPPA Form ....................................... 14-15
  Patient-Health Department Agreement ....... 16
  Temporary Housing Fund Application ....... 17
  Patient-Provider Therapeutic Contract ....... 18
  Patient-Provider Therapeutic Contract/Financial Assistance 19
  Alert Form ........................................ 20
  Monthly Assessment ............................ 21
  Enablers/Incentives Request ................... 22
  Enablers and Incentives Log ................... 23
Overview

The closure of the TB Unit at Northwest Georgia Regional Hospital (NWGRH) required public health to identify alternative housing for homeless patients discharged from acute care hospitals within the State of Georgia. These patients, some of whom are infectious, need stable housing in which to receive Directly Observed Therapy (DOT), meals and referrals for social services. Working in collaboration with Metro TB Task Force, the American Lung Association in Georgia (ALAG), Grady Health System and the Atlanta TB Prevention Coalition (ATPC), this plan addresses these public health needs for the statewide TB Program.

The Division of Public Health, TB Unit, Office of Infectious Disease, contracts with the ALAG to provide alternative housing (including meals, personal supplies, transportation [non TB clinic appointments are coordinated through sub-contracted vendors and MARTA tokens for non-infectious patients] and referrals for social services for the homeless TB patients). Through the contract with ALAG, the VP of Public Policy & Health Promotions, two Health Promotions Managers and a Patient Services Coordinator, manage this Program.

Hundreds of tuberculosis patients have utilized the Alternative Housing Program since 1996. The Program utilizes inexpensive motels, trailers, duplexes, apartments and houses. The Health Departments provide DOT and transportation to TB and Ryan White clinic appointments. July 1, 2005, American Lung Association in Georgia began to extend its services to provide housing services for non-infectious clients.

The plan to place homeless patients in area housing requires frequent communication among ALAG area hospitals, and county TB Clinics. In addition to the formal agreements between ALAG and rental establishments, letters of agreements are on file from all participating districts. These letters demonstrate a commitment to the Alternative Housing Program by each District TB Program. Monthly patient care reviews are mandatory to ensure that continuity of care is maintained and other needed services are being
provided. A designated Outreach Worker (ORW) provide DOT and patient follow-up.

**Procedures for Alternative Housing Program**

**Purpose:**
Funds are provided by the Georgia Department of Public Health, TB Unit, to the American Lung Association in Georgia (ALAG) to provide assistance for temporary housing and to facilitate Directly Observed Therapy (DOT) to ensure completion of therapy among homeless TB patients.

**Organizational Roles:**

<table>
<thead>
<tr>
<th>ALA in Georgia</th>
<th>Health District</th>
<th>Georgia DPH – TB Control Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide technical assistance in locating appropriate housing for 18 health</td>
<td>Identify housing possibilities and work with ALAG to secure contracts, assess</td>
<td>Consultation</td>
</tr>
<tr>
<td>districts and contracts with housing vendors</td>
<td>tuberculosis patients for housing placement and financial assistance</td>
<td></td>
</tr>
<tr>
<td>Maintain weekly communication &amp; conduct monthly case review with Health</td>
<td>Maintain weekly communication &amp; participate in monthly case review with ALAG</td>
<td>Technical Assistance</td>
</tr>
<tr>
<td>Districts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participate/facilitate multidisciplinary team conferences to maintain patient</td>
<td>Provide directly observed therapy and TB medical management</td>
<td>Administrative Support</td>
</tr>
<tr>
<td>continuity of care after hospital discharge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Establish goals that can be used to measure progress</td>
<td>Provide transportation to the TB, Ryan White and Infectious Disease clinics</td>
<td>Disburse Funds</td>
</tr>
<tr>
<td>Preserve and ensure lines of communications</td>
<td>Preserve and ensure lines of communications</td>
<td>Preserve and ensure lines of communications</td>
</tr>
</tbody>
</table>
II. Negotiations with potential housing providers must be initiated prior to the identification of homeless patients. District TB coordinators will identify temporary housing options. ALAG will validate selections and negotiate with housing vendors for appropriate individuals based on medical status and housing needs.

III. ALAG coordinates and approves housing services for the state of Georgia. Funds will be disbursed for housing by check or credit card to the leasing agent only. No funds will be issued to the client or family members. The maximum amount allowable at one time is one month’s rent. ALAG will not be responsible for paying rent and/or utilities prior to client entering Program. Clients should be evaluated monthly and monthly assessments should be reported to ALAG to determine the continued need for housing services or referrals to other housing programs.

Process:

I. **Identify Housing Resources**
Temporary housing may be a motel, hotel, efficiency, apartment, trailer, personal care home or rooming house. Reasonable utilities additionally will be paid, if not included in the rental agreement.

**Housing Options** *
Options include home for patients who can return to a stable home and three levels of facilities for those without a stable home.

**Levels of Housing**

**Level 1:** Acute care hospitals 
Alternative Housing Program - smear positive, medically stable and clinical improving

**Level 2:** Shelters – ones that require negative smears; trained staffs provide DOT. 
Alternative Housing Program - smear positive, medically stable and clinical improving

**Level 3:** Shelters that require negative cultures (extra-pulmonary cases); trained staff for DOT 
Alternative Housing Program – negative cultures (pulmonary cases)
II. **Patient Assessment**

It is the responsibility of the Health Department to assess all possibilities for housing before requesting assistance through the Program.

A. **Eligibility**

Patient should be a suspect or an active case of tuberculosis and must demonstrate that he/she has an unstable home environment.

**Financial Assistance**

If a patient is unable to work because of infectiousness, ALAG will assist with monthly financial obligations; this is based on the availability of funds and patient’s financial status. Funds will immediately cease once the patient has three negative smears unless a medical statement is provided. If a patient is living with a family member, all funds will be distributed to the leasing agent and utility company. ALAG will only pay the patient’s portion of rent and/or utilities.

**Financial Assistance Awards**

Financial Assistance Awards are based on four factors:

1. Income (see chart on Federal Poverty Level) 2. Patient should have been working prior to being diagnosed with tuberculosis and he or she can return to the job.
3. Patient should be smear positive and/or provide a medical statement.
4. Financial Assistance is based on the availability of funds.

<table>
<thead>
<tr>
<th>Size of Family Unit</th>
<th>48 Contiguous States &amp; D.C.</th>
<th>Alaska</th>
<th>Hawaii</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$11,770</td>
<td>$14,720</td>
<td>$13,550</td>
</tr>
<tr>
<td>2</td>
<td>15,930</td>
<td>19,920</td>
<td>18,330</td>
</tr>
<tr>
<td>3</td>
<td>20,090</td>
<td>25,120</td>
<td>23,110</td>
</tr>
</tbody>
</table>
4 | 24,250 | 30,320 | 27,890  
5 | 28,410 | 35,520 | 32,670  
6 | 32,570 | 40,720 | 37,450  
7 | 36,730 | 45,920 | 42,230  
8 | 40,890 | 51,120 | 47,010  

For each additional person, add $4,780

List of Essential Living Expenses/Maximum Monthly Amounts Allowed:

1. Rent - $500.00
2. Water - $100.00
3. Electric - $200.00
4. Gas - $200.00
5. Food - $200.00

The American Lung Association in Georgia (ALAG) will only pay current amounts for utility bills. No late fees and/or deposits will be paid. ALAG has the right to make determinations of maximum amounts allowed outside the above guidelines.

**Housing Placement - without income**

<table>
<thead>
<tr>
<th>Type of Placements</th>
<th>Infectious or Status Unknown</th>
<th>Non-Infectious</th>
<th>Extra Pulmonary</th>
<th>Latent TB Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hotel</td>
<td>No</td>
<td>Yes</td>
<td>Yes (based on funding availability)</td>
<td>No Services</td>
</tr>
<tr>
<td>Motel</td>
<td>Yes</td>
<td>No</td>
<td>Yes (infectious status unknown)</td>
<td>No Services</td>
</tr>
<tr>
<td>Personal Care Homes</td>
<td>No</td>
<td>Yes (based on medical condition)</td>
<td>Yes (based on medical condition)</td>
<td>No Services</td>
</tr>
<tr>
<td>Rooming House</td>
<td>No</td>
<td>Yes</td>
<td>Yes (based of funding availability)</td>
<td>No Services</td>
</tr>
<tr>
<td>*Food</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No Services</td>
</tr>
</tbody>
</table>

*Once a client converts to smear/culture negative. He/she will have 30 days to apply for the Food Stamp Program. Client MUST provide ALAG written documentation at that time.

**Housing Placement - with income (including food stamps) not to exceed $500.00**
<table>
<thead>
<tr>
<th>Type of Placements</th>
<th>Infectious or Status Unknown</th>
<th>Non-Infectious</th>
<th>Extra Pulmonary</th>
<th>Latent TB Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hotel</td>
<td>No</td>
<td>Yes</td>
<td>Yes (based of funding availability)</td>
<td>No Services</td>
</tr>
<tr>
<td>Motel</td>
<td>Yes</td>
<td>No</td>
<td>Yes (infectious status unknown)</td>
<td>No Services</td>
</tr>
<tr>
<td>Personal Care Homes</td>
<td>No</td>
<td>Yes</td>
<td>Yes (based on medical condition and income amount)</td>
<td>No Services</td>
</tr>
<tr>
<td>Rooming House</td>
<td>No</td>
<td>Yes</td>
<td>Yes (based of funding availability)</td>
<td>No Services</td>
</tr>
<tr>
<td>Food</td>
<td>No</td>
<td>No</td>
<td>No (ALAG will provide transportation to store)</td>
<td>No</td>
</tr>
</tbody>
</table>

ALAG has the right to make determinations of eligibility outside the above guidelines.

B. Administrative Procedures

1. The District Health TB Coordinators notifies ALAG, via fax, e-mail or in person, with the following completed forms:

A. Alternative Housing/Social Service Referral;
B. Patient Health Department Agreement for
   Temporary Housing;
C. Temporary Housing Fund Application; and
D. Patient-Provider Therapeutic Contract; or
   Patient-Provider Therapeutic Contract for Financial Assistance.

   All forms must be completed and signed by the appropriate individuals.

2. Once the forms have been submitted, ALAG will respond in writing with the approval time and date within 48 hours.
Once the time and date have been set, it is the responsibility of the Health District to inform ALAG of any change. If both parties have not confirmed a time and date, ALAG will not be responsible for groceries, supplies and/or rent for that day.

**Friday/Weekend Placements:**
Generally, there are no placements on Fridays as available weekend patient care and follow up are limited. If/when a homeless TB case or TB suspect comes into the Health Department on Fridays and it is determined that he/she cannot return to a shelter, the patient will be placed in housing. For situations that require housing placement on weekends ALAG, the hospital, Health Department and State TB Control will conduct a multidisciplinary conference to plan and provide continuity of care for the TB patient.

3. During the first week, **supervised** sputums must be collected by the designated health professional three times, thereafter, once a week until three consecutive negative smears are obtained. Sputum containers should never be left with the patient nor should the patient receive sputum mailers.
4. For additional funding of current patients, the Health Districts MUST submit a new **Temporary Housing Fund Application** along with a **Monthly Assessment** by the **first business day of each month**. It is not the responsibility of ALAG to request additional funding for existing patients. **If the necessary paperwork is not submitted, no funds will be disbursed.**

5. If the patient misses any DOTs, specimen collections, and/or TB clinic appointments, please complete the **Alert Form** and submit it to ALAG within 48 hours. Please also submit an Alert Form for any change in the patient’s status.

6. Once the patient is ready for other housing, it is the responsibility of the Health District to transport patient. Any patient completing treatment or violating the contract is responsible for his/her own transportation. A Health District representative must be present at the time of the move.

   In the Metro-Atlanta area, ALAG will meet the Health District representative at the designated site. All parties must be there at the agreed time. Keys will be collected by ALAG at that time.

   **District Health TB Coordinators MUST adhere to the above protocols to ensure funding in a timely manner to secure patient’s retention in this Program.**
Housing Facility Guidelines for Infectious Patients

1. The housing establishment must have prompt availability of housing, a willingness to provide housing and to receive payment on a bi-weekly and monthly basis.

2. The American Lung Association in Georgia will provide TB education and the Health Districts will provide skin testing for housing facility staff.

3. The rental unit (motel) will have at minimum, a bed, table, chair, clothing chest, rack for hangers, refrigerator, stove/microwave and television. The room will be clean and without noticeable pest or odors.

4. The room will have a linen change at least once a week. To minimize the risk of exposure to the hotel staff, the linen should be left for the patient to change.

5. The room will be accessible only from a door leading to the outside, not to a public hallway or another room.

6. The entrance door will have a lock on the inside that the client can set manually and a peephole for safety.

7. The room will have its own toilet, bath or shower with hot running water.

8. The room will have its own independent air conditioner that vents to the outside.

9. The selected motel will have a clean appearance on the outside, excluding areas that are under renovation.

Housing Facility Guidelines for Non-Infectious Patients

1. The housing establishment must have prompt availability of housing, a willingness to provide housing and to receive payment on a biweekly and monthly basis.

2. The rental unit (hotel, motel, personal care home or a rooming house) must have at a minimum, a bed, a clothing chest, and a rack for hangers. The room will be clean and without noticeable pest or odors.

3. The housing site must be at least within walking distance of a laundry mat or on the bus route.

4. The entrance will have a lock on the inside that the client can set manually and a peephole for safety.

5. The room will be accessible to a toilet, bathroom with hot running water.
TB Enablers/Incentives Program
OPERATIONAL GUIDELINES

POLICY STATEMENT:
Enablers and incentives are used in the Alternative Housing Program to increase compliance with the treatment regimen for infectious and non-infectious TB disease to assure the completion of diagnostic and other procedures.

STANDARD:
Enablers and incentives encourage patients to take medications to completion of treatment, to keep clinic, home or other medical appointments and directly observed therapy (DOT) appointments. The use of patient enablers and incentives in the Alternative Housing Program has proven to be a valuable intervention.

RULES:
1. An incentive is defined as an item needed or desired by the tuberculosis patient that will reward the patient and act as positive reinforcement when the patient complies with the prescribed treatment regimen.
2. An enabler is defined as anything given to the patient that will assist them in keeping appointments.
3. As part of the American Lung Association in Georgia (ALAG) continuing commitment to tuberculosis control, funding for the enablers and incentives program will be provided by ALAG and managed and distributed by the District TB Coordinators to the county health departments.
4. Each District TB Coordinator must submit a formal request to participate in the Enablers/Incentive Program.
5. Request forms may not exceed $500.00 each month.
6. Incentives and/or enablers must be used to ensure compliance with the completion of DOT for treatment of infectious and non-infectious TB disease.
7. ALAG reserves the right to discontinue the program and or individual participation in the program.

PROCEDURE:
1. TB Coordinators who wish to participate in the Enablers/Incentives Program will complete the “Incentives Request Form” and fax it to ALAG.
2. ALAG will disburse the incentives to the health district who will then disburse incentives to the local health departments.
3. TB Incentives may be requested on a monthly basis based on the need and availability of funds.
4. For additional incentive requests, the health districts MUST submit a TB Patient Incentive Report and Enrollment Forms.

6. The selected housing facility will have a clean appearance on the outside, excluding areas that are under renovation.
Forms

Social Service Referral 13

HIPPA Form 14-15

Patient-Health Department Agreement 16

Temporary Housing Fund Application 17

Patient-Provider Therapeutic Contract 18

Patient-Provider Therapeutic Contract/Financial Assistance 19

Alert Form 20

Monthly Assessment 21

Enablers/Incentives Request 22

Enablers/Incentives Log 23

Enablers/Incentives Patient Enrollment Form 24
Alternative

Housing Program / HOPWA AID ATLANTA
SOCIAL SERVICES REFERRAL

Patient's Name: ____________________________ County/District: __________________

Date of Birth: __________ Race: __________ Gender: __________

Previous/Current Address: __________________________________________________________

Address Was: Street Shelter* Abandoned Building Family/Friends Home

*Name of Shelter______________________________________________________________

Reason for services: ______________________________________________________________

Lab Status: (Must have lab work to process referral)

<table>
<thead>
<tr>
<th>Smear</th>
<th>Case</th>
<th>Culture</th>
<th>No Growth</th>
<th>MTB</th>
<th>Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>1+</td>
<td>2+</td>
<td>3+</td>
<td>4+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suspect</td>
<td>1+</td>
<td>2+</td>
<td>3+</td>
<td>4+</td>
<td></td>
</tr>
</tbody>
</table>

Pending at __________ weeks

Expected TB Completion Date: ____________ Site of TB__________________________

Chest x-ray Status: Abnormal Normal Date: ____________

HIV STATUS

Confirmed Positive Confirmed Negative □ Yes or □ No ________________

VETERAN CLIENT ID#

□ Confirmed Positive □ Confirmed Negative □ Yes or □ No ________________

Physical Health Status Healthy Diabetes Hypertension Other

Past Psychiatric History Yes No

Mental Health Status

Diagnosis (where, when, name of Doctor/Therapist) ____________________________________________

______________________________________________________________________________

Income Status:

Employment (Where) __________________________________ $_______ Can

Patient return to work Yes No

Food Assistance $_______ General Assistant $_______ SSI Disability

$_______

TANF $_______

Veterans Benefits $_______

TOTAL MONTHLY INCOME $_______

Substance Abuse:

Alcohol Amphetamine Cocaine Crack IV Drug

Marijuana Denied Services

Requested:

Housing Food Funds for Rent/Utilities Social Services

Anticipated move-in date: ________ TB Representative: __________________________

Date __________________

For ALAG Use Only

Approved Denied __________________________________________________________

Signature and Date

Move in Date: __________________

All sections must be completed in its entirety to be processed.

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.
Alternative Housing Program
PATIENT AUTHORIZATION FOR USE OR DISCLOSURE
OF HEALTH INFORMATION

Completion of this document authorizes the disclosure and/or use of individually identifiable health information, as set forth below, consistent with Georgia and Federal law concerning the privacy of such information. **Failure to provide all information requested may invalidate this Authorization.**

### USE AND DISCLOSURE OF HEALTH INFORMATION

I hereby authorize the use or disclosure of my health information as follows:

Member Name: __________________________________________________

Persons/Organizations authorized to *use or disclose* the information: **American Lung Association in Georgia**

Persons/Organizations authorized to *receive* the information: ___________________________________________(list vendors)

Purpose of requested use or disclosure: ii ________________________________

This Authorization applies to the following information (select *only one* of the following): iii

- All health information pertaining to any medical history, mental or physical condition and treatment received.
  
  [Optional] **Except:** ____________________________________________

  **Only** the following records or types of health information (including any dates). This may consist of psychotherapy notes, if specifically authorized:

__________________________________________________________________________

__________________________________________________________________________

This Authorization expires [insert date or event]: iv ____________________________

______________________________________________________________________

I may refuse to sign this Authorization.
I may revoke this authorization at any time. My revocation must be in writing, signed by me or on my behalf, and delivered to the following address: ___________________

**NOTICE OF RIGHTS AND OTHER INFORMATION**

I may refuse to sign this Authorization.
I may revoke this authorization at any time. My revocation must be in writing, signed by me or on my behalf, and delivered to the following address: ___________________
My revocation will be effective upon receipt, but will not be effective to the extent that the Requestor or others have acted in reliance upon this Authorization.

I have a right to receive a copy of this authorization.v

Neither treatment, payment, enrollment or eligibility for benefits will be conditioned on my providing or refusing to provide this authorization.vi

Information disclosed pursuant to this authorization could be re-disclosed by the recipient and might no longer be protected by federal confidentiality law (HIPAA).

Signature of Member or Authorized Representative / Date

If Signed by Representative, State Relationship or Basis of Authority

******************************************************************************

If the Authorization is being requested by the entity holding the information, this entity is the Requestor. ii The statement “at the request of the individual” is a sufficient description of the purpose when the individual initiates the authorization and does not, or elects not to, provide a statement of the purpose. iii This form may not be used to release both psychotherapy notes and other types of health information (see 45 CFR § 164.508(b)(3))(ii)). If this form is being used to authorize the release of psychotherapy notes, a separate form must be used to authorize release of any other health information. iv If authorization is for use or disclosure of PHI for research, including the creation and maintenance of a research database or repository, the statement “end of research study,” “none” or similar language is sufficient.

v Under HIPAA, the individual must be provided with a copy of the authorization when it has been requested by a covered entity for its own uses and disclosures (see 45 CFR § 164.508(d)(1), (e)(2)). vi If any of the exceptions to this statement, as recognized by HIPAA apply, then this statement must be changed to describe the consequences to the individual of a refusal to sign the authorization when that covered entity can condition treatment, health plan enrollment, or benefit eligibility on the failure to obtain such authorization. A covered entity is permitted to condition treatment, health plan enrollment or benefit eligibility on the provision of an authorization as follows: (i) to conduct research-related treatment, (ii) to obtain information in connection with a health plan’s eligibility or enrollment determinations relating to the individual or for its underwriting or risk rating determinations, or (iii) to create health information to provide to a third party or for disclosure of the health information to such third party. Under no circumstances, however, may an individual be required to authorize the disclosure of psychotherapy notes.

7-15

Alternative Housing Program
PATIENT-HEALTH DEPARTMENT AGREEMENT FOR TEMPORARY HOUSING
I, ___________________ certify that I have no fixed, regular, and/or adequate residence at this time and I am unable to provide shelter for myself. I understand that I have (confirmed or suspected) active TB disease and treatment is necessary. I understand that, at this time, I am (infectious or not infectious) to others. I understand that District Public Health and the __________________ will provide temporary housing during treatment and I must:

1. Be at ____________________________ on ______________ at ___________ am/pm to take my medicine.
2. Keep clinic appointments and have laboratory tests as necessary.
3. Notify the TB nurse of any problems with TB medicine or other emergencies.
4. Avoid alcohol and/or other drug use.
5. Not to participate in any illegal activity at the residential facility.
6. Not visit with other people in the housing area or other indoor areas until the TB nurse tells me I am not infectious to others.
7. Follow lease conditions by not having anyone else stay overnight, unless pre-approved in the lease.
8. Not to make any changes to the housing; and not make any long distance phone calls charged to the housing.
9. Remove all personal items from housing at termination of lease. Neither the American Lung Association in Georgia, District Public Health, nor the residential facility will be responsible for personal items left after termination of lease.
10. Allow the Health Department to identify me by name to the housing agent if needed.
11. Will hold the ___________ District Public Health, the American Lung Association in Georgia, and its agents, from any and all liability.

I understand that if I violate any of the above, I may lose the housing and I may be confined to another appropriate facility to complete my TB disease treatment.

Client: __________________________________ TB Representative: _______________________________
Date:   _____________________

The housing agent hereby agrees to comply with the following and thereby, will hold harmless the American Lung Association in Georgia and its agents from any and all liability. Infectious Patients:

1. Provide housing that meets infection control guidelines.
2. Provide housing with an exit that leads directly to the outside or to a hallway that leads directly outside.
3. Provide single occupancy housing and will report TB patient violations to the TB representative and ALAG.
4. Allow no housing employee to enter the client’s room until 24 hours after the client is determined to be noninfectious by the TB nurse. Housekeeping and linen supply arrangements are as follows:

Non-Infectious Patients:

1. Provide single occupancy housing and will report TB patient violations to the TB representative and ALAG.
2. Provide TB patient with clean linen at least once a week if patient is residing at a hotel, motel or a personal care home. Clients residing at a rooming house will be responsible for their own linen.

Housing Agent: _________________________________  TB Representative:___________________________
Date:  _______________________

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.
Alternative Housing Program
TEMPORARY HOUSING FUND APPLICATION

Patient’s Name:_________________________________________________________

Address:________________________________________________________________

**************************************************************

TB Coordinator Name:____________________________________________________

District:_____________ Health Department:________________________________

Address:________________________________________________________________

County:______________________ Telephone #:_______________________________

E-Mail:____________________  Fax #:_______________________________________

**************************************************************

Housing Vendor:_________________________________________________________

Federal ID Number:____________________

Contact Person:________________________________________

Address:________________________________________________________________

County:______________________ Telephone #:_______________________________

E-Mail:____________________  Fax #:_______________________________________

Charges for Housing
$ ________ Monthly from ________to_________

$ ________ Bi-weekly from ________to_________

$ ________ Weekly from ________to_________

**************************************************************

Signature of TB Representative: __________________________ Date: _____________

Signature of Housing Vendor: ____________________________Date: _____________

*If there is not a vendor signature, Coordinator must provide official documentation of the amount and address.

All Sections must be completed in its entirety to be processed.

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.
Alternative Housing Program
PATIENT-PROVIDER THERAPEUTIC

CONTRACT

The following is a statement of what is expected of each patient who agrees to accept temporary housing paid for by the American Lung Association in Georgia. Please read guidelines carefully and if you agree to abide by the conditions listed, please sign at the bottom.

1. Lodging will be temporarily provided for you during your treatment for TB. The length of time the room will be made available to you will depend on your medical needs, your cooperation and continued participation with follow-up provided by District Public Health.

2. During your stay, you are expected to keep your room clean and undamaged. At the end of your stay, you must remove all personal items and the room must be left in good condition. Neither the American Lung Association in Georgia, District Public Health, nor the residential facility will be responsible for personal items left after termination of lease.

3. You should have no visitors at any time.

4. If it is determined that you need food assistance, food vouchers/certificates may be made available to you so that your family or friends may purchase food for you.

5. You must remain in your room until District Public Health informs you otherwise.

6. Your outreach worker or nurse will visit with you once a day, usually in the morning. Other unannounced visits will be made.

7. Participation in Directly Observed Therapy (DOT) is required in order to stay at the residential facility. DOT will be provided to you by a designated health care professional. Failure to participate in a scheduled DOT session, may lead to the immediate termination of your room rental. As a part of your treatment, you may be transported from time to time to the Health Department for test, or to see physicians.

8. Use of illegal drug or other illegal activities by you and/or any guest(s) in your room will result in the immediate termination of your room rental.

9. Any behavior deemed detrimental and or inappropriate (determined by ALAG, the District Public Health and/or the vendor) to your health, the health of others or the property will result in the immediate termination of your room rental.

10. If your room rental is terminated due to inappropriate behavior by you or your guest(s) or by your inability to comply with DOT, you must return the room key immediately to the outreach worker, TB nurse or designated staff and vacate the premises.

11. If you are diagnosed as not having TB, you will be released from the Program within 48 hours.
ALAG will seek, when possible, to involve and educate family and friends in your aftercare so that they will have a better understanding of how to assist you while you are in the motel and later when you are able to find alternate housing.

Signature: ______________________________ Date: _______________________

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.
Alternative Housing Program
PATIENT-PROVIDER THERAPEUTIC CONTRACT
For Financial Assistance

The following is a statement of what is expected of each patient who agrees to accept financial assistance for (name services) __________________________ paid for by the American Lung Association in Georgia. Please read guidelines carefully and if you agree to abide by the conditions listed, please sign at the bottom.

1. The length of time that ALAG will provide financial assistance will be determined by any financial changes, your medical needs, your cooperation and continued participation with follow-up provided by District Public Health.

2. You should not have visitors until Public Health informs you that you are no longer infectious to others.

3. Your TB representative will visit with you weekly. Other unannounced visits will be made.

4. Participation in Directly Observed Therapy (DOT) is required in order to receive financial assistance. DOT will be provided to you by a designated health care professional. Failure to participate in a scheduled DOT session may lead to the immediate dismissal from the Program. As a part of your treatment, you may be transported from time to time to the Health Department or another site for tests or to see physicians.

5. Any behavior deemed detrimental to your health or the health of others will result in the immediate termination of the agreement.

6. ALAG will immediately cease to provide financial assistance if you fail to comply with DOT due to inappropriate behavior.

7. When you have completed the program and/or have three negative smears, ALAG will immediately cease from financial assistance.

8. If you are diagnosed as not having TB, ALAG will immediately cease financial assistance.

9. We will seek, when possible, to involve and educate family and friends in your aftercare so that they will have a better understanding of how to assist you while you are enrolled in the Program.

Signature: ________________________________     Date: ______________

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.
Alternative Housing Program

ALERT FORM

Date: ______________________

Patient’s Name: __________________________________________________________

Location:________________________________________________________________

Date of field visit: __________________________________________ Time: ________

Name of person conducting field visit:_________________________________________
Title/Health District: ______________________________________________________

Reason for field visit:
Collect Sputum
DOT
Transportation to TB Clinic
Routine visit
Other

**************************************************************

Reason for Alert:
Patient not at designated site
Patient was hospitalized
Patient refused DOT
Patient has unauthorized visitors
Patient left Program
Patient incapable of living alone

Concerns: ______________________________________________________________
_______________________________________________________________________

Plan of Actions: __________________________________________________________
_______________________________________________________________________

Submitted by: ________________________________Date:___________________

Note: Form must be sent to American Lung Association in Georgia’s Alternative
Housing Program within 48 hours of the event.
Fax: (770) 319-0349, Office Phone: (770) 434-5864,
Scan/E-Mail: luvette.baldwin@lungse.org/stephanie.quinn@lungse.org
It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.

Alternative Housing Program

MONTHLY ASSESSMENT

MONTH: ________________

PATIENT’S NAME: _______________________________ DATE OF BIRTH: ________________

ADDRESS: __________________________________________________________________________

COUNTY OF RESIDENCE: ___________________________ DISTRICT: _______________________

LAST CLINIC EVALUATION: __________________ ANTICIPATED CLOSURE DATE: ___________

LAB STATUS:

<table>
<thead>
<tr>
<th>DATE</th>
<th>SMEAR (Please check box)</th>
<th>CULTURE (Please check box)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
<tr>
<td>2.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
<tr>
<td>3.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
<tr>
<td>4.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
<tr>
<td>5.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
<tr>
<td>6.</td>
<td>1+ 2+ 3+ 4+</td>
<td>No Growth MTB Pending</td>
</tr>
</tbody>
</table>

How Results Obtained: Sputum Culture Induced Other _________
(Please Check Appropriate Boxes)

CURRENT TREATMENT REGIMEN - DOT:

Daily Biweekly 3x weekly Total Number of DOT’s ________________
(for the entire month)

If DOT’s missed, please give explanation: _______________________________________________
Number Delivered: _________                                   Number Taken/Observed _________

PATIENT IS PHYSICALLY ABLE TO WORK: Full time    Part time    Not able to work

SUMMARY/RECOMMENDATIONS: ______________________________________________________
____________________________________________________________________________________

Submitted by: __________________________ Date: __________________
All sections must be completed before submitting Monthly Assessment Form.

It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.

Alternative Housing Program
ENABLERS/INCENTIVES REQUEST

Date: __________________

Total Amounts

☐ Fast Food Coupons
   Burger King $____  Kentucky Fried $____  Wendy’s $____  McDonalds $____  $________
   ($5.00 increments) ($5.00 increments) ($10.00 increments) ($5.00 increments)

☐ Grocery/Merchandise Coupons
   Kroger $____  Wal-Mart $____  $________
   ($5.00 increments) ($10.00 increments)

☐ Transportation
   BP Gas $____  QuickTrip $____  Chevron $____  $________
   ($20.00 increments)

   TOTAL AMOUNT OF REQUEST $________

The maximum amount per request per district per month (30 days) is $400.00.
Please attach TB Patient Incentives Report and Enrollment Forms

** MAIL TO: **

__________________________________  ____________________________
District                                  Attention

__________________________________  ____________________________
Address (NO PO BOX)                     City                        Zip
### Alternative Housing Program

**ENABLERS/INCENTIVES LOG**

<table>
<thead>
<tr>
<th>Patient Identifier (DO NOT USE NAME)</th>
<th>Type of Incentive</th>
<th>Type of Enabler</th>
<th>Amount</th>
<th>What type of service</th>
<th>Adherence rate</th>
<th>Case, suspect,</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXAMPLE: #123456</td>
<td>McDonalds food voucher</td>
<td></td>
<td>$5.00</td>
<td>Monthly clinical evaluation</td>
<td>83%</td>
<td></td>
</tr>
</tbody>
</table>

**Please fax/mail request to:**

2452 Spring Road  
Smyrna, Georgia 30080  
Fax (770) 319-0349  
Scan/e-mail to luvette.baldwin@lungse.org/stephanie.quinn@lungse.org
TB Enablers/Incentives Program
PATIENT ENROLLMENT FORM

Name:____________________________________

Address:________________________________________________________________

Date:___________________________________

City:____________________________  State:___________ Zip:______________
Age:__________  Race:__________  Gender:     Female Male

County/District:_________________

**Patient Status:**

<table>
<thead>
<tr>
<th>Case</th>
<th>Suspect</th>
<th>LTBI</th>
</tr>
</thead>
</table>

**********************************************************************

**Substance Abuse:**

- Alcohol
- Amphetamine
- Cocaine
- Crack
- IV Drug
- Marijuana
- Denied

**********************************************************************

*It is the American Lung Association of the Southeast’s (ALASE’s) policy to ensure compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule by establishing sanctions for breaches of confidentiality. All employees are required to be aware of their responsibilities under ALASE privacy policies.*
Appendix J
<table>
<thead>
<tr>
<th>Test Name</th>
<th>Order Code</th>
<th>Description</th>
<th>Specimen Requirements</th>
<th>Test Method</th>
<th>Normal Value</th>
<th>Turn Around Time</th>
<th>Contact Information</th>
<th>CPT Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrine and Ricinine in urine</td>
<td>CT031300</td>
<td>Abrine Ricinine (ABRC)</td>
<td>Specimen: Urine Container: Urine container. Collection: Collect 25-60mL of urine, freeze at -20°C or lower. Transport: Frozen (-20°C) using dry ice.</td>
<td>LC-MS/MS</td>
<td>Not detected</td>
<td>1-3 business days</td>
<td>Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH</td>
<td>82542</td>
</tr>
<tr>
<td>DNA extraction and amplification by PCR</td>
<td>2150</td>
<td>Acanthamoeba-PCR Balamuthia-PCR Naegleria-PCR</td>
<td>Specimen: CSF; pond or pool water Container: Clean vial for CSF; Clean 2-liter container Collection: Add CSF to vial; For pond and pool water fill up 2 liter container Transport: Room temperature</td>
<td>Real-time PCR</td>
<td>No Parasites Found</td>
<td>1-2 Days</td>
<td>Parasitology 404-327-7963</td>
<td>87797</td>
</tr>
<tr>
<td>Detection of Arbovirus IgG antibody to determine immune status</td>
<td>1595</td>
<td>Arbo Virus IgG</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>IFA-CE EE SLE WE</td>
<td>Negative</td>
<td>7-14 days</td>
<td>Immunology 404-327-7970</td>
<td>86651 86652 86653 86654</td>
</tr>
<tr>
<td>Detection of Arbovirus IgM antibody to determine active and/or past infection</td>
<td>1600</td>
<td>Arbo Virus IgM</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>IFA-CE EE SLE WE</td>
<td>Negative</td>
<td>7-14 days</td>
<td>Immunology 404-327-7970</td>
<td>86651 86652 86653 86654</td>
</tr>
<tr>
<td>Measurement of lead in whole blood</td>
<td>W4050</td>
<td>Blood lead</td>
<td>Specimen: Whole blood (capillary or venous) Container: Microtainer (K2) EDTA tubes (purple top) for capillary specimens. Vacutainer (K2) EDTA tubes (purple top) for venous specimens Collection: Capillary specimen – A minimal amount of 250ul. Mix specimen thoroughly after collection. Venous specimen – A minimal amount of 3ml. Mix specimen thoroughly after collection Transport: Room Temperature</td>
<td>Atomic Absorption Spectrometry</td>
<td>&lt;10µg/dl</td>
<td>3 days</td>
<td>Waycross 912-338-7050</td>
<td>83655</td>
</tr>
<tr>
<td>GPHL TEST NAME</td>
<td>ORDER CODE</td>
<td>DESCRIPTION</td>
<td>SPECIMEN REQUIREMENTS</td>
<td>TEST METHOD</td>
<td>NORMAL VALUE</td>
<td>TURN AROUND TIME</td>
<td>CONTACT INFORMATION</td>
<td>CPT CODE</td>
</tr>
<tr>
<td>----------------</td>
<td>------------</td>
<td>-------------</td>
<td>-----------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Bordetella spp.</td>
<td>414000</td>
<td>Detection of <em>Bordetella pertussis</em>, <em>B. parapertussis</em> and <em>B. holmesii</em> by Realtime PCR</td>
<td>Specimen: Polyester, rayon or nylon flocked nasopharyngeal swab, nasopharyngeal aspirates, and cultures exhibiting colony morphology and bio-chemical testing consistent with <em>Bordetella</em> spp.  Container: Sterile container stored at 4°C or culture isolates Collection: Whenever possible, specimens should be collected prior to administration of antimicrobial agents. Transport: Cold (2°-8°C)</td>
<td>Real-time PCR</td>
<td>Bordetella pertussis, <em>B. parapertussis</em> or <em>B. holmesii</em> DNA not detected by real-time PCR</td>
<td>1-3 business days</td>
<td>Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH</td>
<td>87798</td>
</tr>
<tr>
<td>BT agent rule-out</td>
<td>BTC01005 BTC02005 BTC03005 BTC04005 BTC06005</td>
<td>Detection of <em>Bacillus anthracis</em>, <em>Brucella spp.</em>, <em>Burkholderia mallei</em>, <em>Pseudomallei</em>, <em>Francisella tularensis</em> and <em>Yersinia pestis</em> by Real-time PCR</td>
<td>Specimen: Cultures exhibiting colony morphology and biochemical testing consistent with a BT agent Container: Culture with isolated colonies in BAP agar, CHOC agar or TSA slant Collection: Isolate obtained from body fluids or tissue consistent with a BT agent Transport: Room temperature</td>
<td>Real-time PCR</td>
<td>DNA not detected by real-time PCR</td>
<td>1-2 business days</td>
<td>Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH</td>
<td>87798</td>
</tr>
<tr>
<td>Cadmium, Mercury, and Lead</td>
<td>CT021500</td>
<td>Total cadmium, mercury, and lead in whole blood</td>
<td>Specimen: Whole blood Container: Polyethylene vials and vacutainers containing EDTA Collection: Collect at least 3mL of whole blood and store cold (2°-8°C) Transport: Cold (2°-8°C)</td>
<td>ICPMS</td>
<td>Not detected</td>
<td>1-3 business days</td>
<td>Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH</td>
<td>82300 83825 83655</td>
</tr>
<tr>
<td>Campylobacter (enteric isolate ID)</td>
<td>1100</td>
<td>Identification of <em>Campylobacter</em> sp. by conventional Biochemicals and/or PCR</td>
<td>Specimen: Pure isolate Container: Commercially available slant transport media Collection: Single colony aseptically subbed to a slant transport media Transport: Room temperature for up to 3 days</td>
<td>Biochemicals/PCR</td>
<td>N/A</td>
<td>10 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87077</td>
</tr>
<tr>
<td>GPHL TEST NAME</td>
<td>ORDER CODE</td>
<td>DESCRIPTION</td>
<td>SPECIMEN REQUIREMENTS</td>
<td>TEST METHOD</td>
<td>NORMAL VALUE</td>
<td>TURN AROUND TIME</td>
<td>CONTACT INFORMATION</td>
<td>CPT CODE</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------</td>
<td>------------------</td>
<td>--------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| CDC send out (C. botulinum or Other Special Requests) | 1135       | Specimens and isolates will be forwarded to CDC for isolation, confirmation, and/or toxin testing | Specimen: Food, feces, wound, or pure isolate  
Container: Sterile container (food or feces); anaerobic environment system (wound); chopped meat broth or motility test medium (isolate)  
Collection: Submit food or feces specimen in a sterile container, cold (2°- 8°C). Submit material from wound, cold (2°- 8°C), in an anaerobic environment system. Send suspected isolate in chopped meat broth or motility test medium (inoculate near bottom of tube) at ambient temperature  
Transport: Cold (2°- 8°C) - Food, feces or wound material; Room temperature - Pure isolate  
Special arrangement required CALL 404-327-7997  
Epidemiology approval required CALL 404-657-2588 | N/A         | N/A                         | N/A                           | Bacteriology 404-327-7997                      | N/A        |
| Chlamydia (CT) and Gonorrhea (GC)                  | W1000      | Detection of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) by Nucleic Acid Amplification Test (NAAT) | Specimen: Swab - endocervix, rectal, throat or urethra; Urine - female and male  
Container: Aptima Unisex Swab Specimen collection Kit or Aptima Urine Specimen Collection Kit  
Collection: Follow the site specific instructions provided in the Chlamydia & Gonorrhea Nucleic Acid Amplification Test session  
Transport: Room temperature | NAAT dual test | Negative | 3 days       | Waycross 912-338-7050 | 87591 87491 |
| Chlamydia (CT) and Gonorrhea (GC)                  | 1060       | Detection of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) by Nucleic Acid Amplification Test (NAAT) | Specimen: Swab - endocervix, rectal, throat or urethra; Urine - female and male  
Container: Aptima Unisex Swab Specimen collection Kit or Aptima Urine Specimen Collection Kit  
Collection: Follow the site specific instructions provided in the Chlamydia & Gonorrhea Nucleic Acid Amplification Test session  
Transport: Room temperature | NAAT dual test | Negative | 3 days       | Bacteriology 404-327-7997 | 87591 87491 |
<table>
<thead>
<tr>
<th>Test Name</th>
<th>Order Code</th>
<th>Description</th>
<th>Specimen Requirements</th>
<th>Test Method</th>
<th>Normal Value</th>
<th>Turn Around Time</th>
<th>Contact Information</th>
<th>CPT Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV IgG</td>
<td>1545</td>
<td>Detection of CMV IgG antibody to determine immune status</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86644</td>
</tr>
<tr>
<td>CMV IgM</td>
<td>1550</td>
<td>Detection of CMV IgM antibody to determine active and/or past infection</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86645</td>
</tr>
<tr>
<td>Cryptosporidium</td>
<td>2400</td>
<td>Microscopic examination of stained concentrated sample</td>
<td>Specimen: Stool, pool or well water Container: 10% formalin vial for stool; 2-liter container for water samples Collection: Add stool to the vial up to the &quot;fill&quot; line immediately after passage. Mix thoroughly. Fill 2-liter container with water Transport: Room Temperature</td>
<td>Concentration Acid fast stain</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Parasitology 404-327-7963</td>
<td>87015 87206</td>
</tr>
<tr>
<td>Cryptosporidium</td>
<td>W5010</td>
<td>Microscopic examination of stained concentrated sample</td>
<td>Specimen: Stool Container: 10% formalin vial for stool Collection: Add stool to the vial up to the &quot;fill&quot; line immediately after passage. Mix thoroughly. Transport: Room Temperature</td>
<td>Concentration Acid fast stain</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Waycross 912-338-7050</td>
<td>87015 87206</td>
</tr>
<tr>
<td>Cyanide</td>
<td>CT011100</td>
<td>Cyanide in blood</td>
<td>Specimen: Whole blood Container: Polyethylene vials and vacutainers containing EDTA Collection: Collect at least 3mL of whole blood and store cold (2°-8°C) Transport: Cold (2°-8°C)</td>
<td>GC/MSD</td>
<td>Not detected</td>
<td>1-3 business days</td>
<td>Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH</td>
<td>82800</td>
</tr>
</tbody>
</table>
### Cyclospora

<table>
<thead>
<tr>
<th>Test</th>
<th>Order Code</th>
<th>Description</th>
<th>Specimen Requirements</th>
<th>Test Method</th>
<th>Normal Value</th>
<th>Turn Around Time</th>
<th>Contact Information</th>
<th>CPT Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>W5010</td>
<td>Microscopic examination of concentrated sample</td>
<td>Specimen: Stool  Container: 10% formalin vial  Collection: Add stool to the vial up to the &quot;fill&quot; line immediately after passage. Mix thoroughly  Transport: Room Temperature</td>
<td>Concentration epifluorescence</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Waycross 912-338-7050</td>
<td>87015 87206</td>
<td></td>
</tr>
<tr>
<td>2500</td>
<td>Epifluorescent Microscopic examination of concentrated sample</td>
<td>Specimen: Stool  Container: 10% formalin vial  Collection: Add stool to the vial up to the &quot;fill&quot; line immediately after passage. Mix thoroughly  Transport: Room Temperature</td>
<td>Concentration Acid fast stain</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Parasitology 404-327-7963</td>
<td>87015 87206</td>
<td></td>
</tr>
</tbody>
</table>

### GPHL Test Name

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Order Code</th>
<th>Description</th>
<th>Specimen Requirements</th>
<th>Test Method</th>
<th>Normal Value</th>
<th>Turn Around Time</th>
<th>Contact Information</th>
<th>CPT Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclospora-PCR Cryptosporidium-PCR</td>
<td>2150</td>
<td>DNA extraction and amplification by PCR</td>
<td>Specimen: Stool; Pool or Well water samples  Container: Vial with 100% alcohol or 5% potassium dichromate; Clean 2-liter container  Collection: Add stool to vial with solution to about 1/2 the solution volume; For pool and well water fill up 2 liter container  Transport: Room temperature</td>
<td>Real-time PCR</td>
<td>No Parasites Found</td>
<td>1-2 Days</td>
<td>Parasitology 404-327-7963</td>
<td>87797</td>
</tr>
<tr>
<td>Cytomegalovirus Culture</td>
<td>62050</td>
<td>Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal antiserum</td>
<td>Specimen: Urine, throat swab, pericardial fluid  Container: Viral transport media provided by GPHL  Collection: Collect throat swab in viral transport media, urine and pericardial fluid in sterile container  Transport: Cold (2°-8°C)</td>
<td>Virus culture tube/CPE Virus culture shell vial Virus culture shell vial IFA</td>
<td>No virus isolated and detected</td>
<td>3 weeks</td>
<td>Virology 404-327-7980</td>
<td>87252 87253 87254 87140</td>
</tr>
</tbody>
</table>
**E. histolytica -PCR**

- **Order Code**: 2150
- **Test Method**: DNA extraction and amplification by PCR
- **Specimen**:
  - Stool: Liver abscess
  - Container: Vial containing 100% ethanol or 5% potassium dichromate; or clean vial for liver abscess
- **Collection**:
  - Add stool to vial to about 1/2 volume of solution. Place liver abscess in clean vial or 100% ethanol vial or leave in aspiration syringe
- **Transport**:
  - Room temperature for stools; Cold (2°-8°C) for liver abscess
- **Test Name**: Parasitology
- **CPT Code**: 404-327-7963

**E. dispar - PCR**

- **Order Code**: 2150
- **Test Method**: DNA extraction and amplification by PCR
- **Specimen**:
  - Stool: Liver abscess
  - Container: Vial containing 100% ethanol or 5% potassium dichromate; or clean vial for liver abscess
- **Collection**:
  - Add stool to vial to about 1/2 volume of solution. Place liver abscess in clean vial or 100% ethanol vial or leave in aspiration syringe
- **Transport**:
  - Room temperature for stools; Cold (2°-8°C) for liver abscess
- **Test Name**: Parasitology
- **CPT Code**: 404-327-7963

**Enterovirus Culture**

- **Order Code**: 1385
- **Test Method**: Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal antiserum
- **Specimen**:
  - Throat swab, feces, CSF, pericardial fluid vesicle scraping
  - Container: Viral transport media provided by GPHL
  - Collection: Collect throat swab in viral transport media, feces, CSF and pericardial fluid vesicle in a sterile container
- **Transport**: Cold (2°-8°C)
- **Test Name**: Virology
- **CPT Code**: 404-327-7980

**GPHL TEST NAME** | **ORDER CODE** | **DESCRIPTION** | **SPECIMEN REQUIREMENTS** | **TEST METHOD** | **NORMAL VALUE** | **TURN AROUND TIME** | **CONTACT INFORMATION** | **CPT CODE**
--- | --- | --- | --- | --- | --- | --- | --- | ---
Environmental/ Food (C. perfringens) | 1180 | Isolation of *Clostridium perfringens* by culture | Specimen: Suspected food based on epidemiological investigation Container: Sterile container Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions Transport: Cold (2°-8°C) Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A
Environmental/ Food (B. cereus) | 1180 | Isolation of *Bacillus cereus* by culture | Specimen: Suspected food based on epidemiological investigation Container: Sterile container Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions Transport: Cold (2°-8°C) Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A
| Environmental/ Food (Campylobacter) | 1180 | Isolation of Campylobacter sp. by culture | Specimen: Suspected food based on epidemiological investigation  
Container: Sterile container  
Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
Transport: Cold (2° - 8°C)  
Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |
| Environmental/ Food (Listeria) | 1180 | Isolation of Listeria monocytogenes by culture | Specimen: Suspected food based on epidemiological investigation  
Container: Sterile container  
Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
Transport: Cold (2° - 8°C)  
Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |
| Environmental/ Food (S. aureus) | 1180 | Isolation of Staphylococcus aureus by culture | Specimen: Suspected food based on epidemiological investigation  
Container: Sterile container  
Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
Transport: Cold (2° - 8°C)  
Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |

<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| Environmental/ Food (Salmonella) | 1180 | Isolation of Salmonella ssp. by culture | Specimen: Suspected food based on epidemiological investigation  
Container: Sterile container  
Collection: Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
Transport: Cold (2° - 8°C) within 24 hours from collection  
Special arrangement required CALL 404-327-7997 | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |
| **Environmental/ Food (Shigella)** | 1180 | **Isolation of Shigella ssp. by culture** | **Specimen:** Suspected food based on epidemiological investigation  
**Container:** Sterile container  
**Collection:** Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
**Transport:** Cold (2°- 8°C)  
**Special arrangement required CALL 404-327-7997** | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |
| **Environmental/ Food (STEC)** | 1180 | **Isolation of STEC by culture** | **Specimen:** Suspected food based on epidemiological investigation  
**Container:** Sterile container  
**Collection:** Epidemiology or Environmental staff will collect 100 grams of the suspected food sample under sterile conditions  
**Transport:** Cold (2°- 8°C)  
**Special arrangement required CALL 404-327-7997** | Culture | Negative | 7 days | Bacteriology 404-327-7997 | N/A |
| **Filarial Parasite** | 2710 | **Identification of microfilaria by microscopic examination of Giemsa-stained blood smear** | **Specimen:** Giemsa or Wright stained thick and thin blood smears plus EDTA whole blood  
**Container:** EDTA (lavender top) tube  
**Collection:** Draw blood sample by venipuncture  
**Transport:** Slides in slide holder at room temperature; EDTA blood in cold (2°- 8°C) | Microscopy | No Parasites Found | 1-3 Days | Parasitology 404-327-7963 | 87207 |
| **Gonorrhea culture** | 1010 | **Isolation of Neisseria gonorrhoeae (GC) by culture.** When positive, identification of GC by conventional Biochemicals and DNA probe confirmation. | **Specimen:** Endocervix, urethra, throat, or rectal  
**Container:** Commercially available Thayer Martin or Martin Lewis Transport media  
**Collection:** Use a sterile polyester (dacron), rayon, or nylonflocked swab and follow the site specific instructions provided in the Gonorrhea Culture session  
**Transport:** CO2 enriched atmosphere within 24 hours | Culture  
**Biochemicals DNA probe** | Negative | 2 days | Bacteriology 404-327-7997 | 87081  
87077  
87590 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A Streptococcus</td>
<td>1030</td>
<td>Isolation of GAS from throat culture. When positive, identification of GAS by conventional Biochemicals and Serotyping</td>
<td>Specimen: Throat swab  Container: Streptococcus outfit 560 or commercially available Amies or Stuart transport media  Collection: Throat swab taken from the tonsil areal and/or posterior pharynx, with care taken to avoid the tongue and uvula  Transport: Room temperature within 24 hours from collection</td>
<td>Culture Biochemicals Serotyping</td>
<td>Negative</td>
<td>2 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87070 87077 87147</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>1400 1405</td>
<td>Present during acute phase and recovery phase. Provides lifelong immunity to Hepatitis A. Present during acute phase of Hepatitis A disease</td>
<td>Specimen: Serum  Container: Serum Separator Tube (SST), or Red Top  Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>Immunoassay IgG  IgM</td>
<td>Nonreactive</td>
<td>5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86708 86709</td>
</tr>
<tr>
<td>Hepatitis B Prenatal</td>
<td>1411</td>
<td>Present during acute infections and persists in chronic infections</td>
<td>Specimen: Serum  Container: Serum Separator Tube(SST), or Red Top  Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  Transport: Overnight at room-temperature, cold over 24 hours (2°-8°C)</td>
<td>Immunoassay HBsAg Neutralization Hbe Antigen</td>
<td>Nonreactive</td>
<td>3-5 days Antigen positives (5-7 days)</td>
<td>Immunology 404-327-7970</td>
<td>87340 87341 87350</td>
</tr>
<tr>
<td>Hepatitis B Routine Screen Panel</td>
<td>1410</td>
<td>Present during acute infections and persists in chronic infections. Determination of carrier status appears at the onset of illness and can persist indefinitely. Presence indicates seroconversion from HBV infection Can be used to monitor post vaccination</td>
<td>Specimen: Serum  Container: Serum Separator Tube (SST), or Red Top  Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>Immunoassay HBsAg Neutralization Hbe Antigen HBcAb (total) HBsAb</td>
<td>Nonreactive</td>
<td>3-5 days Antigen positives (5-7 days)</td>
<td>Immunology 404-327-7970</td>
<td>87340 87341 87350 86704 86706</td>
</tr>
<tr>
<td>GPHL TEST NAME</td>
<td>ORDER CODE</td>
<td>DESCRIPTION</td>
<td>SPECIMEN REQUIREMENTS</td>
<td>TEST METHOD</td>
<td>NORMAL VALUE</td>
<td>TURN AROUND TIME</td>
<td>CONTACT INFORMATION</td>
<td>CPT CODE</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>-------------</td>
<td>-----------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>1480</td>
<td>Indicates the presence of Hepatitis C Antibody to aid in the diagnosis of Hepatitis C infection. Measures the amount of hepatitis C virus in the blood</td>
<td>Specimen: Serum  Container: Serum Separator Tube (SST)  Collection: 4-6ml , SST centrifuge and transfer serum to a transfer tube  Transport: Send frozen or over 24 hours cold (2°-8°C)</td>
<td>Immunoassay (serum antibody) RT-PCR (viral load)</td>
<td>Nonreactive  Not detected</td>
<td>5-7 days  7-14 days (depends on number of specimens received)</td>
<td>Immunology 404-327-7970</td>
<td>86803</td>
</tr>
<tr>
<td></td>
<td>1490</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87522</td>
</tr>
<tr>
<td>Herpes Simplex Culture (HSV)</td>
<td>1330</td>
<td>Virus isolation: inoculation, observation, presumptive ID and for each isolate by centrifuged enhanced (shell vials or multiwell technique), includes ID with nonimmunologic method other than CPE such as virus specific enzymatic activity (ELVIS) for HSV detection</td>
<td>Specimen: Vesicle scraping (lesion), brain biopsy  Container: Viral transport media provided by GPHL  Collection: Collect vesicle scraping and brain biopsy in viral transport media  Transport: Cold (2°-8°C)</td>
<td>Virus culture and ELVIS</td>
<td>No virus isolated and detected</td>
<td>5-7 days</td>
<td>Virology 404-327-7980</td>
<td>87255</td>
</tr>
<tr>
<td>HIV Combo Ag/Ab EIA</td>
<td>13500</td>
<td>Qualitative detection of acute and primary infection for HIV-1/HIV-2 Ab and HIV-1 p24 Ag screens, differentiates and confirms when Combo EIA is repeatedly</td>
<td>Specimen: 2.5ml serum or plasma  Container: PPT, SST or Red Top Tube  Collection: Collect 5 ml whole blood in PPT, SST or red top tube. Centrifuge PPT or SST tube  Transport: Cold (2°-8°C)</td>
<td>HIV Combo EIA  HIV-1 Multispot  HIV-2 Multispot  HIV-1 RNA RT-PCR  HIV-1 WB</td>
<td>Negative</td>
<td>2-7 days</td>
<td>Virology 404-327-7980</td>
<td>87389</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87390</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87391</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87535</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>86689</td>
</tr>
</tbody>
</table>
### HIV-1 RNA Quantitative RT-PCR

**Order Code:** 1340  
**Description:** Monitor HIV-1 RNA levels from HIV-1 infected patients in plasma  
**Specimen:** 2.5ml plasma  
**Container:** PPT  
**Collection:** Collect 5 ml whole blood in PPT tubes. Centrifuge PPT tube  
**Transport:** Frozen with dry ice at -20°C  
**Test Method:** HIV-1 RNA RT-PCR (quantitative)  
**Normal Value:** Negative  
**Turn Around Time:** 3 days  
**Contact Information:** Virology 404-327-7980  
**CPT Code:** 87536

<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| HIV-1 Western Blot Confirmation | 1360 | Confirmation of HIV-1 Ab in serum, plasma and dried blood spots | Specimen: 2.5ml serum or plasma  
**Container:** PPT, SST or Red Top Tube  
**Collection:** Collect 5 ml whole blood in PPT, SST or red top tube. Centrifuge PPT or SST tube  
**Transport:** Cold (2°-8°C) | HIV-1 WB | Negative | 5-7 days | Virology 404-327-7980 | 86689 |
| HSV 1 | 1560 | Detection of Herpes antibody to GP type 1 determines active and/or past infection | Specimen: Serum  
**Container:** Serum Separator Tube (SST), or Red Top  
**Collection:** 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
**Transport:** Overnight at room-temperature, cold over 24 hours (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86695 |
| HSV 2 | 1565 | Detection of Herpes antibody to GP type 2 determines active and/or past infection | Specimen: Serum  
**Container:** Serum Separator Tube (SST), or Red Top  
**Collection:** 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
**Transport:** Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86696 |
**Influenza by rRT-PCR**

Detection of Influenza A and Influenza B virus by rRT-PCR including subtypes of Influenza A virus such as A/H3, A/H1, 2009 A/H1N1, A/S, and A/H7.

**Specimen:** Nasal swabs, nasopharyngeal swabs, nasal aspirates, nasal washes, dual nasopharyngeal/throat swabs, bronchoalveolar lavage, tracheal aspirate and bronchial wash

**Container:** Nylon or dacron swabs with aluminum or plastic shaft in viral transport media. Sterile screw cap containers for bronchoalveolar lavage, tracheal aspirate, and bronchial wash

**Collection:** Swabs collected in a minimum of 500ul of transport media. A minimum of 200ul of bronchoalveolar lavage, tracheal aspirate and bronchial wash in a sterile container

**Transport:** Cold (2°- 8°C) within 3 days of collection. Frozen on dry ice if greater than 3 days

**Reverse transcription realtime PCR**

**Influenza A not detected by rRT-PCR, Influenza B not detected by rRT-PCR**

1-3 business days

Molecular Biology 404-327-7900

For after hours call 866-PUB-HLTH 87502

87503X3

---

**GPHL TEST NAME** | **ORDER CODE** | **DESCRIPTION** | **SPECIMEN REQUIREMENTS** | **TEST METHOD** | **NORMAL VALUE** | **TURN AROUND TIME** | **CONTACT INFORMATION** | **CPT CODE**
--- | --- | --- | --- | --- | --- | --- | --- | ---
Influenza Culture (Flu A and B) | 1375 | Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal antiserum | **Specimen:** Throat washing or swab, nasopharyngeal washing or swab
**Container:** Viral transport media provided by GPHL
**Collection:** Collect throat and nasopharyngeal specimens in viral transport media and washings in sterile container
**Transport:** Cold (2°-8°C) | Flu DFA Virus culture tube/CPE Virus culture shell vial Virus culture shell vial Flu B IFA Flu A IFA Respiratory Panel IFA | No virus isolated and detected | 3 weeks | Virology 404-327-7980 | 87804 87252 87253 87254 87275 87276 87300
Malaria Parasite | 2700 | Speciation of malaria parasites by microscopic examination of Giemsa-stained blood smear | **Specimen:** Giemsa or Wright stained thick and thin blood smears plus EDTA whole blood
**Container:** EDTA (lavender top) tube
**Collection:** Draw successive blood samples in between chills if possible
**Transport:** Slides in slide holder at room temperature; EDTA blood in cold (2°- 8°C) | Microscopy | No Parasites Found | 1-3 Days | Parasitology 404-327-7963 | 87207
Malaria Parasites - PCR

DNA extraction and amplification by PCR

**Specimen**: Whole blood preferably less than 72 hrs

**Container**: EDTA (Lavender top) tube

**Collection**: At least 1 ml of blood by venipuncture

**Transport**: Cold (2°- 8°C) (NOTE: Do not freeze)

Real-time PCR

**No Parasites Found**

1-2 Days

Parasitology 404-327-7963

87797

Measles

416100 Detection of Measles virus by rRT-PCR

**Specimen**: Cotton and Dacron Throat or nasopharyngeal swab in (VTM). Nasopharyngeal aspirate in a sterile container. (Urine, cataracts, lens aspirate, oral fluid, cerebrospinal fluid (CSF), dry blood spots, and tissue samples will be referred to CDC)

**Container**: Viral transport media for swabs and sterile container for CSF

**Collection**: Swabs only with a Dacron tip and aluminum shaft collected in a minimum of 500ul of transport media or a minimum of 200ul of CSF on a screw cap sterile container

**Transport**: Cold (2°-8°C)

Reverse transcription realtime PCR

**Measles virus RNA not detected by rRT-PCR**

1-3 business days

Molecular Biology 404-327-7900

For after hours call 866-PUB-HLTH

87798

<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| Measles Culture | 62040 | Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal antiserum | **Specimen**: Urine, throat swab, and CSF

**Container**: Viral transport media provided by GPHL

**Collection**: Collect throat swab in viral transport media, urine and CSF in sterile container

**Transport**: Cold (2°-8°C) | Virus culture tube/CPE Virus culture shell vial/IFA Virus culture shell vial/IFA | No virus isolated and detected | 3 weeks | Virology 404-327-7980 | 87252 87253 87254 |
| Mercury | CT021600 | Total mercury in urine | **Specimen**: Urine

**Container**: Urine container

**Collection**: Collect 25-60mL of urine, freeze at -20°C or lower.

**Transport**: Frozen (-20°C) using dry ice | ICPMS | Not detected | 1-3 business days | Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH | 83825 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mumps Culture</td>
<td>60000</td>
<td>Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal</td>
<td><strong>Specimen:</strong> Urine, throat swab, and CSF&lt;br&gt;<strong>Container:</strong> Viral transport media provided by GPHL&lt;br&gt;<strong>Collection:</strong> Collect throat swab in viral transport media, urine and CSF in sterile container&lt;br&gt;<strong>Transport:</strong> Cold (2°-8°C)</td>
<td>Virus culture tube/CPE&lt;br&gt;Virus culture shell vial/IFA&lt;br&gt;Virus culture shell vial/IFA</td>
<td>No virus isolated and detected</td>
<td>3 weeks</td>
<td>Virology 404-327-7980</td>
<td>87252 87253 87254</td>
</tr>
</tbody>
</table>

**Metabolic Toxins Panel (MTP)**

- **CT031200** Monofluoroacetate & monochloroacetate in urine
  - **Specimen:** Urine<br>**Container:** Urine container<br>**Collection:** Collect 25-60mL of urine, freeze at -20°C or lower.<br>**Transport:** Frozen (-20°C) using dry ice
  - **Test Method:** LC-MS/MS
  - **Normal Value:** Not detected
  - **Turn Around Time:** 1-3 business days
  - **Contact Information:** Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH

**Mumps**

- **1555** Detection of Mumps IgG antibody to determine immune status
  - **Specimen:** Serum<br>**Container:** Serum Separator Tube (SST), or Red Top<br>**Collection:** 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube<br>**Transport:** Overnight at room-temperature; Over 24 hours cold (2°-8°C)
  - **Test Method:** Immunoassay
  - **Normal Value:** Negative
  - **Turn Around Time:** 5-7 days
  - **Contact Information:** Immunology 404-327-7970

- **413000** Detection of Mumps virus by rRT-PCR
  - **Specimen:** Oral/buccal or oropharyngeal swab or CSF<br>**Container:** Viral transport media for swabs and sterile container for CSF<br>**Collection:** Swabs only with a Dacron tip and aluminum shaft collected in a minimum of 500ul of transport media or a minimum of 200ul of CSF on a screw cap sterile container<br>**Transport:** Cold (2°-8°C)
  - **Test Method:** Reverse transcription realtime PCR<br>**Normal Value:** Mumps RNA virus not detected by rRT-PCR
  - **Turn Around Time:** 1-5 business days
  - **Contact Information:** Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH
Mycobacteria Culture with Smear

Concentration Culture by broth & solid media Identification Susceptibility (initial isolate of MTB)

Specimen: Sputum, Bronchial Washings, Fluids, Tissue, Urine, Stool
Container: Sterile
Collection: Three morning deep cough specimens are ideal for initial diagnosis however other specimens can be submitted. Transport: Cold (2°-8°C), if not shipped day of collection; Ship using Category B container

Smear: No Acid Fast Bacilli Seen
Culture: No Mycobacteria Isolated
6-8 weeks
TB Unit 404-327-7945

Mycobacteria Identification

Isolate of AFB submitted for identification

HPLC
N/A
7 days
TB Unit 404-327-7945

Mycobacteria Microscopic Exam Only

Microscopic Exam only for AFB

Fluorochrome Staining
No Acid Fast Bacilli Seen
1 working day
TB Unit 404-327-7945

Mycobacterium tuberculosis Susceptibility

MTB Susceptibility Level I

MGIT 960 broth susceptibility
N/A
14-28 days
TB Unit 404-327-7945

GPHL TEST
NAME
Polymerase Chain Reaction testing on concentrated specimen for rapid detection of MTB

Polymerase Chain Reaction testing on concentrated specimen for rapid detection of MTB

Specimen: Sputum, BAL
Container: Sterile
Collection: A deep morning cough specimen is ideal
Transport: Cold (2°-8°C) if not shipped day of collection; Ship using Category B container

MGIT 960 broth susceptibility
Cepheid GeneExpert
MTB not detected Rifampin Resistance not Detected
1 working day
TB Unit 404-327-7945

CPT
CODE
NAME
ORDER
CODE
DESCRIPTION
SPECIMEN REQUIREMENTS
TEST METHOD
NORMAL
VALUE
TURN AROUND
TIME
CONTACT
INFORMATION
CPT
CODE
Mycobacterium tuberculosis PCR
30800
Polymerase Chain Reaction testing on concentrated specimen for rapid detection of MTB
Specimen: Sputum, BAL
Container: Sterile
Collection: A deep morning cough specimen is ideal
Transport: Cold (2°-8°C) if not shipped day of collection; Ship using Category B container

Cepheid GeneExpert
MTB not detected Rifampin Resistance not Detected
1 working day
TB Unit 404-327-7945

87556
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| **Mycobacterium tuberculosis Genotyping Referral** | 30750 | Isolate of MTB sent for gene analysis for epidemiology | Specimen: Isolate of MTBC on solid or broth media  
**Container:** Slant, tube, or bottle  
**Collection:** Subculture loopful of colony to a fresh slant or tube  
**Transport:** Ambient with Category A Shipping container | N/A | N/A | N/A | TB Unit 404-327-7945 | N/A |
| **Newborn Screening** | N/A | Newborn screen for 28 metabolic, endocrine, and hematologic disorders | Specimen: Dried blood spot (DBS)  
**Container:** Filter paper (Form 3491)  
**Collection:** 5 DBS circles  
**Transport:** Room temperature for up to 7 days | Various | Various (See NBS Website) | 2-3 days | Newborn Screening 404-327-7950 | N/A |
| **Norovirus by rRT-PCR** | 1305 | RNA extraction and amplification by rRTPCR duplex assay for the qualitative detection of Norovirus GI and GII strains | Specimen: Fresh whole stool  
**Container:** Carrie Blair Media (Para Pak), sterile container  
**Collection:** Add stool to vial up to the "fill" line immediately after passage. Then mix specimen thoroughly  
**Transport:** Room Temperature | Reverse transcription realtime PCR | Norovirus GI or GII strain virus RNA not detected by rRT-PCR. | 1-3 business days | Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH | 87798 |
| **Organophosphate Nerve Agent metabolites (OPNA)** | CT031100 | Nerve agent metabolites in urine | Specimen: Urine  
**Container:** Urine container  
**Collection:** Collect 25-60mL of urine, freeze at -20°C or lower.  
**Transport:** Frozen (-20°C) using dry ice | LC-MS/MS | Not detected | 1-3 business days | Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH | 82542 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertussis culture</td>
<td>1050</td>
<td>Screening procedure for the isolation and identification of <em>Bordetella pertussis</em> and <em>Bordetella parapertussis</em> by culture; utilizing conventional Biochemicals and Direct Fluorescent Antibody (DFA) testing</td>
<td>Nasopharyngeal secretions collected with a dacron, rayon, or nylon-flocked swab</td>
<td>Commercially available Regan Lowe transport media slant</td>
<td>Pass nasopharyngeal swab gently into a nostril until the posterior nares is reached, leave swab in place for 10 seconds, remove slowly. Streak slides (frosted side up) then insert swab into the transport media</td>
<td>Transport specimen at room temperature or cold (2°C - 8°C) within 24 hours from collection</td>
<td>Culture DFA Biochemicals</td>
<td>Negative</td>
<td>7-10 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87081</td>
<td>87265</td>
<td>87077</td>
</tr>
<tr>
<td>Pertussis Direct Fluorescent Antibody (DFA)</td>
<td>1040</td>
<td>Screening procedure of <em>Bordetella pertussis</em> by Direct Fluorescent Antibody</td>
<td>Slides prepared from nasopharyngeal swab</td>
<td>Pertussis outfit 525</td>
<td>Prepare 2 dime-sized smears on each of 2 microscope slides (one slide per nostril). Use frosted-end slides with pre-stamped circles if possible (frosted side up). Label slide holder with the patient's name or other unique identifier and date of specimen collection</td>
<td>Transport slide specimens at room temperature within 24 hours from collection</td>
<td>DFA</td>
<td>Negative</td>
<td>1 day</td>
<td>Bacteriology 404-327-7997</td>
<td>87265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pinworm slide</td>
<td>2200</td>
<td>Microscopic examination of pinworm slide for eggs and/or worms</td>
<td>Scotch® Tape slide preparation of perianal region</td>
<td></td>
<td>First thing in the morning before a bowel movement or bath per instructions provided</td>
<td>ASAP to the lab at Room temperature</td>
<td>Microscopy</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Parasitology 404-327-7963</td>
<td>87172</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pinworm slide</td>
<td>W5030</td>
<td>Microscopic examination of pinworm slide for eggs and/or worms.</td>
<td>Scotch® Tape slide preparation of perianal region</td>
<td></td>
<td>First thing in the morning before a bowel movement or bath per instructions provided</td>
<td>ASAP to the lab at Room temperature</td>
<td>Microscopy</td>
<td>No Parasites Found</td>
<td>1 Day</td>
<td>Waycross 912-338-7050</td>
<td>87172</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Rabies | 1300 | Direct antigen detection by fluorescent antibody technique in animal brain parts | Specimen: Animal head  
Container: Rabies shipper provided by GPHL  
Collection: Remove animal head except for bats and animals with similar size. Brain material for larger animals such as cows, horses, goats  
Transport: Cold (2°-8°C) | Direct fluorescent antibody staining | No virus detected | 1 day | Virology 404-327-7980 | N/A |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GPHL TEST NAME</strong></td>
<td><strong>ORDER CODE</strong></td>
<td><strong>DESCRIPTION</strong></td>
<td><strong>SPECIMEN REQUIREMENTS</strong></td>
<td><strong>TEST METHOD</strong></td>
<td><strong>NORMAL VALUE</strong></td>
<td><strong>TURN AROUND TIME</strong></td>
<td><strong>CONTACT INFORMATION</strong></td>
<td><strong>CPT CODE</strong></td>
</tr>
</tbody>
</table>
| Rabies | W6000 | Direct antigen detection by fluorescent antibody technique in animal brain parts. | Specimen: Animal head  
Container: Rabies shipper provided by GPHL  
Collection: Remove animal head except for bats and animals with similar size. Brain material for larger animals such as cows, horses, goats  
Transport: Cold (2°-8°C) | Direct fluorescent antibody staining | No virus detected | 1 day | Waycross 912-338-7050 | N/A |
| Rapid Toxic Screen (RTS) | N/A | Shipped to CDC for screening for chemical agents | Specimen: Urine and whole blood  
Container: Urine container, purple top and green or grey top vacutainers  
Transport: Urine- frozen (-20°C) on dry ice, blood cold (2°- 8°C) | N/A | N/A | N/A, performed at CDC | Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH | N/A |
| Rash Illness Panel | BTC05000 | Detection of non variola orthopox virus by Real-time PCR | Specimen: Vesicular tissue and fluid, scabs from a crusted vesicle or Dacron swabs from unroofed vesicle  
Container: Sterile screw-capped sterile vial  
Collection: Add 2 to 4 lesions (scab) into sterile container or swab an unroofed vesicle and placed in sterile container  
Transport: Cold (2°-8°C) | Real-time PCR | Orthopox virus DNA Not detected by real-time PCR | 1-3 business day | Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH | 87801 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rotavirus</td>
<td>60030</td>
<td>Infectious agent antigen detection by enzyme immunoassay technique in feces</td>
<td>Specimen: Feces/Stool Container: Sterile container Collection: Collect feces/stool in sterile container Transport: Cold (2°-8°C)</td>
<td>Enzyme Immunoassay</td>
<td>No virus detected</td>
<td>1-2 days</td>
<td>Virology 404-327-7980</td>
<td>87425</td>
</tr>
<tr>
<td>Routine RPR</td>
<td>1610</td>
<td>RPR qualitative titer detection of nontreponemal antibodies during syphilis infection in serum</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>NonTreponemal Agglutination</td>
<td>Negative</td>
<td>3-5days</td>
<td>Immunology 404-327-7970</td>
<td>86592</td>
</tr>
<tr>
<td>Routine RPR</td>
<td>W2000</td>
<td>RPR qualitative titer detection of nontreponemal antibodies during syphilis infection in serum</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>NonTreponemal Agglutination</td>
<td>Negative</td>
<td>3-5days</td>
<td>Waycross 912-338-7050</td>
<td>86592</td>
</tr>
<tr>
<td>RPR with confirmation</td>
<td>1615</td>
<td>RPR quantitative titer with EIA confirmation even if RPR is negative</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube. Transport: Overnight at room-temperature; Over 24 hours cold (2°C-8°C)</td>
<td>Agglutination Immunoassay</td>
<td>Negative Nonreactive</td>
<td>3-5days 5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86592 89593</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----</td>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>---------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>RPR with confirmation</td>
<td>W2000</td>
<td>RPR quantitative titer with EIA confirmation even if RPR is negative</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube. Transport: Overnight at room-temperature; Over 24 hours cold (2°C-8°C)</td>
<td>Agglutination Immunoassay</td>
<td>Negative Nonreactive</td>
<td>3-5days 5-7 days</td>
<td>Waycross 912-338-7050</td>
<td>86592 89593</td>
</tr>
<tr>
<td>Rubella IgG</td>
<td>1510</td>
<td>Detection of Rubella IgG antibody to determine immune status</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube. Transport: Overnight at room-temperature, cold over 24 hours (2°C-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7days</td>
<td>Immunology 404-327-7970</td>
<td>86762</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubella IgM</td>
<td>1515</td>
<td>Detection of Rubella IgM antibody to determine active and/or past infection</td>
<td>Specimen: Serum Container: Serum Separator Tube(SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube. Transport: Overnight at room-temperature, cold over 24 hours (2°C-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7days</td>
<td>Immunology 404-327-7970</td>
<td>86762</td>
</tr>
<tr>
<td>Rubeola IgG</td>
<td>1520</td>
<td>Detection of Rubeola IgG antibody to determine immune status</td>
<td>Specimen: Serum Container: Serum Separator Tube(SST), or Red Top Collection: 4-6ml if tube other than a gel-barrier tube is used, transfer seperated serum to a plastic transport tube. Transport: Overnight at room-temperature, cold over 24 hours (2°C-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7days</td>
<td>Immunology 404-327-7970</td>
<td>86765</td>
</tr>
<tr>
<td>GPHL TEST NAME</td>
<td>ORDER CODE</td>
<td>DESCRIPTION</td>
<td>SPECIMEN REQUIREMENTS</td>
<td>TEST METHOD</td>
<td>NORMAL VALUE</td>
<td>TURN AROUND TIME</td>
<td>CONTACT INFORMATION</td>
<td>CPT CODE</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Shiga toxin producing Escherichia coli - STEC (enteric isolate ID)</td>
<td>1070</td>
<td>Identification of STEC by conventional Biochemicals, Serotyping, and Pulse Field Gel Electrophoresis (PFGE), and toxin detection by Enzyme Immunoassay (EIA)</td>
<td>Specimen: Pure isolate Container: Commercially available slant transport media Collection: Single colony aseptically subbed to a slant transport media Transport: Room temperature within 24 hours</td>
<td>Biochemicals Serotyping EIA PFGE</td>
<td>N/A</td>
<td>4-6 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87077 87147 87335 87152</td>
</tr>
<tr>
<td>Rubeola IgM</td>
<td>1525</td>
<td>Detection of Rubeola IgM antibody to determine active and/or past infection</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>Immunoassay</td>
<td>Negative</td>
<td>5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86765</td>
</tr>
<tr>
<td>Salmonella (enteric isolate ID)</td>
<td>1110</td>
<td>Identification of Salmonella ssp. by conventional Biochemicals, Serotyping, and Pulse Field electrophoresis (PFGE) as appropriate for surveillance and outbreak investigations</td>
<td>Specimen: Pure isolate Container: Commercially available slant transport media Collection: Single colony aseptically subbed to a slant transport media Transport: Room temperature for up to 3 days</td>
<td>Biochemicals Serotyping PFGE</td>
<td>N/A</td>
<td>3-5 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87077 87147 87152</td>
</tr>
<tr>
<td>Test Name</td>
<td>Code</td>
<td>Description</td>
<td>Specimen</td>
<td>Container</td>
<td>Collection</td>
<td>Transport</td>
<td>Test Method</td>
<td>Normal Value</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Shigella (enteric isolate ID)</td>
<td>1080</td>
<td>Identification of <em>Shigella</em> spp. by conventional Biochemicals, serotyping, Pulse Field electrophoresis (PFGE) as appropriate for surveillance</td>
<td>Specimen: Pure isolate</td>
<td>Container: Commercially available slant transport media</td>
<td>Collection: Single colony aseptically subbed to a slant transport media</td>
<td>Transport: Room temperature for up to 3 days</td>
<td>Biochemicals Serotyping, PFGE</td>
<td>N/A</td>
</tr>
<tr>
<td>Special Bacteriology (Haemophilus influenzae)</td>
<td>1130</td>
<td>Identification of <em>Haemophilus influenzae</em> by conventional Biochemicals and Serotyping</td>
<td>Specimen: Pure isolate</td>
<td>Container: Commercially available chocolate slant transport media</td>
<td>Collection: For serotyping and/or culture confirmation, submit a fresh 18-24 hours subculture of the organism on chocolate slant transport media</td>
<td>Transport: Room temperature within 24 hours</td>
<td>Biochemicals Serotyping</td>
<td>N/A</td>
</tr>
<tr>
<td>Special Bacteriology (Listeria monocytogenes)</td>
<td>1130</td>
<td>Identification of <em>Listeria monocytogenes</em> by conventional Biochemicals and Pulse Field electrophoresis (PFGE)</td>
<td>Specimen: Pure isolate</td>
<td>Container: Commercially available slant transport media</td>
<td>Collection: Single colony aseptically subbed to a slant transport media</td>
<td>Transport: Room temperature within 24 hours</td>
<td>Biochemicals PFGE</td>
<td>N/A</td>
</tr>
<tr>
<td>Special Bacteriology (Neisseria meningitidis)</td>
<td>1130</td>
<td>Identification of <em>Neisseria meningitidis</em> by conventional Biochemicals and Serotyping</td>
<td>Specimen: Pure isolate</td>
<td>Container: Commercially available chocolate slant transport media</td>
<td>Collection: For serotyping and/or culture confirmation, submit a fresh 18-24 hours subculture of the organism on chocolate slant transport media</td>
<td>Transport: Room temperature within 24 hours</td>
<td>Biochemicals Serotyping</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Special Bacteriology (Other agents ID)

**Identification of pure isolate by conventional Biochemicals, Serotyping, and/or Cell Wall Fatty Acid Analysis (CWFAA)**

**Specimen:** Pure isolate  
**Container:** Commercially available slant transport media  
**Collection:** Single colony aseptically subbed to a slant transport media  
**Transport:** Room temperature for up to 3 days

**Biochemicals CWFAA Serotyping**  
**N/A**  
**7-15 days**  
**Bacteriology 404-327-7997**  

### Special Bacteriology (Vibrio sp.)

**Identification of Vibrio sp. by conventional Biochemicals, Serotyping, and/or Cell Wall Fatty Acid Analysis (CWFAA)**

**Specimen:** Pure isolate  
**Container:** Commercially available slant transport media  
**Collection:** Single colony aseptically subbed to a slant transport media  
**Transport:** Room temperature for up to 24 hours

**Biochemicals CWFAA Serotyping**  
**N/A**  
**7-15 days**  
**Bacteriology 404-327-7997**  

### Stool - Formalin feces

**Microscopic examination of concentrated wet mount and stained samples for parasites**

**Specimen:** Three stool samples collected every other day is recommended but single sample collection is also acceptable  
**Container:** 10% formalin vial (Para-Pak)  
**Collection:** Add stool to vial up to the "fill" line immediately after passage. Mix thoroughly  
**Transport:** Room Temperature

**Concentration/ Microscopy Acid fast stain**  
**No Parasites Found**  
**1-4 Days**  
**Parasitology 404-327-7963**  

### Stool - Formalin feces

**Microscopic examination of concentrated wet mount and stained samples for parasites**

**Specimen:** Three stool samples collected every other day is recommended but single sample collection is also acceptable  
**Container:** 10% formalin vial (Para-Pak)  
**Collection:** Add stool to vial up to the "fill" line immediately after passage. Mix thoroughly  
**Transport:** Room Temperature

**Concentration/ Microscopy Acid fast stain**  
**No Parasites Found**  
**1-4 Days**  
**Waycross 912-338-7050**  

### GPHL TEST NAME | ORDER CODE | DESCRIPTION | SPECIMEN REQUIREMENTS | TEST METHOD | NORMAL VALUE | TURN AROUND TIME | CONTACT INFORMATION | CPT CODE
---|---|---|---|---|---|---|---|---
Stool - PVA feces | 2300 | Microscopic examination of Trichrome stained smear for parasites | Specimen: Three stool samples every other day is recommended but single sample is also acceptable  
**Container:** LV/PVA vial (Para-Pak)  
**Collection:** Add stool to the vial up to the "fill" line immediately after passage. Mix thoroughly  
**Transport:** Room Temperature | Trichrome-stained slide | No Parasites Found | 1-4 Days | Parasitology 404-327-7963 | 87209
Stool - PVA feces

**Specimen:** Three stool samples every other day is recommended but single sample is also acceptable
**Container:** LV/PVA vial (Para-Pak)
**Collection:** Add stool to the vial up to the "fill" line immediately after passage. Mix thoroughly
**Transport:** Room Temperature

**Trichrome-stained slide**
**No Parasites Found**

1-4 Days  
Waycross 912-338-7050  
87209

Stool culture - Fresh (B. cereus)

**Specimen:** Fresh Stool
**Container:** Commercially available sterile container
**Collection:** Collect fresh stool specimens within 48 hours from the time symptoms begin and place in a leak-proof, noncrushable, sterile container (not provided by GPHL). Do not use the enteric ParaPak C&S stool culture outfit
**Transport:** Store and ship cold (2°- 8°C) within 24 hours from collection

**Culture Biochemicals CWFAA**
**Negative**

4-6 days  
Bacteriology 404-327-7997  
87046  
87077

Stool culture - Fresh (C. perfringens)

**Specimen:** Stool in sterile container
**Container:** Commercially available sterile container
**Collection:** Collect fresh stool specimens within 48 hours from the time symptoms begin and place in a leak-proof, noncrushable, sterile container (not provided by GPHL). Do not use the enteric ParaPak C&S stool culture outfit
**Transport:** Store and ship cold (2°- 8°C) within 24 hours from collection

**Culture Biochemicals CWFAA**
**Negative**

4-6 days  
Bacteriology 404-327-7997  
87046  
87077

<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| Stool - PVA feces | W5020 | Microscopic examination of Trichrome stained smear for parasites | **Specimen:** Three stool samples every other day is recommended but single sample is also acceptable  
**Container:** LV/PVA vial (Para-Pak)  
**Collection:** Add stool to the vial up to the "fill" line immediately after passage. Mix thoroughly  
**Transport:** Room Temperature | **Trichrome-stained slide** | **No Parasites Found** | 1-4 Days | Waycross 912-338-7050 | 87209 |
| Stool culture - Fresh (B. cereus) | 1140 | Isolation of *Bacillus cereus* by culture. When positive, identification of *Bacillus cereus* by conventional Biochemicals and/or CWFAA | **Specimen:** Fresh Stool  
**Container:** Commercially available sterile container  
**Collection:** Collect fresh stool specimens within 48 hours from the time symptoms begin and place in a leak-proof, noncrushable, sterile container (not provided by GPHL). Do not use the enteric ParaPak C&S stool culture outfit  
**Transport:** Store and ship cold (2°- 8°C) within 24 hours from collection | **Culture Biochemicals CWFAA** | **Negative** | 4-6 days | Bacteriology 404-327-7997 | 87046  
87077 |
| Stool culture - Fresh (C. perfringens) | 1140 | Isolation of *Clostridium perfringens* by culture. When positive, identification of *Clostridium perfringens* by conventional Biochemicals and/or CWFAA | **Specimen:** Stool in sterile container  
**Container:** Commercially available sterile container  
**Collection:** Collect fresh stool specimens within 48 hours from the time symptoms begin and place in a leak-proof, noncrushable, sterile container (not provided by GPHL). Do not use the enteric ParaPak C&S stool culture outfit  
**Transport:** Store and ship cold (2°- 8°C) within 24 hours from collection | **Culture Biochemicals CWFAA** | **Negative** | 4-6 days | Bacteriology 404-327-7997 | 87046  
87077 |
<table>
<thead>
<tr>
<th>Test Description</th>
<th>Code</th>
<th>Specimen Details</th>
<th>Collection Details</th>
<th>Transport Details</th>
<th>Culture Method</th>
<th>Identification Method</th>
<th>turnaround</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stool culture - Preserved (Routine Salmonella, Shigella, Campylobacter, Aeromonas, STEC, and Yersinia)</td>
<td>1120</td>
<td>Specimen: Preserved Stool&lt;br&gt;Container: Para-Pak C&amp;S transport vial (Stool culture outfit 555)&lt;br&gt;Collection: The specimen of choice is the diarrheal stool collected during the acute stage of the disease, portions containing blood or mucus usually contain the highest number of pathogens&lt;br&gt;Transport: Room Temperature for up to 3 days</td>
<td>Culture&lt;br&gt;EIA&lt;br&gt;Biochemicals&lt;br&gt;Serotyping&lt;br&gt;Pulse Field electrophoresis (PFGE)</td>
<td>Negative</td>
<td>4-6 days</td>
<td>Bacteriology 404-327-7997</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stool culture - Preserved (S. aureus)</td>
<td>1120</td>
<td>Specimen: Preserved Stool&lt;br&gt;Container: Para-Pak C&amp;S transport vial (Stool culture outfit 555)&lt;br&gt;Collection: The specimen of choice is the diarrheal stool collected within 24 hours after onset&lt;br&gt;Transport: Room Temperature within 24hrs from collection&lt;br&gt;Special arrangement required CALL 404-327-7997</td>
<td>Culture&lt;br&gt;Biochemicals&lt;br&gt;CWFAA</td>
<td>Negative</td>
<td>4-6 days</td>
<td>Bacteriology 404-327-7997</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetramine (TET)</td>
<td>CT011300</td>
<td>Specimen: Urine&lt;br&gt;Container: Urine container&lt;br&gt;Collection: Collect 25-60mL of urine, freeze at -20°C or lower.&lt;br&gt;Transport: Frozen (-20°C) using dry ice</td>
<td>GC/MSD</td>
<td>Not detected</td>
<td>1-3 business days</td>
<td>Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tick; Arthropod</td>
<td>2800</td>
<td>Specimen: Tick; Arthropod; Skin Scraping&lt;br&gt;Container: Alcohol vial; Glass Slide&lt;br&gt;Collection: Place tick or arthropod in alcohol vial, Scrape skin from multiple sites and place on glass slide with a smear of mineral oil. Cover with coverslip&lt;br&gt;Transport: Slide in slide holder and tick or arthropod in vial at room temperature</td>
<td>Macroscopy&lt;br&gt;microscopy</td>
<td>NA</td>
<td>1-2 Days</td>
<td>Parasitology 404-327-7963</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPHL TEST NAME</td>
<td>ORDER CODE</td>
<td>DESCRIPTION</td>
<td>SPECIMEN REQUIREMENTS</td>
<td>TEST METHOD</td>
<td>NORMAL VALUE</td>
<td>TURN AROUND TIME</td>
<td>CONTACT INFORMATION</td>
<td>CPT CODE</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td>------------------</td>
<td>---------------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| Tissue Parasite   | 2150       | Identification of tissue parasites by microscopic exam of H&E-stained tissue sections           | Specimen: H&E-stained tissue section  
Container: Vial with alcohol; Glass Slide  
Collection: Place worm or arthropod in the alcohol vial  
Transport: Room Temperature | Microscopy | No Parasites Found | 1-2 Days | Parasitology 404-327-7963 | 87207 |
| TORCH PANEL       | 14001      | Determination of IgG antibody titers for toxo, rubella, CMV, and herpes 1 and 2                | Specimen: Serum  
Container: Serum Separator Tube (SST), or Red Top  
Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86777 |
| Toxic Elements Screen (TES) | CT021700 | Trace metals (Be, As, Cd, Ba, Th, Pb, U) in urine                                               | Specimen: Urine  
Container: Urine container  
Collection: Collect 25-60mL of urine, freeze at -20°C or lower.  
Transport: Frozen (-20°C) using dry ice | ICPMS | Not detected | 1-3 business days | Chemical Threat 404-321-2259 For after hours call 866-PUB-HLTH | 83018 |
| Toxoplasmosis IgG | 1530       | Detection of Toxoplasmosis IgG antibody to determine immune status                               | Specimen: Serum  
Container: Serum Separator Tube (SST), or Red Top  
Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86777 |
| Toxoplasmosis IgM | 1530       | Detection of Toxoplasmosis IgM antibody to determine active and/or past infection               | Specimen: Serum  
Container: Serum Separator Tube (SST), or Red Top  
Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86778 |
| TP PA             | 1640       | Detection of Treponemal palladium antibody by particle                                         | Specimen: Serum  
Container: Serum Separator Tube (SST), or Red Top  
Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube  
Transport: Overnight at room-temperature; Over 24 hours cold | Treponemal Particle Agglutination (IgG, IgM) | Nonreactive | 5-7 days | Immunology 404-327-7970 | 86780 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| Varicella (Herpes) Zoster Culture (VZV) | 62000 | Virus isolation: inoculation, observation, presumptive ID and for each isolate by CPE in tubes and shell vials. Infectious agent detection by IFA monoclonal antiserum | Specimen: Vesicle scraping (lesion), brain biopsy
Container: Viral transport media provided by GPHL
Collection: Collect vesicle scraping and brain biopsy in viral transport media
Transport: Cold (2°-8°C) | Virus culture tube
Virus culture shell vial
Virus culture shell vial IFA | No virus isolated and detected | 3 weeks | Virology 404-327-7980 | 87252 87253 |
| Varicella Zoster Virus (VZV) | 1540 | Detection of Varicella IgG antibody to determine immune status | Specimen: Serum
Container: Serum Separator Tube (SST), or Red Top
Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube
Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Immunoassay | Negative | 5-7 days | Immunology 404-327-7970 | 86787 |
| Varicella Zoster Virus (VZV) | 421000 | DNA extraction and amplification by realtime PCR for the qualitative detection of Varicella Zoster Virus (VZV) | Specimen: Vesicular tissue and fluid, scabs from a crusted vesicle or Dacron swabs from unroofed vesicle
Container: Sterile screw-capped sterile vial
Collection: Add 2 to 4 lesions (scab) into sterile container or swab an unroofed vesicle and place in sterile container
Transport: Cold (2°-8°C) | Real-time PCR | Varicella Zoster Virus DNA not detected by real-time PCR. | 1-3 business day | Molecular Biology 404-327-7900 For after hours call 866-PUB-HLTH | 87798 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
</table>
| VDRL (spinal fluid)               | 1630       | VDRL Qualitative titer detection on nontreponemal antibodies during syphilis infection in CSF | Specimen: CSF  
Container: Sterile Tube  
Collection: 1-2ml  
Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C) | Non-Treponemal Agglutination  
Negative | 3-5days | Immunology 404-327-7970 | 86592 |
<table>
<thead>
<tr>
<th>GPHL TEST NAME</th>
<th>ORDER CODE</th>
<th>DESCRIPTION</th>
<th>SPECIMEN REQUIREMENTS</th>
<th>TEST METHOD</th>
<th>NORMAL VALUE</th>
<th>TURN AROUND TIME</th>
<th>CONTACT INFORMATION</th>
<th>CPT CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yersinia (enteric isolate ID)</td>
<td>1160</td>
<td>Identification of <em>Yersinia enterocolitica</em> by conventional Biochemicals and Serotyping</td>
<td>Specimen: Pure isolate Container: Commercially available slant transport media Collection: Single colony aseptically subbed to a slant transport media Transport: Room temperature for up to 3 days</td>
<td>Biochemicals Serotyping</td>
<td>N/A</td>
<td>3-5 days</td>
<td>Bacteriology 404-327-7997</td>
<td>87077 87147</td>
</tr>
<tr>
<td>WNV IgM</td>
<td>1585 1590</td>
<td>Detection of West Nile Virus IgM antibody to determine active and/or past infection IgM (CSF)(indicates active infection)</td>
<td>Specimen: Serum Container: Serum Separator Tube (SST), or Red Top Collection: 4-6ml Red Top spin down, SST centrifuge and transfer serum to a transfer tube Transport: Overnight at room-temperature; Over 24 hours cold (2°-8°C)</td>
<td>EIA - serum EIA - CSF</td>
<td>Negative</td>
<td>5-7 days</td>
<td>Immunology 404-327-7970</td>
<td>86788 86788</td>
</tr>
<tr>
<td>Worm ID</td>
<td>2800</td>
<td>Macroscopic and microscopic identification</td>
<td>Specimen: Worm Container: Vial with alcohol Collection: Place worm in the alcohol vial Transport: Room Temperature</td>
<td>Macroscopy microscopy</td>
<td>N/A</td>
<td>1-2 Days</td>
<td>Parasitology 404-327-7963</td>
<td>87169</td>
</tr>
</tbody>
</table>

Disclaimer: The CPT codes are provided for informational purposes only. CPT coding is the sole responsibility of the billing party.

Specimen must be accompanied by the Georgia Public Health Laboratory Submission Form #3583 located at: www.health.state.ga.us/programs/lab/index.asp
Appendix K
MEMORANDUM

From: Sidney R. Barrett, Jr., General Counsel
Date: 30 December 2015

Re: Notification to Persons Exposed to Tuberculosis

This memorandum will address when you may notify someone that they have been exposed to tuberculosis, what you should and should not say, and what efforts should be made to provide notice.

What is the authority of Public Health to notify third parties of possible exposure to TB?

Public Health has broad legal powers to track and fight communicable diseases, including the general power to isolate and treat persons with TB.1 Public Health has the authority to require that health care providers and others notify Public Health when someone is or may be infected with TB.2

One of Public Health’s traditional tactics in fighting communicable disease is to contact persons who are or may have been infected, and encourage them to seek testing and treatment. This often can be done only by disclosing personal health information of the person who may have passed the infection on to them. HIPAA expressly permits the disclosure of personal health information, without the patient’s consent, if disclosure is necessary “to prevent or lessen a serious and imminent threat to the health or safety of a person or the public,” and if the disclosure is made to someone who is “reasonably able to prevent or lessen the threat.”3

Is there a duty to notify? What does “best efforts” mean?

Public Health is authorized to share health information with persons who might be exposed to TB, but the law does not specifically say that we must do so. Notification is a matter within the discretion of Public Health. How and when to notify is a judgment call, based on all the circumstances and what is best for the patients and the community. Of course, since it is our mission to prevent the spread of disease, it is expected that we will always make a good faith attempt to notify persons who have been exposed to disease and encourage them to seek testing and treatment.

---

1 s 31-2A-4(2, 4), 31-12-2, 31-14-1 et seq
2 1-12-2, 31-17-3, 31-22-7.
3 45 C.F.R. 164.512(j)(1)(i).
There is no specific legal definition of what constitutes “good faith efforts” – that is, there is no specific list of actions you must take, or a particular number of letters you must send or phone calls you must make. “Good faith efforts” will vary from one situation to the next, depending on the circumstances. Most judges will candidly tell you “I know it when I see it.” At the end of the day, the question is whether you took reasonable action in light of the information available to you, and in light of the serious consequences of untreated TB.

Who may be notified of a possible exposure?

HIPAA permits Public Health to protect against a threat to the health of a person or the public by disclosing personal health information to anyone who is “reasonably able to prevent or lessen the threat.” In most cases, that will be the person who was exposed to the infectious agent. In other cases, the person who may be “reasonably able to prevent or lessen the threat” may be a parent or legal guardian, or the manager of a jail or homeless shelter. In general, it is left to the discretion of Public Health to decide which persons should be notified.

Who may provide the notice?

The law does not dictate who may provide notice. Any properly trained member of the Public Health workforce may notify a person who may have been exposed to TB. It does not have to be a licensed medical professional, such as a physician or registered nurse.

What information should be provided?

In general, when disclosing someone’s personal health information, HIPAA requires that you disclose only the “minimum necessary” to accomplish your objective. How much information should be disclosed, and what type, will depend on the individual circumstances of the case. For example, it may or may not be necessary to disclose the name of the contact who may have exposed the person to disease.

What information to disclose in a particular situation is a judgment call. If it is not necessary to disclose the name of the index patient, then don’t. If you believe the possibly infected person will not take the threat of disease seriously unless they are confronted with names and details, then you may disclose that information.

45 C.F.R. 164.512(j)(1)(i)
5 C.F.R. 164.514(d).